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1 ABSTRACT 
The TGFβ pathway is a multi-functional signaling system regulating cellular processes ranging from 
proliferation and migration to differentiation and cell death. Upon ligand binding and receptor 
activation, SMAD proteins translocate to the nucleus and induce expression of numerous target genes. 
While many components of the TGFβ pathway have been identified, we are still challenged to 
understand how pathway activation is translated into distinct cellular responses. As the cellular 
response to a given stimulus often varies even in genetically identical cells, I focused on measuring 
pathway activity on the single cell level. By combining fluorescent reporter cell lines with time-lapse 
live-cell microscopy and automated image analysis, I monitored the cytoplasmic to nuclear 
translocation of SMADs with high temporal and spatial resolution in hundreds of individual cells. Our 
experiments demonstrated that pathway activity can be divided into a first synchronous phase of 
SMAD translocation, followed by adaptation and a second signaling phase with high variability in the 
extent and duration of nuclear accumulation. Furthermore, I observed that cells clustered into 
subpopulations according to their dynamic features show different phenotypic responses. I was 
interested in identifying the network interactions that shape these dynamics and focus on crosstalk 
with non-canonical components of the TGFβ pathway. I could show that inhibition of the MAP kinases 
p38 and ERK specifically abrogates the second signaling phase. This dynamic remodeling led to changes 
in target gene expression and cell fate decisions. I explored the molecular mechanisms underlying this 
interaction of the canonical and non-canonical pathways. This will provide a deeper understanding of 
the molecular networks regulating TGFβ signaling and open opportunities to modulate it in diseased 
cells.  
1.1 Zusammenfassung 
Der TGFβ-Signalweg ist ein multifunktionales System, das zelluläre Prozesse reguliert, die von 
Proliferation und Migration bis zu Differenzierung und Zelltod reichen. Nach Ligandenbindung und 
Rezeptoraktivierung translozieren SMAD-Proteine zum Zellkern und induzieren die Expression 
zahlreicher Zielgene. Während viele Komponenten des TGFβ-Signalweges identifiziert wurden, 
verstehen wir noch nicht genau, wie die Aktivierung des Signalwegs in verschiedene zelluläre 
Antworten übersetzt wird. Da die zelluläre Antwort auf einen gegebenen Stimulus oft sogar in 
genetisch identischen Zellen variiert, konzentrierte ich mich auf die Messung der Signalwegaktivität 
auf der Einzelzellebene. Durch die Kombination fluoreszierender Reporterzelllinien mit Zeitraffer-
Lebendzellmikroskopie und automatisierter Bildanalyse beobachtete ich die zytoplasmatische und 
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nukleäre Translokation von SMADs mit hoher zeitlicher und räumlicher Auflösung in Hunderten 
einzelner Zellen. Unsere Experimente zeigten, dass die Signalwegaktivität in eine erste synchrone 
Phase der SMAD-Translokation, gefolgt von einer Adaption und einer zweiten Signalphase mit hoher 
Variabilität in Stärke und Dauer der nuklearen Akkumulation unterteilt werden kann. Darüber hinaus 
beobachtete ich, dass Zellen, die aufgrund ihrer dynamischen Eigenschaften in Subpopulationen 
gruppiert sind, unterschiedliche phänotypische Reaktionen zeigen. Ich war nun daran interessiert, die 
Netzwerkinteraktionen zu identifizieren, die diese Dynamiken formen und fokussierte mich auf den 
Crosstalk mit nicht-kanonischen Komponenten des TGFβ-Signalweges. Ich konnte zeigen, dass die 
Hemmung der MAP Kinasen p38 und ERK die zweite Signalphase spezifisch aufhebt. Diese dynamische 
Remodellierung führt zu Veränderungen in der Zielgenexpression und den Zellschicksalen. Ich 
untersuchte außerdem die molekularen Mechanismen, die dieser Wechselwirkung der kanonischen 
und nicht-kanonischen Wege zugrunde liegen. Dies wird zu einem tieferen Verständnis der 
molekularen Netzwerke führen, die die TGFβ-Signaltransduktion regulieren und Möglichkeiten 
eröffnen, es in erkrankten Zellen zu modulieren. 
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2 INTRODUCTION 
2.1 Signaling dynamics in individual cells 
A fundamental property of living cells is the ability to detect, process and respond appropriately to 
altering environmental conditions and numerous other stimuli. Recent studies reveal that cells can 
send and receive information by controlling the temporal behavior (“dynamics”) of their signaling 
proteins, which subsequently induce corresponding programs of gene expression that modulate cell 
behavior (Purvis & Lahav, 2013). Characterizing the quantity, localization and activity of proteins with 
high temporal and spatial resolution is therefore critical for understanding molecular mechanisms of 
cellular processes, including those involved in disease progression, and for targeted discovery and 
development of novel therapeutics, vaccines and diagnostics. This mode of signaling encodes 
information in the frequency, amplitude, duration or other features of the temporal signal. It is 
therefore richer and more complex than transmitting information through the state of a signaling 
molecule at only a single point in time (Purvis & Lahav, 2013). These data are complementary to the 
information provided by genetics, genomics and proteomics of describing the structure of biological 
networks and have great potential to provide new insight into the relationship between network 
architecture and function. One promising technique to measure the dynamics of key proteins within 
the network is using high-resolution live-cell imaging of fluorescent reporters (Spiller et al, 2010). This 
technology allows to determine the quantity and even the subcellular localization of specific proteins 
in living cells. The dynamics of signaling proteins can be investigated across a population of cells or in 
individual cells. Cells are heterogeneous in nature and hence, population-averaged data can mask the 
underlying molecular mechanisms, since genetically identical cells differ widely in their dynamical 
behaviors even when challenged with the same external stimulus (Cohen et al, 2008; Lee et al, 2009; 
Batchelor et al, 2009; Spiller et al, 2010). A well-known example is the response of bacteria to 
antibiotics, at certain doses some cells live while others die (Cohen et al, 2008).  
Moreover, one of the unanswered questions in cancer therapy has been why essentially identical cells 
respond differently to a drug. Single-cell level analyses of proteins have already revealed valuable 
insight into mechanisms that dictate heterogeneity in cellular response to drugs and other external 
stimuli (Paek et al, 2016). 
For instance, it was shown that dynamics of tumor suppressor protein p53 in response to DNA damage 
derived from population studies measured by western blot was misleading (Lev Bar-Or et al, 2000; 
Batchelor et al, 2009). Instead of damped oscillations seen in population- averaged data, observation 
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of single cells revealed series of undamped p53 pulses with fixed height and duration, independent of 
the amount of γ-irradiation (Lahav et al, 2004). 
Similarly, the transcription factor nuclear factor kappa B (NF-κB) in single cells shows variability in the 
oscillatory dynamics of nuclear localization upon stimulation (Hoffmann et al, 2002; Nelson et al, 
2004). 
Moreover, single cell analyses are crucial for stem cell research as decisions in individual cells 
determines their cellular outcome. For instance, in hematopoietic stem cells it is reported, by studying 
the varying levels of Sca-1 protein in individual cells, that Sca-1 protein abundance determines the 
timing and type of differentiation (Chang et al, 2008). 
Hence, single cell analyses of signaling systems have already revealed important information about the 
role of dynamics in regulating various cellular fates. It has been reported that the dynamics of p53 play 
a role in the specificity of the response with pulsed p53 favoring DNA repair and cell-cycle arrest genes, 
and sustained p53 triggering activation of senescence and apoptotic genes (Batchelor et al, 2011; 
Purvis et al, 2012). Another example is found in the dynamics of ERK activity, where two separate 
growth factors trigger different ERK dynamics and thus different cell fates of rat neuronal precursors. 
Specifically, epidermal growth factor (EGF) triggers a transient response leading to cell proliferation, 
whereas nerve growth factor (NGF) induces sustained ERK activation leading to differentiation 
(Marshall, 1995). Similarly, different inflammatory stimuli induce distinct temporal dynamics of the 
transcription factor NF-κB. Thus, activation by tumor necrosis factor-α (TNFα) generates oscillations of 
transcriptionally active NF- kB and single cell analysis of luciferase expression from a synthetic NF-κB 
responsive promoter suggested that the pulses determine the degree and timing of downstream gene 
expression (Hoffmann et al, 2002; Nelson et al, 2004; Sung et al, 2009; Tay et al, 2010). On the other 
hand, bacterial lipopolysaccharide (LPS) leads to slower accumulation and a single prolonged wave of 
NF-κB activity (Covert et al, 2005; Lee et al, 2009; Werner et al, 2005). Moreover, stimulus strength 
and patterns influence the dynamics of NF-κB activity. Increasing the concentration of TNFα reveals a 
shortened delay in NF-κB nuclear translocation (Cheong et al, 2006; Tay et al, 2010) and increasing the 
frequency of TNFα stimulation reveals smaller amplitude oscillations (Ashall et al, 2009). 
These different outcomes might reflect differences in the initial state of the cell, including cell cycle 
stage, external influences such as the local environment, basal level of network components or 
stochastic intracellular events (Loewer & Lahav, 2011; Snijder & Pelkmans, 2011), which in turn lead 
to variation in the quantitative behavior of the information-processing network. By visualizing the 
dynamical behavior and identifying how it varies among cells (or cell types), we might be able to explain 
varying behaviors both within cell populations and in different cell types. 
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Thus, cellular fates upon TGFβ (transforming growth factor beta) stimulation are manifold and vary 
amongst various cell types and environmental conditions (Sporn et al, 2006). Even though the main 
molecular components of the canonical and the non-canonical TGFβ signaling pathways have been 
largely studied, the mechanism that underlies the well-established context dependent physiological 
responses remains largely unexplored. Therefore, recent studies quantitatively characterized several 
mechanisms shaping the temporal dynamics of SMAD signaling, the main components of TGFβ 
signaling transduction (Clarke & Liu, 2008; Schmierer et al, 2008; Zi et al, 2012). The duration and 
pattern of SMAD signaling response are context dependent. Thus, it has been reported that 
keratinocyte epithelial cells reveal sustained phospho-SMAD responses to TGFβ stimulation, while 
some fibroblast and tumor cells expose transient SMAD activation (Nicolas & Hill, 2003; Ahn et al, 
2011). It was hypothesized that sustained TGFβ signaling may be required for cell cycle arrest, while 
transient signaling may cause the resistance to anti-proliferative effects of TGFβ in certain tumor cells 
(Nicolas & Hill, 2003). However, previous quantitative studies of SMAD dynamics mainly focused on 
the average behavior of a cell population at defined time points, whereas the long-term response at 
the level of single cells with high temporal und spatial resolution is not well characterized. Recent 
studies showed that SMAD nuclear translocation of fluorescently labeled SMAD proteins revealed high 
variability in individual cells (Warmflash et al, 2012; Zieba et al, 2012).  
However, to understand how TGFβ signaling elicits defined responses in a cell-specific and 
concentration-dependent manner, we need to systematically characterize its dynamics on the single-
cell level and detect the underlying molecular interactions that shape the dynamic response. This 
would allow us to predict how single cells respond to specific inputs and to design targeted 
perturbations of the TGFβ pathway to exploit its role for therapeutic treatments, such as personalized 
cancer medicine (Strasen et al, 2018). 
2.2 Diverse effects of TGFβ signaling and a dual role in cancer 
Members of the TGFβ superfamily are multifunctional cytokines and important regulators of many 
fundamental cellular and developmental processes, including cell cycle arrest, differentiation, 
morphogenesis and apoptosis, as well as cancer progression (Massagué, 1998; Whitman, 1998, Piek et 
al, 1999, Siegel & Massagué, 2003).  The TGFβ superfamily is subdivided into two branches: (1) the 
TGFβ branch and (2) the Bone Morphogenetic Protein (BMP) branch. 
Considering TGFβ signaling, the effects vary according to the cell type and the environmental and 
physiological conditions (Moustakas & Heldin, 2005; Massagué et al, 2000).  
Thus, TGFβ is a potent growth inhibitor to most normal epithelial cells, however it can also promote 
proliferation of some fibroblastic cell lines, such as NIH 3T3 (Koskinen et al, 1991). One key event that 
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leads to TGFβ induced growth arrest is the induction of expression of the CDK inhibitors p15INK4B 
(Hannon & Beach, 1994; Reynisdóttir et al, 1995) and/or p21CIP1(Datto et al, 1995).  
Furthermore, TGFβ can mediate apoptosis in epithelial cells, hepatocytes (Herzer et al, 2005; Perlman 
et al, 2001) and induces expression and activation of the Fas receptor, leading to caspase-8 activation 
and apoptosis of gastric carcinoma cells (Kim et al, 2004). On the other hand, TGFβ has an anti-
apoptotic function and can promote cell survival and differentiation (Derynck et al, 2001). Thus, 
abrogation of TGFβ signaling in T cells leads to spontaneous T-cell differentiation and autoimmune 
disease, indicating that TGFβ signaling is required for T-cell homeostasis (Gorelik, et al, 2000).  
Morphogenetic responses to TGFβ members include epithelial -mesenchymal transitions (EMT) and 
cell migration, which are crucial during embryogenesis, development of fibrotic diseases and advanced 
carcinoma spreading. EMT is characterized by the disassembly of cell–cell contacts, remodeling of the 
actin cytoskeleton and separation of cells, which generates fibroblast-like cells that express 
mesenchymal markers and become more motile and invasive (Hay, 1995; Shook et al, 2003; Baum et 
al, 2008; Guan et al, 2009). 
Whether cells undergo EMT or apoptosis in response to TGFβ is dependent on their cell cycle state, 
and TGFβ regulates the cell cycle via survivin (Lee et al, 2013). 
TGFβ also plays a paradoxical dual role in tumorigenesis. During normal development and early stages 
of tumor formation, TGFβ exhibits a suppressive role by inducing cell cycle arrest, apoptosis and 
inhibiting tumor growth. However later on, with tumor progression, dedifferentiated tumor cells 
become refractory to the growth inhibition mediated by TGFβ, either because of genetic loss of TGFβ 
signaling components or downstream perturbation of the signaling pathway (Waite & Eng, 2003). 
Moreover, late-stage tumors often display increased TGFβ expression (Dalal et al, 1993) and secreted 
TGFβ protein enhances tumor immunosuppression and facilitates tumor angiogenesis, invasion and 
metastasis (Walker & Dearing, 1992, Connolly et al, 2012). Thus, TGFβ signaling plays a dual role in 
breast cancer, acting as a tumor suppressor in early carcinomas while promoting tumor metastasis in 
more advanced breast carcinoma (Hachim et al, 2016). 
Studying the signaling mechanisms through which the diverse effects of TGFβ are mediated is 
therefore crucial to better understand various cellular processes and can form the basis for new 
disease treatments. 
2.3 TGFβ signaling and SMAD translocation 
There exist three different TGFβ isoforms in mammals, TGFβ1, 2 and 3, which are encoded by different 
genes and which all function through the same receptor signaling systems (Massagué, 1998). TGFβ1 is 
the prototypical ligand of the TGFβ superfamily and is translated into a proprotein that is 
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proteolytically cleaved into noncovalently linked mature TGFβ and latency-associated protein (LAP) 
(Annes et al, 2003, Blobe et al, 2000). The inactive LAP-TGFβ complex is bound to another protein 
called Latent TGFβ Binding Protein (LTBP) during the secretion process. LTBP binds the extracellular 
matrix and sequesters LAP-TGFβ (Annes et al, 2003). Thus, the matrix acts as a reservoir from which 
TGFβ can readily be mobilized without the need for new synthesis (Taipale et al, 1998). Through the 
activities of various proteases LAP and LTBP are cleaved to release the highly stable, bioactive TGFβ 
(Shi & Massagué, 2003). Thus, the inactive complex can be activated for example by the 
metalloproteases MMP-9 and MMP-2, which are frequently expressed by malignant cells, especially 
at sites of tumor cell invasion (Yu & Stamenkovic, 2000; Stamenkovic, 2000; Stetler-Stevenson, 2001). 
Therefore, various mechanisms regulate TGFβ activation in different physiological contexts. The active 
TGFβ1 ligand is a 25 kDa dimer, covalently linked by a disulfide bond between cysteine residues from 
each monomeric peptide.  
TGFβ signals through association with a complex of two types of transmembrane serine/threonine 
kinases and binds first a homodimer of TGFβ type II receptors (TGFβRII) (Massagué, 1998). Binding of 
the ligand causes bridging of the preformed dimers of type II receptors and dimers of type I receptors 
to form heterotetrameric, active receptor complexes (Feng & Derynck, 2005). Within the active 
receptor complex, the TGFβRII, which is a constitutively active kinase, undergoes autophosphorylation, 
as well as catalyzes transphosphorylation of TGFβRI at several Ser and Thr residues in a domain that is 
rich in Glycine and Serine (Shi & Massagué, 2003). Phosphorylation of this GS-domain enables the 
recruitment of the receptor-regulated SMADs (R-SMADs) SMAD2 and SMAD3. Transphosphorylation 
of the TGFβRI activates kinase activity and the type I receptor then phosphorylates the R-SMADs at a 
C-terminal SSXS motif. Once phosphorylated, the R-SMADs form homotrimeric complexes or 
heterotrimeric complexes with the common mediator SMAD4 (Heldin et al, 1997, Shi & Massagué, 
2003). Trimers of one SMAD4 molecule and two receptor-phosphorylated R-SMAD molecules are the 
predominant effectors. The complexes then translocate to the nucleus, where they regulate the 
transcription of TGFβ target genes, like PAI-1, SMAD7, SMAD6, TIEG, SnoN, c-myc, p21, Snail, in 
conjunction with other transcription factors to coordinate the cellular response. (Schmierer & Hill, 
2007; Peinado et al, 2003; Subramaniam et al, 1995; Deheuninck & Luo, 2009; Boehm et al, 1999; Yan 
et al, 2009; Moustakas et al, 2002). A scheme is shown in Figure 1. 
Within the nucleus, the SMAD complexes reversibly dissociate and the monomeric phospho-R-SMADs 
are dephosphorylated by a nuclear phosphatase (Lin et al, 2006), upon which they join the pool of R- 
SMADs available for nuclear export. The cycle of SMAD activation and deactivation persists for as long 
as receptors are active (Inman et al, 2002b).  
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In the basal state, R-SMADs are predominantly localized in the cytoplasm, whereas SMAD4 is 
distributed in both the cytoplasm and the nucleus. SMAD proteins consist of two well-conserved 
domains connected by a proline-rich linker that differs substantially between the different SMAD 
classes. The main function of the SMAD N-terminal domain, or “Mad homology 1” (MH1) domain, is to 
bind DNA, except for SMAD2 which cannot bind DNA directly (Massagué, 1998; Yagi et al, 1999; Chai 
et al, 2003; Shi et al, 1998). The C-terminal domain, or MH2 domain, mediates protein- protein 
interaction with numerous regulator and effector proteins, including the TGFβ receptors, certain 
cytoplasmic anchor proteins, lineage-specific DNA-binding cofactors and chromatin modifiers 
(Massagué, 1998). Whereas the MH1 and MH2 domains are functionally well characterized, much less 
is known about the role of the interdomain linker region. The linker region is phosphorylated by kinases 
such as mitogen-activated protein kinases (MAPKs), glycogen synthase kinase-3 (GSK-3) and cyclin-
dependent kinases (cDKs) and is thus thought to integrate positive and negative regulatory inputs from 
other signaling pathways. Thus, CDK8/9-mediated phosphorylation in the linker region maximizes the 
transcriptional activity of R-SMADs by favoring interactions with co-activators (Alarcón et al, 2009). 
Likewise, in SMAD4, the region of the linker is involved in transcriptional activation, mediated by the 
coactivator histone acetyltransferase p300/ CBP (de Caestecker et al, 1997, de Caestecker et al, 2000). 
Moreover, GSK3 switches the linker region from a binding site for co- activators to a binding site for 
HECT family E3 ubiquitin ligases that mark R-SMADs for proteasome-mediated degradation (Aragón et 
al, 2011; Gao et al, 2009). Furthermore, phosphorylation of the R-SMADs in the linker region by 
extracellular signal-regulated kinases (ERKs) leads to sequestration of at least a proportion of the R-
SMADs in the cytoplasm, even in the presence of a TGFβ signal (Kretzschmar et al, 1997; Kretzschmar 
et al, 1999). Therefore, the linker region has a function in regulating the subcellular localization of 
SMADs.  
In conclusion, these phosphorylation events lead R-SMADs to peak transcriptional activity followed by 
degradation, constituting an activation-turnover switch in the SMAD signaling cycle. 
2.4 Regulatory mechanisms and dynamics of SMADs 
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2.3 Figure 1. Scheme of canonical TGFβ pathway activation. 
Scheme of the canonical TGFβ pathway. Extracellular TGFβ binds to TGFβ-receptors, thereby creating a binding platform 
for the proteins SMAD2 and 3. Binding of SMADs to the TGFβ receptors results in their phosphorylation and this leads to 
formation of complexes with SMAD4. These complexes then accumulate in the nucleus and regulate the expression of 
their target genes, like PAI-1, SMAD7, SMAD6, TIEG, SnoN, p21 and Snail. 
2.4 Regulatory mechanisms and dynamics of SMADs 
The fundamental step in TGFβ signaling is the translocation of the SMADs from the cytoplasm to the 
nucleus, however many regulatory mechanisms are involved to induce appropriate programs of gene 
expression, which in turn modulate cell behavior.  
The responses of cells to TGFβ depend on the ligand concentration to which they are exposed (Clarke 
et al, 2008). Therefore, cells are somehow able to sense the concentration of TGFβ ligands at the 
exterior of the cell and orchestrate a specific response. How cells read, interpret and respond to TGFβ 
concentration is thus a question of important relevance to understanding TGFβ signaling.  
In contrast to the rapid kinetics of signaling by tyrosine kinase receptors, the kinetics of SMAD 
phosphorylation are slow with SMAD2 phosphorylation peaking about 1 hour after ligand exposure, 
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then declining over the next hours (Schmierer & Hill, 2007, Inman et al, 2002b). Several mechanisms 
have been proposed to explain the signal intensity and duration (Itoh & ten Dijke, 2007). 
The recognition of R-SMADs by the receptors are facilitated by auxiliary proteins. Thus, a membrane-
associated protein, SARA (SMAD anchor for receptor activation), binds SMAD2 and SMAD3 in the 
cytoplasm and presents them to the activated type I receptors for phosphorylation and therefor 
promotes TGFβ signaling (Qing et al, 2000; Di Guglielmo et al, 2003; Hocevar et al, 2001; Tsukazaki et 
al, 1998). The interactions occur between a peptide sequence of SARA and an extended hydrophobic 
surface area on SMAD2/SMAD3 (Wu et al, 2000). SARA contains a phospholipid binding FYVE domain, 
which targets the molecule also to the membrane of early endosomes (Tsukazaki et al, 1998). These 
interactions allow more efficient recruitment of SMAD2 or SMAD3 to the receptors, since the activated 
receptor complex is internalized in SARA-rich early endosomes via clathrin- coated pits (Di Guglielmo 
et al, 2003; Hayes et al, 2002; Lu et al, 2002; Tsukazaki et al, 1998). 
Indeed, TGFβ signaling intensity and duration can be regulated through the control of receptor 
trafficking. The ligand bound activated receptor complex is internalized via endocytosis, although 
receptors are internalized constitutively with similar efficiencies in the absence and presence of a 
signal (Di Guglielmo et al, 2003; Chen, 2009). They internalize by two distinct, competing routes: either 
by clathrin-dependent internalization into EEA1-positive endosomes; or by a clathrin-independent, 
lipid-raft–caveolin-dependent pathway into a distinct endocytic compartment. Because EEA1-positive 
endosomes also contain SARA, internalization through clathrin-coated pits is thought to facilitate 
signaling. Ligand-bound receptor complexes in the early endosomes are further sorted to late 
endosomes, where TGFβ and the receptors are separated. Some of the unbound receptors can be 
recycled to the plasma membrane, while others are degraded, along with TGFβ, upon fusion with the 
lysosomes (Di Guglielmo et al, 2003). In contrast, endocytosis through caveolae shuffles TGFβ 
receptors into a distinct endocytic compartment that promotes receptor degradation. Multiple protein 
interactions are likely to control subcellular receptor localization and cell-surface receptor availability. 
These parameters may in turn control the duration of SMAD phosphorylation and activation, and thus 
give rise to qualitatively different responses resulting to a given TGFβ stimulus. 
Since TGFβ is not recycled, internalization of TGFβ by endocytosis is the primary means of removing 
active TGFβ from the cell surface, and lysosomal degradation is the primary means of termination of 
TGFβ signaling (Clarke et al, 2009; Zi et al, 2011). 
Once activated, the TGFβ family receptors are negatively regulated by the I-SMADs (inhibitory SMADs), 
SMAD6 and SMAD7 (Itoh & ten Dijke, 2007). I-SMADs have a clearly recognizable MH2 domain but are 
more divergent from the other SMADs in the N-terminal and central regions. I-SMADs are 
transcriptionally induced in response to TGFβ in a SMAD-dependent manner and can inhibit signaling 
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by distinct and diverse mechanisms. Both SMAD6 and SMAD7 can interact with type I receptors, thus 
competitively preventing R-SMADs from being phosphorylated. Furthermore, SMAD7 controls SMAD 
signaling by inducing receptor complex degradation through the recruitment of ubiquitin-ligases, 
SMURF1 and SMURF2. The TGFβ receptor-SMAD7-SMURF complex is internalized via caveolin-positive 
vesicles toward the proteasome for degradation (Di Guglielmo et al, 2003; Hayashi et al, 1997; Kavsak 
et al, 2000; Ebisawa et al, 2001; Zhang et al, 2001). In addition, SMAD7 was also shown to recruit and 
stabilize GADD34, a regulatory subunit of protein phosphatase-1 (PP1) to the activated TGFβ receptors, 
thereby inducing receptor dephosphorylation and deactivation (Shi et al, 2004). Moreover, SMAD7 has 
been proposed to bind to SMAD-responsive elements through its MH2 domain and to inhibit SMAD-
dependent promoter activation, indicating a nuclear role for SMAD7 (Zhang et al, 2007). 
Moreover, phosphatases such as PPM1A can deactivate phospho-R-SMADs, resulting in the 
disassembly of the SMAD complex and providing a means for negative regulation of TGFβ signaling in 
the nucleus (Clarke & Liu, 2008). 
The TGFβ dependent recruitment of Smad complexes to the transcription machinery also allows the 
accumulation of additional coactivators or corepressors, which regulate the amplitude of 
transcriptional activation. Besides the interaction of the SMAD complex with CBP/p300, SMAD4 can 
also engage another coactivator named MSG1 into the transcription complex to enhance the SMAD 
response (Shioda et al, 1998; Yahata et al, 2000). 
By contrast, recruitment of a corepressor decreases the SMAD and TGFβ responsiveness. The 
corepressors c-Ski or SnoN antagonize TGF- signaling through direct interactions with SMAD4 and the 
R-SMADs (Luo et al, 1999; Akiyoshi et al, 1999; Stroschein et al, 1999; Liu et al, 2001; Wang et al, 2000). 
SnoN-mediated negative regulation on the SMAD proteins is removed during TGFβ signaling by at least 
two distinct ways. In the presence of TGFβ signaling, SMAD2 interacts with both SnoN and SMURF2, 
allowing the HECT domain of SMURF2 to target SnoN for ubiquitin- mediated degradation by the 
proteasome (Bonni et al, 2001). SMAD2 and SMAD3 can also recruit the E3 ubiquitin ligase anaphase 
promoting complex (APC), resulting in the ubiquitination and degradation of SMAD bound SnoN 
(Stroschein et al, 2001; Wan et al, 2001). 
Furthermore, ubiquitin–proteasome-mediated degradation controls the levels of SMADs 
posttranslationally. Thus, C-terminally phosphorylated SMAD2 or SMAD3 can form a stable complex 
with SMURF2 and undergo proteasomal degradation that regulates nuclear R-Smad levels (Bonni et al, 
2001). Therefore, inhibition of proteasomal degradation enhances its nuclear accumulation (Lo & 
Massagué, 1999). However, only a small fraction of SMAD2 and SMAD3, in the absence or presence of 
TGFβ, is ubiquitinated. Thus, the bulk of nuclear SMAD2 or SMAD3 is not targeted for degradation, but 
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dephosphorylated and relocated to the cytoplasm (Inman et al, 2002b; Xu et al, 2002). Interestingly, 
sumoylation of SMAD4 enhances its stability (Lee et al, 2003). 
In conclusion, the cell has various means to regulate SMAD signal intensity and duration and positive 
and negative signals are equally important in controlling TGFβ signaling responses. 
2.5 Non- canonical TGFβ signaling and crosstalk with MAPK pathways 
The complexity of TGFβ signaling responses is influenced not only by core pathway components 
including ligands, receptors, SMADs and SMAD-dependent transcription factors, but also by the ability 
of TGFβ receptors to activate other SMAD-independent (non- canonical) pathways, including the 
mitogen-activated protein kinase (MAPK) pathways. Indeed, SMAD signaling interacts with a complex 
network of cross-talks with other signaling pathways that modify the initial SMAD signals and result in 
the multitude of effects induced by TGFβ. Thus, TGFβ has been shown to activate MAPK pathways in 
many cell types (Wakefield and Roberts, 2002; Derynck and Zhang, 2003). The MAPK cascades are key 
membrane-to-nucleus signaling modules that respond to various stimuli resulting in the 
phosphorylation and regulation of transcription factors, co-regulatory proteins and chromatin proteins 
required for gene expression. They mainly comprise three subfamilies: the extracellular signal-
regulated kinases (ERKs), the c-Jun N-terminal kinases (JNKs) and the p38/MAPKs (Chang and Karin, 
2001). The mechanisms of crosstalk cover among others regulation of co-activators and co-repressors 
recruited during the process of transcription, regulation of R-SMADs activity through phosphorylation, 
regulation of I-SMADs (SMAD6,7) expression and other interactions that could activate or inhibit 
certain molecules in the pathways (Zhang & Derynck, 1999). Downstream activation of distinct MAPK 
pathways by TGFβ occur either with slow or rapid kinetics. Slow activation of these pathways is 
mediated by SMAD-dependent transcription responses whilst the rapid activation is mediated by 
SMAD-independent responses (Hartsough & Mulder, 1995).  
The p38 MAPK pathway is activated by several stresses such as heat shock, osmotic shock and hypoxia 
and plays diverse roles in cell proliferation, differentiation, survival and migration in different cell 
types. Moreover, p38 MAPK is involved in sustaining tumor growth (Fang & Richardson, 2005). p38 is 
at the tertiary layer of MAPK cascades, as it is activated by MAP kinase kinases (MKKs) through 
phosphorylation: specifically by MKK3 and MKK6 and sometimes by MKK4 (Yamashita et al, 2008; 
Sorrentino et al, 2008; Hanafusa et al, 1999; Sano et al, 1999; Yu et al, 2002). Further upstream, MKKs 
are activated by the MAP3Ks, like MAP3K 4, 10 and the TGFβ-activated kinase 1 (TAK1). A scheme is 
shown in Figure 2A. A direct physical interaction between TGFβ type II receptor and TAK1 was found 
(Watkins et al, 2006). TRAF6, which plays an important role in the activation of TAK1, was reported to 
be essential for TGFβ-induced activation of the TAK1/p38 pathways (Yamashita et al, 2008; Sorrentino 
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et al, 2008). Besides SMAD-dependent pathways, the TRAF6-TAK1-p38 pathway is fundamental for 
TGFβ- induced apoptosis and EMT. Thus, knockdown of TRAF6 inhibited TGFβ-mediated EMT 
(Yamashita et al, 2008). TGFβ induces both a rapid and a late activation of p38 in a cell-type-specific 
manner. Rapid and transient p38 activation has been observed in numerous cell types including human 
neutrophils, HEK293 and C2C12 cells, and may be mediated by activation of TAK1. In contrast, the 
delayed and sustained p38 activation reported in pancreatic carcinoma cells, hepatocytes or 
osteoblasts, requires SMAD-mediated expression of Gadd45b, an upstream activator of MKK4 
(Takekawa et al, 2002). Furthermore, cooperation with the p38 pathway enables TGFβ-induced growth 
arrest (Kamaraju and Roberts, 2005) through phosphorylation of the R-SMAD linker region, resulting 
in an increased transactivation potential of R-SMADs, finally leading to cell cycle arrest. Moreover, 
MAPKs may indirectly influence SMAD signaling by controlling SMAD7 expression depending on the 
cell type (Uchida et al, 2001; Dowdy et al, 2003). Interestingly, the p38 pathway regulates post-
translational modifications of SMADs, since p38 is involved in sumoylation of SMAD4, contributing to 
enhanced SMAD4-dependent transcription (Ohshima and Shimotohno, 2003). 
The ERK 1/2 pathway is known to promote cell growth and survival (Lu & Xu, 2006), but under certain 
conditions it can have pro-apoptotic effects. Since the initial reports that TGFβ activates ERK1/2 in 
epithelial cells and breast cancer cells (Hartsough and Mulder, 1995), ERK1/2 activation has been 
linked to a number of TGFβ-regulated cellular events, including p21Cip1 gene expression and growth 
arrest (Hartsough et al, 1996; Frey and Mulder, 1997), EMT (Zavadil et al, 2001) and breast cancer 
development (Dumont et al, 2003). The kinetics of ERK phosphorylation induced by TGFβ depend on 
the cell type and physiological state of the cell. In diverse cell lines, a delayed response of ERK to TGFβ 
was found, typically with the peak of ERK phosphorylation occurring hours after ligand stimulation, 
suggesting an indirect response requiring protein translation (Simeone et al, 2001). In contrast, in 
epithelial cells, breast cancer cells and fibroblasts, activation can occur rapidly within 5–10 min of TGFβ 
stimulation, which is comparable to the time course of ERK activation by mitogenic factors such as EGF 
(Olsson et al, 2001; Frey & Mulder, 1997). TGFβ receptors directly participates in the activation of ERK 
by recruiting and phosphorylating Src Homology 2 Domain-Containing Transforming Protein 1 (ShcA) 
on its serine and tyrosine residues. The phosphorylated ShcA then associates with TGFβR1 via its 
phosphotyrosine-binding domain and recruits growth factor receptor binding protein 2 (Grb2) and Sos 
proteins, that activates the Ras–Raf–MEK1/2–ERK1/2 cascade pathways (Lee et al, 2007; Rojas et al, 
2009). A scheme is shown in Figure 2B. ERK and Ras then regulate target gene transcription through 
their downstream transcription factors in conjunction with SMADs to control the cellular response (Lee 
et al, 2007). Moreover, it has been shown that activation of ERK result in the phosphorylation of the 
linker segments of SMAD1, SMAD2 and SMAD3, which blocks their nuclear translocation (Kretzschmar 
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et al, 1997, 1999). This could explain how oncogenic Ras overrides TGFβ-mediated growth arrest in 
cancer cells (Kretzschmar et al, 1999). Other studies have not found impaired nuclear translocation of 
SMADs in Ras-transformed cells or in cells with activated MAPK signaling (de Caestecker et al, 1998; 
Funaba et al, 2002; Engel et al, 1999). The TGFβRs also play an important role in the ERK-TGFβ 
crosstalk. Mainly, the expression levels and the ratio of TGFβR2/ TGFβR1 hetero-oligomers contribute 
to different downstream signaling modules (Huang et al, 2011]. Furthermore, TGFβ-induced activation 
of Ras/ERK MAPK signaling can induce TGFβ1 expression, thereby amplifying the TGFβ response and 
inducing secondary TGFβ responses (Yue & Mulder, 2000). Furthermore, cooperativity between 
Ras/MAP kinase signaling and TGFβ signaling has been reported during tumor development (Oft et al, 
1996; Lehmann et al, 2000). In kidney epithelial cells, activation of Raf confers protection against 
TGFβ-induced apoptosis while enhancing its pro invasive effects (Lehmann et al, 2000), and induction 
of EMT in breast tumor cells is dependent on the presence both of activated Ras and of a functional 
TGFβ autocrine loop that is enhanced by Ras (Lehmann et al, 2000; Xie et al, 2004). 
The c-Jun N-terminal kinase (JNK) cascade controls several transcription and non-transcription factors 
in response to external stimuli and is involved in various biological processes including cell 
proliferation, apoptosis and tumor development. TGFβ stimulation rapidly increased JNK activity 
(within 5–10min) (Yue et al, 2004). JNKs are a third layer of MAPK cascade activated by upstream 
MKKs—MKK4 and MKK7. The rapid SMAD-independent activation of JNK through TGFβ is 
accomplished specifically through a MKK4–TAK1 axis (Yamashita et al, 2008; Sorrentino et al, 2008). 
The TRAF6–TAK1–JNK cascade, in cooperation with SMADs, is reported to regulate TGFβ-mediated 
apoptosis and EMT (Sorrentino et al, 2008; Liu et al, 2012) suggesting a close conjunction between 
these cellular outcomes. Moreover, overexpression of SMAD7 has been shown to induce persistent 
JNK activation in HepG2 cells (Mazars et al, 2001). Also, the JNK pathway may contribute to regulate 
autocrine TGFβ1 expression, as JNK-deficient fibroblasts constitutively express TGFβ1 expression that 
can be repressed by complementation of the cells with JNK (Ventura et al, 2004). 
Thus, the balance between direct activation of SMADs and MAPK pathways determines the outcome 
of cellular response to TGFβ. 
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2.5 Figure 2. Scheme of non-canonical TGFβ pathway activation. 
A Scheme of the non-canonical p38 MAP Kinase pathway upon TGFβ activation. TGFβ receptors activate MAP3Ks 
(Mitogen-activated protein kinase kinase kinases or MEKKs) like TAK1 (Transforming growth factor beta-activated kinase 
1 or MAP3K7), which in turn activates MKKs (Mitogen-activated protein kinase kinases) like 3, 4, 6 and finally 
phosphorylate p38. 
B Scheme of the non-canonical ERK MAP Kinase pathway upon TGFβ activation. TGFβ can induce phosphorylation of the 
receptors I and II and on Shc, which leads to recruiting of Grb2/Sos to activate Erk 1/2 (pp44/pp42) through Ras, Raf, and 
MEK1 (Mitogen-activated protein kinase kinase 1) and 2.  
2.6 Aim of the study 
The TGFβ pathway is a multi-functional signaling system regulating various cellular processes. 
Moreover, TGFβ signaling plays a dual role in cancer. The mechanisms underlying the basis of these 
wide range of physiological effects to TGFβ have not been elucidated in detail. Therefore, I aimed to 
clarify to what extent signaling dynamics determine the cellular fate upon TGFβ stimulation. 
As the cellular response to a given stimulus often varies even in genetically identical cells, my approach 
will be to study TGFβ dynamics at the level of single cells. I am using the cellular model system MCF10A, 
a human non-cancerous breast epithelial cell line. By combining fluorescent reporter cell lines with 
live-cell microscopy and automated image analysis, I monitor the cytoplasmic to nuclear translocation 
of SMADs with high temporal and spatial resolution in hundreds of individual cells. Using this approach, 
I investigate how SMAD signaling encode information in individual cells over time and study how the 
TGFβ network architecture shape its dynamic response. 
Moreover, I focus on understanding dynamic network interactions and thus, I examine the function of 
distinct interaction partners in the networks and investigate how the canonical and non- canonical 
pathways interact to determine long-term dynamics and specify cellular decisions. 
I plan to investigate how dynamics are translated into physiological responses to predict these and 
understand how a misregulated pathway can lead to cancer. 
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3 RESULTS 
3.1 Dynamics and variability of SMAD signaling in single cells 
3.1.1 Live-cell reporter for TGFβ pathway activation 
In order to get a systematic view of TGFβ dynamics and to follow pathway activation in single cells by 
monitoring the translocation of SMADs from the cytoplasm to the nucleus with high temporal and 
spatial resolution, I combined fluorescent reporter cell lines with live-cell microscopy and automated 
image analysis. First, I established stable clonal reporter cell lines for SMAD2 and SMAD4 by expressing 
a fusion of the corresponding cDNA with the yellow fluorescent protein mVenus (YFP) under the 
control of a constitutive promoter (UbCp) in the TGFβ-responsive breast epithelial cell line MCF10A 
(Figure 3A, 6.2, Soule et al, 1990; Debnath et al, 2003). A constitutive promoter can be used, because 
neither SMAD2 nor SMAD4 are transcriptionally regulated upon TGFβ treatment  and translocation of 
the YFP-SMAD2 or YFP-SMAD4 fusion protein into the nucleus acts as a surrogate for the activity of 
the pathway. In addition, the cell lines also stably express the nuclear marker histone H2B-CFP under 
the control of UbCp to track the nucleus over time and enable automated image analysis (Figure 3A).  
Next, to measure SMAD nuclear translocation quantitatively in hundreds of individual living cells, I 
performed time-lapse microscopy imaging every five minutes over a 24h time interval after stimulation 
with a saturating TGFβ concentration of 100pM. As expected (Nicolás et al, 2004; Schmierer & Hill, 
2005), initially SMADs are predominantly located in the cytoplasm, followed by strong accumulation 
into the nucleus after TGFβ treatment until adaptation mechanisms and negative feedback loops 
terminated pathway activation and SMADs shuttled back to the cytoplasm. I employed automated 
image analysis to measure the changing fluorescent intensities of the fusion proteins (YFP-SMADs) 
over time in the nucleus by tracking the nuclear H2B-CFP marker. Furthermore, cytoplasmic SMAD 
intensities were taken as the average YFP intensities in a ring around the nuclear area (6.6). Finally, I 
determined the signaling pathway activity as the ratio of the average nuclear and cytoplasmic 
intensities (nuc/cyto SMAD ratio), as this measure was robust against correlated fluctuations due to 
heterogeneity of transgene expression or measurement aberrations such as photobleaching or 
unequal illumination. In Figure 3B & C, one individually tracked cell of the YFP-SMAD2- reporter cell 
line was analyzed and the resulting trajectories of nuclear, cytoplasmic and ratio SMAD2 levels are 
presented. Before TGFβ treatment SMAD2 was located in the cytoplasm and accumulated in the 
nucleus within 1h of stimulation. Followed then by a strong adaption phase where SMAD2 re-localized 
to the cytoplasm, before it accumulated again in the nucleus around 8h after the initial response and 
re- localized to the cytoplasm. Figure 3D & E represent one individual tracked and analyzed cell of the 
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YFP-SMAD4- reporter cell line. After TGFβ stimulation SMAD4 shuttled from the cytoplasm to the 
nucleus within 1h, followed by a short adaption phase and a second re-location in the nucleus with a 
subsequent re-localization to the cytoplasm.  
 
 
 
 
 
3.1.1 Figure 3. Live-cell time-lapse microscopy of the reporter cell lines. 
A Fluorescent reporter system to measure SMAD signaling dynamics in individual cells. SMAD2 was fused to the yellow 
fluorescent protein mVenus (YFP) under the control of the human ubiquitin C promoter (UbCp) with the selection marker 
3.1.2 Verification of these reporters by comparing kinetics of endogenous and tagged proteins 
19 
 
G418 (Geneticin). As a nuclear marker, histone 2B (H2B) was fused to the cyan fluorescent protein mCerulean (CFP) under 
the control of UbCp with the selection marker hygromycin. 
B Live-cell time-lapse microscopy images of MCF10A cells expressing SMAD2-YFP following treatment with 100pM TGFβ. 
White circles indicate the segmented nucleus, and the estimated cytoplasmic area is represented by red annuli. 
C The indicated cell in (A) was tracked over 24 hours (h) and the corresponding nuclear (nuc) level, cytoplasmic (cyto) level 
and the nuclear-to-cytoplasmic (nuc/cyto) SMAD2-YFP ratio was plotted over time. 
D Live-cell time-lapse microscopy images of MCF10A cells expressing SMAD4-YFP following treatment with 100pM TGFβ. 
White circles indicate the segmented nucleus, and the estimated cytoplasmic area is represented by red annuli. 
E The indicated cell in (C) was tracked over 24 hours (h) and the corresponding nuclear (nuc) level, cytoplasmic (cyto) level 
and the nuclear-to-cytoplasmic (nuc/cyto) SMAD4-YFP ratio was plotted over time. 
3.1.2 Verification of these reporters by comparing kinetics of endogenous and tagged 
proteins  
The next step was to validate these reporter cell lines to make sure that the dynamics and cellular 
response of TGFβ signaling are not disturbed. As shown in Figure 4A Western Blot experiments 
revealed that the YFP-SMAD2 or YFP-SMAD4 fusion proteins are expressed at lower levels, 
corresponding to approximately 65% or 32.5% of endogenous proteins in the parental WT cell line, 
respectively. Data points for 0h, 2h and 3h post TGFβ stimulation are shown. This overexpression 
apparently did not change the dynamics of SMAD signaling, since I observed similar TGFβ- induced 
phosphorylation profiles of endogenous SMAD2 in the parental WT and YFP-SMAD2 reporter cell line 
by Western Blot analysis (Figure 4B). Immunofluorescence experiments indicated that the kinetics of 
endogenous SMADs at fixed time points in the parental WT cell line reflected changes at the 
corresponding time points in the nuc/cyto ratio of the SMAD2 or SMAD4 reporter cell lines measured 
by live- cell imaging (Figure 4C). By staining the nucleus of the fixed cells with Hoechst, nuclear SMAD2 
or SMAD4 intensities could be calculated over time. Furthermore, cytoplasmic SMAD intensities were 
taken as the average YFP intensities in a ring around the nuclear area. Exemplary fixed cells for 0, 1 
and 8h post TGFβ stimulus are shown in Figure 4D.  
Finally, I checked the induction of well-characterized SMAD2/4 target genes (SMAD7, SnoN and PAI-1) 
in response to TGFβ stimulation by RT-PCR and observed essentially no differences between the 
parental WT and reporter cell lines (Figure 5A & B). 
In conclusion the validation experiments showed comparable dynamics of endogenous and tagged 
proteins and did not alter the cellular response to TGFβ stimulus. Therefore, the SMAD2 and SMAD4 
reporter faithfully represents the activity of the pathway. 
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3.1.2 Figure 4. Verification of the reporter cell lines by comparing kinetics of endogenous and tagged proteins. 
A Western blot analysis of endogenous and YFP-tagged SMAD2 or SMAD4 in stable clonal reporter cell lines and the 
corresponding parental cell line. Cells were stimulated with 100pM TGFβ and analyzed after 2 and 3 h. GAPDH was used 
as a loading control.  
B Western blot analysis of SMAD2 activation in SMAD2-YFP reporter and parental MCF10A cells. Cells were stimulated 
with 100pM TGFβ, and SMAD2 phosphorylation was analyzed at indicated time points. GAPDH was used as a loading 
control. 
C Comparison of endogenous SMAD2 and SMAD2-YFP translocation or SMAD4 and SMAD4-YFP translocation. The 
nuc/cyto ratio of SMAD-YFP upon 100pM TGFβ stimulation was measured in reporter cells by time-lapse microscopy at 
the indicated time points; the nuc/cyto ratio of endogenous SMAD2 and SMAD4 was measured in parental MCF10A WT 
cells by immunofluorescence under the same conditions. Data was normalized by minimum subtraction and division 
through the overall maximum.  
D Exemplary MCF10A WT cells for immunofluorescence analyzed in (A). The nucleus was stained with Hoechst and labeled 
with a red ring. For SMAD2, the secondary antibody Alexa Fluor 488 and for SMAD4 Alexa Fluor 647 were used. Cytoplasmic 
SMAD2 area is represented by red annuli. 
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3.1.2 Figure 5. Verification of the reporter cell lines by comparing kinetics of target genes by RT-qPCR 
A Expression of SMAD target genes in parental and SMAD2 reporter cell lines. Expression kinetics of SMAD7, SnoN and 
PAI-1 upon 100pM TGFβ stimulation were measured by RT-qPCR at indicated time points. β-Actin was used as an internal 
control. Error bars indicate standard deviation of technical triplicates.  
B Expression of SMAD target genes in parental and SMAD4 reporter cell lines. Expression kinetics of SMAD7, SnoN and 
PAI-1 upon 100pM TGFβ stimulation were measured by RT-qPCR at indicated time points. β-Actin was used as an internal 
control. Error bars indicate standard deviation of technical triplicates.  
3.1.3 Average SMAD dynamics are TGFβ dose dependent 
In order to investigate TGFβ pathway activity I examined the dynamics of SMAD2 and SMAD4 under 
varying TGFβ concentrations (0, 1, 2.5, 5, 25 and 100pM TGFβ) over a 24h time period of hundreds of 
cells by time-lapse imaging (Figure 6A). By analyzing the median nuc/cyto SMAD2 ratio of the cell 
population, one synchronous initial response of SMAD translocation at 1h, followed by adaptation 
could be monitored. Specifically, I observed that a decrease in the TGFβ concentration lowers the peak 
amplitude, renders signaling more transient and leads to rapid adaptation to the pre-stimulus level. 
Cells stimulated with 100pM TGFβ are characterized by a saturated amplitude, strong adaption phase 
and a second lower signaling plateau afterwards. The nuclear and cytoplasmic SMAD2 level reflected 
the ratio values. The SMAD4 reporter showed a comparable median response when cells treated with 
varying TGFβ doses, although with a lower amplitude of the initial response (Figure 6B). In summary, 
the average SMAD dynamics are TGFβ dose dependent.  
As shown in Figure 6C the median nuc/ cyto ratio of the cell population was very reproducible between 
biological replicates for 2.5pM and 100pM TGFβ treated cells. 
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3.1.3 Figure 6. Average SMAD dynamics are TGFβ dose dependent. 
A Median nuc/cyto SMAD2 ratio, nuclear (nuc) and cytoplasmic (cyto) level of cells stimulated with 0, 1, 2.5, 5, 25 or 
100pM TGFβ and tracked over 24h. Shaded area represent data between 25th and 75th percentiles.  
B Median nuc/cyto SMAD4 ratio of cells stimulated with 0, 1, 2.5, 5, 25 or 100pM TGFβ and tracked over 24h. Shaded area 
represent data between 25th and 75th percentiles.  
C Median SMAD2-YFP ratio of cells plated in three independent glass bottom plates stimulated with 2.5 or 100pM TGFβ 
at the same day and tracked over 24h (biological triplicates). Shaded area represent data between 25th and 75th 
percentiles. 
3.1.3.1 Target genes are TGFβ dose dependent 
TGFβ is known to control multiple cell fates in a TGFβ- concentration manner (Schmierer & Hill, 2007). 
In support of these effects, I checked the impact of different TGFβ doses, and therefor different 
corresponding SMAD dynamics, on target gene expression (SMAD7, PAI1 and TIEG). Cells were 
simultaneously stimulated with 1, 2.5, 5, 25 and 100pM TGFβ and harvested at defined time points 
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during 24h post stimulus. RT-PCR measurements revealed that changing the TGFβ stimulus alters the 
induction levels of the selected target genes in cell populations (Figure 7). The first peak appeared to 
be strongly TGFβ concentration-dependent in a graded manner, while this correlation slightly 
diminished at later time points. However, target gene expression 24h after the 100pM TGFβ stimuli 
show clear differences in comparison to lower doses. In particular PAI-1 represents a more switch-like 
behavior. While expression decreased to basal levels after a maximum at 3 or 6h for concentrations of 
25pM or below, stimulation with 100pM led to an about 20-fold induction at the end of the 
observation period. In conclusion expression of TGFβ target genes are dose-dependent like the median 
response in the time-lapse data. 
 
3.1.3.1 Figure 7. Target genes are TGFβ dose dependent. 
Expression of SMAD target genes in MCF10A WT cells with varying concentrations of TGFβ over 24h. Expression kinetics 
of SMAD7, PAI-1 and TIEG were measured by RT-qPCR at indicated time points. β-Actin was used as an internal control. 
Error bars indicate standard deviation of technical triplicates. 
3.1.3.2 Target genes are stimulation period dependent 
Since target gene expression correspond to the average TGFβ dose response of SMADs, these finding 
further leads to the question which phases or stimulation periods are essential for the full target gene 
transcription and the cellular outcome. Thus, I terminated the TGFβ response after 0.25, 0.75, 1.5, 3, 
4.5, 6 and 8 hours by washing out the media five times and measured subsequently by RT-PCR the 
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expression of target genes (PAI-1 and SnoN) 24 hours post TGFβ treatment (Figure 8A). Interestingly, 
the full 24h TGFβ stimulation was necessary for the induction of PAI-1 and SnoN and shorter 
stimulation periods had no effect on the cells (Figure 8B). In summary the cells reacted to the current 
TGFβ state and needed long-term stimulation and continued SMAD signaling to achieve full target gene 
transcription 24 hours post TGFβ. Consequentially I was interested in the memory of the system, 
mainly determined by signaling adaptation and mRNA decay.  Thus, I stimulated the cells either for 1 
hour or 6 hours with 100pM TGFβ and terminated the stimulation with the TGFβReceptor I Kinase 
inhibitor SB431542 and measured the target gene expression every 0.5- 1h post termination (Figure 
8C). First of all, the memory time of the mRNA response was gene dependent. In Detail SMAD7 and 
TIEG mRNA got back to basal level after 2 hours and PAI-1 after 4.5 hours post termination and even 
dipped below basal level (Figure 8D). These observations confirmed that cells respond strongly to the 
current TGFβ state and full gene expression depends on sustained SMAD signaling including the 
different phases.  
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3.1.3.2 Figure 8. Target genes are stimulation period dependent. 
A Scheme of experimental setup. TGFβ response was terminated after 0.25, 0.75, 1.5, 3, 4.5, 6 and 8 hours by washing out 
the media five times (red line) and the expression of target genes (PAI-1 and SnoN) 24h post 100pM TGFβ treatment (blue 
line) were measured. The median nuc / cyto SMAD2 ratio of time-lapse microscopy experiments upon 100pM TGFβ 
stimulation is shown for illustrative purposes. 
B Expression of SMAD target genes in MCF10A WT cells with varying duration of 100pM TGFβ stimulation. Expression of 
PAI-1 and SnoN were measured by RT-qPCR at 24h post TGFβ stimulation with indicated stimulation periods. Control (co) 
was measured at time point 0 without TGFβ treatment. β-Actin was used as an internal control. Error bars indicate 
standard deviation of technical triplicates. 
C Scheme of experimental setup. Cells were stimulated with 100pM TGFβ either for 1h or 6h and terminated with the 
TGFβReceptor I Kinase inhibitor SB431542 (orange line) and target gene expression every 0.5- 1h post termination was 
measured (blue line). The median nuc / cyto SMAD2 ratio of time-lapse microscopy experiments upon 100pM TGFβ 
stimulation is shown for illustrative purposes. 
D Expression of SMAD target genes in MCF10A WT cells with varying duration of 100pM TGFβ stimulation. Expression 
kinetics of SMAD7, PAI-1 and TIEG upon 100pM TGFβ stimulation and termination at 1h or 6h with the TGFβReceptor I 
Kinase inhibitor SB431542 were measured by RT-qPCR at indicated time points. β-Actin was used as an internal control. 
Error bars indicate standard deviation of technical triplicates.  
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3.1.4 SMAD translocation depends on receptor activity at all time points 
The next step was to verify that nuclear translocation of SMADs in the reporter systems depend on 
TGFβ receptor activity. From literature is known, that the TGFβR I Kinase inhibitor SB431542 
immediately prevents phosphorylation and therefore nuclear accumulation of SMAD2 (Inman et al, 
2002a).  Western Blot experiments in MCF10 WT cells confirmed that phosphorylation of SMAD2 is 
prevented when receptor 1 is inhibited 45 min before TGFβ stimulation (Figure 9). SMAD2 reporter 
cells treated with the specific inhibitor at the same time or 30 minutes before TGFβ stimulation showed 
no accumulation in the nucleus at all, while inhibitor treatment 1h after TGFβ stimulation rapidly and 
synchronously terminated the response and ratio values 2 hours post termination are comparable to 
DMSO treated control cells (3.5 hours of time-lapse imaging) (Figure 10A, B & C). Interestingly, 
inhibitor treatment 6h after TGFβ stimulus showed that the late SMAD2 response is also fully receptor-
dependent, since ratio values are comparable 1-hour post termination to control cells (7.5 hours of 
time-lapse imaging). The SMAD4 reporter cell line showed similar results (Figure 10D). In conclusion 
the TGFβ response of the reporter cell lines was at all time points receptor-dependent. 
 
3.1.4 Figure 9. SMAD translocation depends on receptor activity at all time points shown in western blot experiment.  
Western blot analysis of MCF10A WT cells treated with the TGFβReceptor I Kinase inhibitor SB431542 (TGFβRi) 0.75h pre 
100pM TGFβ stimulation. SMAD2 phosphorylation was analyzed at indicated time points. GAPDH was used as a loading 
control. 
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3.1.4 Figure 10. SMAD translocation depends on receptor activity at all time points shown in time-lapse microscopy 
experiments. 
A Median nuc/cyto SMAD2 ratio of reporter cells stimulated with 100pM TGFβ and treated with TGFβReceptor I Kinase 
inhibitor SB431542 (TGFβRi) at indicated time points. DMSO was used for the control. Shaded area represent data between 
25th and 75th percentiles. 
B Heat maps of SMAD2 translocation in individual cells over 24h. Cells were stimulated with 100pM TGFβ and treated with 
TGFβReceptor I Kinase inhibitor SB431542 (TGFβRi) at indicated time points. Each horizontal line represents a single cell 
and the nuc/cyto ratio is shown as indicated in the legend. Cells were sorted by the time of the first division as indicated 
by red marks.  
C Nuc/cyto SMAD2 ratio values at 1.5, 3.5, 6.5 and 7.5h for reporter cells stimulated with 100pM TGFβ and treated with 
TGFβReceptor I Kinase inhibitor SB431542 (TGFβRi) at indicated time points. White lines indicate median; boxes include 
data between the 25th and 75th percentiles; whiskers extend to maximum values within 1.5× the interquartile range; 
crosses represent outliers. 
D Median nuc/cyto SMAD4 ratio of reporter cells stimulated with 100pM TGFβ and treated with TGFβReceptor I Kinase 
inhibitor SB431542 (TGFβRi) at indicated time points. DMSO was used for the control. Shaded area represent data between 
25th and 75th percentiles. 
3.1.5 SMAD translocation is dynamic and heterogeneous in individual cells  
So far I only analyzed median dynamics across the population.  However, heat maps of treated SMAD2 
reporter cells with varying TGFβ doses showed a high cell-to-cell variability for all conditions (Figure 
11A). Focusing on one specific concentration of 100pM TGFβ, several example trajectories and the 
median of the population demonstrate the broad variability of dynamics, although all cells were 
genetically identical (Figure 11B). In Figure 11C five reacting single cells are highlighted and compared 
to the median 100pM TGFβ response. While the first cell showed a very high peak amplitude, strong 
adaptation and moderate second signaling, the second one was marked by a lower amplitude and 
adaptation to a very low signaling plateau afterwards. The third and fourth cell were characterized by 
even two or three nuclear translocation peaks and the last one was marked by a low first amplitude 
and a strong late accumulation of SMAD2. These complex and heterogeneous dynamics were not 
limited to saturating TGFβ concentrations, as I also noticed pronounced variability when treating the 
cells with lower ligand concentrations (Figure 11D). Analysis of the SMAD4 reporter cell line also 
revealed, that the extent and duration of SMAD nuclear accumulation was highly variable (Figure 11E). 
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3.1.5 Figure 11. SMAD translocation is dynamic and heterogeneous in individual cells.  
A Heat maps of SMAD2 translocation in individual cells over 24h. Cells were stimulated with varying concentrations of 
TGFβ. Each horizontal line represents a single cell and the nuc/cyto ratio is shown as indicated in the legend. Cells were 
sorted by the time of the first division as indicated by red marks.  
B Time-resolved analysis of the SMAD2 nuclear to cytoplasmic localization for individual cells (thin lines) compared to the 
median nuc/cyto SMAD2 ratio of the entire population (thick line) upon stimulation with 100pM TGFβ.  
C Exemplary individual cells (thin lines) compared to the median nuc/cyto SMAD2 ratio of the entire population (thick line) 
upon stimulation with 100pM TGFβ.  
D Time-resolved analysis of the SMAD2 nuclear to cytoplasmic localization for individual cells (thin lines) compared to the 
median nuc/cyto SMAD2 ratio of the entire population (thick line) upon stimulation with 25, 5, 2.5, 1 and 0pM TGFβ. 
E Time-resolved analysis of the SMAD4 nuclear to cytoplasmic localization for individual cells (thin lines) compared to the 
median nuc/cyto SMAD4 ratio of the entire population (thick line) upon stimulation with 100, 25, 5, 2.5, 1 and 0pM TGFβ. 
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3.1.6 Extraction of signaling features from single cell data 
Next, to investigate the heterogeneous signaling more detailed, I extracted in collaboration with 
Marcel Jentsch single cell features in order to address the questions, which features change in a dose 
and time dependent manner and which of these features are robust and which are variable across 
individual cells. In Figure 12A I defined a complete response when increase and decrease are 
completed. Special features are schematically shown in Figure 12B. First, I examined the proportion of 
responding SMAD2 reporter cells for the varying TGFβ doses (Figure 12C). Almost all cells treated with 
5pM - 100pM TGFβ ligand reacted to the stimulus. Furthermore, over 90% for 2.5pM, nearly 65% for 
1pM and 20% of untreated cells responded above the threshold. The length of the first increase was 
robust over all conditions at about an hour, as well as the time of the maximum amplitude (around 2 
hours) for the whole time-lapse imaging. However, the maximum amplitude increased with rising TGFβ 
concentrations and showed already saturation for 25pM ligand concentration. Accordingly, the first 
slope (Amax - Amin) is maximal increased at 25pM TGFβ stimulation. The length of the first response is 
for all varying TGFβ concentrations 5 hours, only for 5pM TGFβ I noticed an extension to almost 7.5 
hours. In addition, this extension (about 7 hours) is also visible for the measured length of a complete 
response over the entire imaging period compared to 5 hours for the other ligand concentrations. 
Considering the integrated first response, a rise at 5pM TGFβ is apparent. Furthermore, the mean ratio 
value 5 hours after the first response is up to 25pM TGFβ increased and only for 100pM TGFβ was the 
final value after 24 hours of imaging significantly above the basal level. Moreover, feature detection 
of the SMAD4 reporter cell line showed similar results, although the proportion of responding cells 
was lower than for SMAD2 (Figure 12D). Over 80% for 25 and 100pM, over 70% for 5pM and 2.5pM, 
over 50% for 1pM and less than 30% of untreated cells responded above the threshold.  
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3.1.6 Figure 12. Extraction of signaling features from single cell data. 
A Scheme for defining a complete response (in yellow) consisting of increase (red) and decrease (green) using an exemplary 
individual cell. 
B Scheme of the individual signaling features and representation on an exemplary individual cell (Amax = maximum amplitude, 
time Amax = time maximum amplitude, Amin= basal level). 
C Signaling features for the SMAD2 reporter cells stimulated with varying TGFβ concentrations as indicated. White lines 
indicate median; boxes include data between the 25th and 75th percentiles; whiskers extend to maximum values within 1.5× 
the interquartile range; crosses represent outliers. 
D Signaling features for the SMAD4 reporter cells stimulated with varying TGFβ concentrations as indicated. White lines 
indicate median; boxes include data between the 25th and 75th percentiles; whiskers extend to maximum values within 1.5× 
the interquartile range; crosses represent outliers. 
3.1.7 Individual cells are clustered according to their dynamic response 
Next, I aimed to understand how phenotypic responses and cell fates of TGFβ can be specifically 
encoded by SMAD signaling. I hypothesized that the phenotypic effects are determined by the 
individual SMAD signaling pattern rather than by a specific ligand concentration applied to a 
population of cells. Since the separation of dynamic signaling responses according to varying TGFβ 
doses is not complete due to the strong cell- to- cell variability, we used a clustering approach to 
achieve a better separation in more homogenous groups. Marcel Jentsch established a method based 
on dynamic time warping (DTW) that calculates a distance matrix by pair-wise comparison of single 
time series and grouped cells according to this distance using hierarchical clustering. Applying all the 
cells from the varying TGFβ dose experiment (around 2000), cells were re-sorted in six clusters 
according to their dynamic behavior, irrespective of the stimulus level applied. The median response 
of cells in each cluster showed qualitatively distinct signaling behavior (Figure 13A). The identified 
signaling classes differ in their dynamic features, for instance in the amplitude, adaptation and late 
response. Cells in cluster 1 hardly respond to stimulation and can therefore be considered as non- 
responders. As expected this cluster shrinks with increasing TGFβ concentration (Figure 13B). Cells in 
other clusters respond either more transiently (cluster 2 and 3) or show sustained dynamics (cluster 
4-6). Specifically, cells in cluster 2 and 3 show barely a second response and differ in a lower (cluster 
2) and a very high amplitude with strong adaptation (cluster 3). Cluster 4 is characterized by lower 
amplitude, but a moderate late signaling response. While cluster 5 show a high amplitude and a strong, 
but shrinking second response, cluster 6 is marked by a strong and sustained second response with a 
moderate amplitude. Interestingly cluster 6 only exists for 100pM TGFβ. The distribution of the distinct 
signaling clusters changes with the stimulation dose of TGFβ. As expected, increasing ligand 
concentrations induce a shift from non-responders towards transient and then sustained signaling 
(Figure 13B). However, this separation is not sharp but rather gradual and obviously the clustering 
provides a better separation than sorting to different TGFβ concentration as shown in the silhouette 
plots (Figure 13C & D). The technique provides a graphical representation of how well each trajectory 
lies within its cluster. On the right side of each plot you can see trajectories that are more similar to 
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the own group and on the left side trajectories that are more similar to other groups. In conclusion 
these clusters are more homogeneous in SMAD dynamics than groups based on the TGFβ stimulation 
strength.  
 
 
3.1.7 Figure 13. Individual cells are clustered according to their dynamic response. 
A Individual cells were clustered into six signaling classes (cluster) according to their time-resolved nuc/cyto SMAD2 ratio 
using dynamic time warping (DTW). Each line represents the median over all cells of the indicated cluster. Cells stimulated 
with varying TGFβ concentrations were included in the analysis.  
B Distributions of signaling classes (cluster) depending on TGFβ dose.  
C Silhouette plots of cells sorted according to signaling classes (cluster). Plots provide a graphical representation of how 
well the nuc/cyto SMAD2 ratios of each cell correspond to trajectories of other cells in its own group according to the 
cDTW measure. Positive silhouette scores indicate that SMAD2 responses are more similar to the own group, while 
negative scores signify that the corresponding trajectory is closer to any of the other groups.  
D Silhouette plots of cells sorted according to TGFβ concentration.  
3.1.8 Cell fate decisions encoded in heterogeneous signaling dynamics 
In order to understand information processing, I finally addressed the question whether phenotypic 
responses and cell fates are primarily encoded by the extracellular ligand concentration or by specific 
dynamics of SMAD signaling. TGFβ is known to block proliferation and to induce migration based on 
EMT (Katsuno et al, 2013). Therefore, we quantified changes in proliferation by calculating the 
cumulative fraction of the dividing cells over time and motility based on the movement of each cell 
calculated by the summed distance in pixel made over the last 4 hours of time-lapse imaging. 
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Considering first the varying TGFβ doses, the results in Figure 14A revealed that cells divide slightly 
less with increasing extracellular TGFβ concentration. Furthermore, 1pM and 2.5pM TGFβ stimulated 
cells showed the same motility around 80 pixels as untreated cells (Figure 14B). 5pM- 100pM TGFβ 
stimulated cells move faster at around 100- 120 pixels. In contrast sorting cells by the distinct signaling 
clusters led to a better separation of phenotypic responses. Cluster 6 was characterized by a 
considerably lower fraction of dividing cells, cluster 5 and 4 showed an intermediate number of cell 
divisions and cluster 3 and 2 proliferated with the rate as non-responders (Figure 14C). In addition, 
motility increased with the cluster number (Figure 14D).  This data suggests that migration and 
proliferation may be controlled by different aspects of the dynamic SMAD signaling response. 
Migration tended to be affected already by a transient peak of SMAD translocation (cluster 2-5), 
whereas the anti-proliferative effects seemed to require sustained SMAD signaling (cluster 4-6) and a 
very high amplitude is not sufficient (cluster 3). It needs to be highlighted that a clear shift to migration, 
EMT and cell cycle arrest required a strong and sustained second signaling phase (cluster 6) rather than 
a high first amplitude. In conclusion, phenotypic responses and cell fate decisions are correlated with 
signaling classes of distinct long- term dynamic behavior.  
 
 
3.1.8 Figure 14. Cell fate decisions encoded in heterogeneous signaling dynamics. 
A Cell proliferation of SMAD2 reporter cells shown as fraction of dividing cells 24h after a varying TGFβ stimulus. Above 1 
means that cells have divided several times. 
B Motility of each cell as summed distance in pixel (pxl) covered between 20 and 24h after stimulation with varying TGFβ 
concentrations. Cells were sorted according to TGFβ concentrations. White lines indicate median; boxes include data 
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between the 25th and 75th percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses 
represent outliers.  
C Cell proliferation of SMAD2 reporter cells shown as fraction of dividing cells within 24h for the different signaling classes 
(cluster). Above 1 means that cells have divided several times. 
D Motility of each cell as summed distance in pixel (pxl) covered between 20 and 24h after stimulation with varying TGFβ 
concentrations. Cells were sorted according to signaling classes (cluster). White lines indicate median; boxes include data 
between the 25th and 75th percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses 
represent outliers. 
3.1.9 Combining smFISH of target genes with single cell trajectories  
Phenotypic responses and cell fate decisions are determined by modulated target gene expression. 
But it is still unknown how the highly heterogeneous SMAD dynamics encode and transmit information 
to the level of target gene expression. In order to gain a better understanding of the decoding of SMAD 
dynamics on the RNA level, I correlated the single-cell target gene expression of PAI- 1 with single-cell 
SMAD signaling by combining 3 hours and 14 hours of live- cell imaging of the SMAD2- reporter cell 
line stimulated with 25pM TGFβ with subsequent single molecule fluorescent in situ hybridization 
(smFISH). An illustration of the approach is shown in Figure 15A. In brief, cells are seeded on a 
relocation grid for the time-lapse microscopy experiment and SMAD2 translocation was measured and 
clustered as described in 3.1.1, 3.1.7 and 6.12. Subsequently, cells were fixed and specific PAI-1 probes 
for smFISH labeled with CalFluor-610 were applied and imaged as z-stacks. The RNA amount of each 
cell was calculated using Star Search analysis tool and matched manually to the identical tracked single 
cell from the microscopy experiment. Considering the absolute RNA counts per cell before treatment, 
3 hours or 14 hours post 25pM TGFβ ligand stimulation, the target gene expression also showed high 
cell-to- cell variability with a median of 59 RNA/cell at basal level, 444 RNA/cell (7.5 fold) at 3 hours 
and 242 RNA/cell (4.1 fold) at 14 hours (Figure 15B and C). Interestingly, the amount of PAI-1 at basal 
level had a wide distribution as indicated by a coefficient of variation (CV) of almost 1.2 (Figure 15D). 
More important was indeed how 3 hours of individual SMAD signaling correlate to the PAI-1 RNA count 
in the respective cell at 3 hours post stimulation, which correspond to the peak of PAI-1 target gene 
expression. First, I grouped the trajectories of SMAD2 signaling into 6 clusters, as illustrated in the heat 
map, and then looked at the distribution of the RNA to the respective cluster (Figure 15E). Although 
the clusters are characterized by distinct dynamic behavior, the RNA count per cell was around 400 for 
all clusters. I also grouped the RNA results into 3 clusters ranging from high to low RNA counts per cell 
and looked at the distribution of the respective median trajectories (Figure 15F). Obviously, the 
heterogeneous SMAD2 dynamics are not correlated with PAI-1 expression 3 hours post stimulation. 
However, considering 14 hours of individual SMAD signaling, I observed a correlation of long-term 
SMAD2 dynamics to the PAI-1 target gene expression. Similarly, I grouped the trajectories of SMAD2 
signaling into 4 clusters and then looked at the distribution of the RNA to the respective cluster (Figure 
15G). Cells in cluster 1 are marked by a low amplitude, low second signaling and a lower median count 
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of RNA per cell of 187. Cells of cluster 3 are characterized by a moderate amplitude, strong sustained 
signaling and a higher count of RNA per cell of 329.  While cells of cluster 2 showed an intermediate 
amplitude and intermediate second response, cells of cluster 4 showed a very high amplitude, strong 
but decreasing late response, both clusters showed intermediate counts of RNA per cell of around 240. 
Obviously, the first peak amplitude of SMAD2 dynamics is not responsible for the altered RNA 
distribution but features of the long-term dynamics since cluster 3 with a strong sustained late 
signaling showed the highest amount of RNA. In addition, dividing the RNA results into 3 clusters from 
high to low RNA counts per cell (140, 292 and 588), showed that cluster 1 with low RNA amount 
correlates with the median trajectory with a lower late signaling and cluster 3 with high RNA amount 
correlates with the median trajectory with a higher late signaling (Figure 15H). The amplitude of 
SMAD2 dynamics was not correlated to PAI-1 target gene expression 14 hours post stimulation. In 
conclusion, considering 14 hours of individual SMAD signaling, I observed a correlation of long-term 
SMAD2 dynamics to the PAI-1 target gene expression. Nevertheless, further experiments are needed 
to get conclusive results. 
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3.1.9 Figure 15. Combining smFISH of target genes with single cell trajectories. 
A Individual steps of the method: combining time-lapse microscopy experiments and smFISH using the example of 3h 
25pM TGFβ stimulation and subsequent PAI-1 smFISH analysis. SMAD2 reporter cells are seeded on a relocation grid for 
the time-lapse microscopy experiment (three upper panel) and SMAD2 translocation was measured and clustered (middle 
right picture). Subsequently, cells were fixed and specific PAI-1 probes for smFISH labeled CalFluor-610 were applied and 
imaged with z-stacks. The RNA amount of each cell was calculated using Star Search Analysis tool and matched manually 
to the identical tracked single cell from the microscopy experiment (remaining panels). 
B Bee swarm plot of PAI-1 RNA distribution 0, 3 and 14h after 25pM TGFβ treatment.  
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C Box plot of PAI-1 RNA distribution 0, 3 and 14h after 25pM TGFβ treatment. Median of 59 RNA/cell at basal level, 444 
RNA/cell at 3h and 242 RNA/cell at 14h post TGFβ treatment. Red lines indicate median; boxes include data between the 
25th and 75th percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent 
outliers. 
D Coefficient of variation (CV) of PAI-1 RNA distribution 0, 3 and 14h after 25pM TGFβ treatment. 
E Individual cells were clustered into six signaling classes (cluster) according to their time-resolved nuc/cyto SMAD2 ratio 
3h after 25pM TGFβ stimulation (left panel). Each line represents the median over all cells of the indicated cluster. Shaded 
area represent data between 25th and 75th percentiles. Cluster are illustrated in the heat map (red line, right upper panel) 
and PAI-1 RNA distribution of the respective cluster is shown as a box plot (right lower panel). Red lines indicate median; 
boxes include data between the 25th and 75th percentiles; whiskers extend to maximum values within 1.5× the 
interquartile range; crosses represent outliers. 
F Individual cells were clustered into three cluster according to the PAI-1 RNA amount per cell 3h after 25pM TGFβ 
stimulation (left upper panel). Cluster are illustrated in the heat map (red line, left lower panel) matching with the 
corresponding nuc/cyto SMAD2 ratio trajectories. The distribution of the respective median nuc/cyto SMAD2 ratio of the 
three RNA cluster are shown in the right panel.  
G Individual cells were clustered into four signaling classes (cluster) according to their time-resolved nuc/cyto SMAD2 ratio 
14h after 25pM TGFβ stimulation (left panel). Each line represents the median over all cells of the indicated cluster. Shaded 
area represent data between 25th and 75th percentiles. PAI-1 RNA distribution of the respective cluster is shown as a box 
plot (right panel). Red lines indicate median; boxes include data between the 25th and 75th percentiles; whiskers extend 
to maximum values within 1.5× the interquartile range; crosses represent outliers. 
H Individual cells were clustered into three cluster according to the PAI-1 RNA amount per cell 14h after 25pM TGFβ 
stimulation (left panel). The distribution of the respective median nuc/cyto SMAD2 ratio of the three RNA cluster are 
shown in the right panel. 
3.1.10 SMAD2 and SMAD4 show similar dynamics in the same individual cell  
Next, I focused on the question whether SMAD2 or SMAD4 individual response pattern are crucial for 
the target gene expression and cell fate decisions. I observed that the average response and signaling 
features are similar to varying TGFβ doses (3.1.3, 3.1.6). But what happens in the same individual cell? 
Are SMAD2 and SMAD4 dynamics coupled and protein fluctuations co-related? To this end I generated 
a combined fluorescent reporter cell line (E9) by fusing SMAD4 to the yellow fluorescent protein Venus 
(YFP) and SMAD2 to the red fluorescent protein mCherry under the control of a constitutive promoter 
(UbCp), respectively (Figure 16A). As an inverse variant I generated a combined cell line (A3) by fusing 
SMAD2 to YFP and SMAD4 to mCherry. In addition, both cell lines also stably express the nuclear 
marker histone H2B-CFP under the control of UbCp to enable automated image analysis. I created both 
variants to exclude possible influences by the distinct fluorescence proteins. First, I examined the 
average response of SMAD2 and SMAD4 of the SMAD2-mCherry- SMAD4-YFP (E9) cell line for the 
different TGFβ concentrations as shown in Figure 16B. The results for both transcription factors look 
similar. Example trajectories for the varying TGFβ doses in Figure 16C showed that patterns of the 
individual SMAD2 and SMAD4 trajectories were strongly correlated. Furthermore, the correlation 
coefficient for all the trajectories over time confirmed that SMAD2 and SMAD4 dynamics were highly 
co-regulated although the signaling peak is marked with a slightly lower correlation (Figure 16D). 
Moreover, the inverse cell line A3 showed similar dynamics for SMAD2 and SMAD4 in the average 
response as well, but with lower fluorescence intensities than the previously presented YFP-tagged 
cell lines (Appendix Figure A1). However, example trajectories and the correlation coefficient showed 
high accordance of SMAD2 and SMAD4 signaling in the same individual cell (Appendix Figure A2 and 
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A3). In conclusion, translocation of SMAD2 and SMAD4 into the nucleus and shuttling back to the 
cytoplasm were co-regulated and coupled and fluctuations were synchronized, hence they regulate 
target gene expression und cell fate decisions together.  
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3.1.10 Figure 16. SMAD2 and SMAD4 show similar dynamics in the same individual cell. 
A Schematic figure of the SMAD2-YFP- SMAD4-mCherry reporter cell line (A3) and of the SMAD4-YFP- SMAD2-mCherry 
reporter cell line (E9). A3: SMAD2 was fused to mVenus (YFP) under the control of UbCp with the selection marker G418 
(Geneticin) and SMAD4 was fused to the red fluorescent protein mCherry under the control of UbCp with the selection 
marker blasticidin (Blast) 
As a nuclear marker, H2B was fused to the cyan fluorescent protein mCerulean (CFP) under the control of UbCp with the 
selection marker hygromycin. E9: SMAD4 was fused to mVenus (YFP) under the control of UbCp with the selection marker 
G418 (Geneticin) and SMAD2 was fused to mCherry under the control of UbCp with the selection marker blasticidin (Blast). 
As a nuclear marker, H2B was fused to CFP under the control of UbCp with the selection marker hygromycin. 
B Median nuc/cyto SMAD2 and SMAD4 ratio of the combined SMAD4-YFP- SMAD2-mCherry (E9) reporter cell line 
stimulated with 0, 1, 2.5, 5, 25 or 100pM TGFβ and tracked over 24h. Shaded area represent data between 25th and 75th 
percentiles.  
C Time-resolved analysis of SMAD2 (red lines) and SMAD4 (blue lines) translocation in the same individual (E9) reporter 
cells stimulated with varying concentrations of TGFβ. 
D Heat map of correlation coefficient of SMAD2 and SMAD4 translocation in (E9) reporter cells is shown as indicated in 
the legend (left panel) and correlation coefficient over 24h (right panel).  
3.2 Regulatory and adaption mechanisms 
In the next step I aimed to understand what molecular mechanisms control dynamic signal processing, 
especially what mechanisms underlying the decomposition into distinct signaling classes.  How do 
different adaption mechanisms act together to control long term dynamics? Which changes in protein 
levels and activities determine the response of individual cells to a given stimulus? In order to address 
these questions systematically, I investigated several regulatory mechanisms that are known to 
influence the TGFβ response: ligand depletion, receptor internalization and degradation, proteasomal 
degradation and transcriptional feedback loops (Clarke et al, 2009; Chen, 2009; Zhang & Laiho, 2003; 
Yan, et al, 2009; Wegner et al, 2012).  
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3.2.1 Full ligand decay correlate with signaling termination 
Studies indicate that TGFβ depletion plays a significant role in determining the duration of signaling in 
cells (Clarke et al, 2009). To gain a better understanding how complete adaptation of the signaling 
pathway is connected to TGFβ ligand depletion by cellular uptake and lysosomal degradation, we 
measured extracellular TGFβ ligand concentration by using Mink lung epithelial cells (MLEC), stably 
transfected with an expression construct containing a truncated PAI-1 promoter fused to the firefly 
luciferase reporter gene (Abe et al, 1994). Conditions are the same as for the microscopy experiments. 
Cells were stimulated with 25pM or 100pM TGFβ and supernatant was removed and analyzed at 
several time points in separate dishes (Figure 17). I found that the estimated ligand decay of an initial 
TGFβ concentration of 25pM is completed within 20 hours with a half-life around 6 hours. These 
findings correspond with the complete adaptation of the signaling pathway to basal pre-stimulation 
level in the microscopy experiments. Furthermore, cells stimulated with 100pM TGFβ revealed an 
extracellular ligand concentration around 20pM after 24 hours, which is estimated with a half- life 
around 9 hours. This agrees with the non-complete adaptation to basal level for 100pM TGFβ 
stimulation within 24 hours. In conclusion, the half-lives differ for both concentrations and these time-
lapse imaging experiments suggest that the full ligand decay mainly affects the signaling termination 
and as long as extracellular TGFβ is present, SMADs accumulate into the nucleus.  
 
3.2.1 Figure 17. Full ligand decay correlate with signaling termination. 
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TGFβ concentration measurement to estimate the TGFβ decay and half-life for different initial concentrations in time-
lapse microscopy experiments. MCF10A SMAD2 reporter cells were seeded two days before stimulation with 25pM or 
100pM and supernatants from live-cell microscopy experiments were collected at indicated time points. Mink lung 
epithelial cells (MLECs) stably transfected with a reporter containing a truncated PAI-1 promoter (3TP promoter with three 
consecutive TPA response elements) fused to the firefly luciferase gene were used and luciferase activity was measured. 
The fit to a standard curve was used to convert measured relative luciferase activities into absolute TGFβ concentrations. 
Red lines indicate median; boxes include data between the 25th and 75th percentiles; whiskers extend to maximum values 
within 1.5× the interquartile range; crosses represent outliers. 
3.2.2 Role of negative feedback loops 
What is the role of negative feedback loops in regulating TGFβ dynamics? As mentioned before, 
SMAD7 as the main transcriptional feedback down-regulates TGFβ signaling by blocking receptor 
bindings, preventing formation and nuclear accumulation of SMAD2/SMAD3/SMAD4, repression of 
SMAD target genes, receptor dephosphorylation and degradation and SMAD7 competes with SMAD4 
to associate with R-SMADs and recruits the E3 ubiquitin ligase NEDD4L to activated R-SMADs, leading 
to their polyubiquitination and proteasomal degradation (Hayashi et al, 1997; Kavsak et al, 2000; Yan 
et al, 2009; Wegner K et al, 2012; Yan et al, 2016).  
3.2.2.1 SMAD7 transcription is strongly correlated to the first peak amplitude of SMAD2 
signaling 
In order to systematically investigate the role of feedback loops in shaping SMAD dynamics, it was first 
necessary to clarify how the SMAD7 transcription is coupled to TGFβ pathway activation.  
So far, I could show that expression of TGFβ target genes are dose-dependent like the median response 
in the time-lapse data (3.1.3.1). To examine this more specifically, I combined smFISH of SMAD7 with 
time-lapse imaging of SMAD2 1.5h and 14h post 100pM TGFβ stimulation. Considering first the 
absolute RNA counts per cell at basal level (376 cells analyzed) and 1.5 hours (623 cells) or 14 hours 
(174 cells) post 100pM TGFβ ligand stimulation, the target gene expression also showed high cell-to- 
cell variability with a median of 29 RNA/cell at basal level, 57 RNA/cell (2 fold) at 1.5 hours and 39 
RNA/cell (1.3 fold) at 14 hours (Figure 18A, B and C). The coefficient of variation (CV) is moderate for 
all three conditions between 0.45- 0.65 (Figure 18D). More important was how 1.5 hours of individual 
SMAD2 signaling correlate to the SMAD7 RNA count in the respective cell at 1.5 hours post stimulation, 
which correspond to the peak of SMAD7 target gene expression (Figure 18E). I grouped the trajectories 
of SMAD2 signaling into 4 clusters, which is illustrated in the heat map, and then looked at the 
distribution of the RNA to the respective cluster (Figure 18F). Cells in cluster 1 are marked by a low 
amplitude and little nuclear accumulation of SMAD2 and low counts of RNA per cell of 41. Cells of 
cluster 2-4 are characterized by an increasing amplitude and slope and coinciding higher amounts of 
RNA per cell of 50, 62 and 62, respectively. Obviously, the first peak amplitude of SMAD2 dynamics 
was correlated to the RNA distribution. To confirm this result, I divided the RNA results into 4 clusters 
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from high to low RNA counts per cell and looked at the distribution of the respective median 
trajectories (Figure 18G). Cluster 1 is characterized by a low RNA amount (median of 29 RNA/cell) 
correlated with the trajectories with a lower amplitude and cluster 3 with the highest RNA amount 
(median of 129 RNA/cell) correlate with the median with a higher amplitude and slope. Nonetheless, 
considering 14 hours of individual SMAD signaling, trajectories of SMAD2 signaling are grouped into 3 
clusters with distinct dynamic behavior, but RNA counts per cell were around 40 for all clusters (Figure 
18H). Equally, I divided the RNA results into 4 clusters from high to low RNA counts per cell, but the 
distribution of the respective median trajectories looked the same (Figure 18I). In conclusion early 
SMAD7 transcription reflected strongly SMAD2 signaling, but for long-term dynamics the correlation 
was not obvious.  
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3.2.2.1 Figure 18. SMAD7 transcription is strongly correlated to the first peak amplitude of SMAD2 signaling. 
A Bee swarm plot of SMAD7 RNA distribution 0, 1.5 and 14h after 100pM TGFβ treatment.  
B Box plot of SMAD7 RNA distribution 0, 1.5 and 14h after 100pM TGFβ treatment. Median of 29 RNA/cell at basal level, 
57 RNA/cell at 1.5h and 39 RNA/cell at 14h post TGFβ treatment. Red lines indicate median; boxes include data between 
the 25th and 75th percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent 
outliers. 
C Exemplary analysis of basal SMAD7 RNA distribution. SMAD7 probes for smFISH labeled CalFluor-610 were applied and 
RNA amount of each cell was calculated using Star Search Analysis tool.  
D Coefficient of variation (CV) of SMAD7 RNA distribution 0, 1.5 and 14h after 100pM TGFβ treatment. 
E Combining time-lapse microscopy experiment (100pM TGFβ stimulation 1.5h) and SMAD7 smFISH analysis. SMAD2 
reporter cells are seeded on a relocation grid for the time-lapse microscopy experiment (three upper panels). 
Subsequently, cells were fixed and specific SMAD7 probes for smFISH labeled CalFluor-610 were applied. The RNA amount 
of each cell was calculated using Star Search Analysis tool.  
F Individual cells were clustered into four signaling classes (cluster) according to their time-resolved nuc/cyto SMAD2 ratio 
1.5h after 100pM TGFβ stimulation (left panel). Each line represents the median over all cells of the indicated cluster. 
Shaded area represent data between 25th and 75th percentiles. Cluster are illustrated in the heat map (red line, right 
upper panel) and SMAD7 RNA distribution of the respective cluster is shown as a box plot (right lower panel). Red lines 
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indicate median; boxes include data between the 25th and 75th percentiles; whiskers extend to maximum values within 
1.5× the interquartile range; crosses represent outliers. 
G Individual cells were clustered into four cluster according to the SMAD7 RNA amount per cell 1.5h after 100pM TGFβ 
stimulation (left panel). The distribution of the respective median nuc/cyto SMAD2 ratio of the four RNA cluster are shown 
in the right panel. 
H Individual cells were clustered into three signaling classes (cluster) according to their time-resolved nuc/cyto SMAD2 
ratio 14h after 100pM TGFβ stimulation (left panel). Each line represents the median over all cells of the indicated cluster. 
Shaded area represent data between 25th and 75th percentiles. Cluster are illustrated in the heat map (red line, right 
upper panel) and SMAD7 RNA distribution of the respective cluster is shown as a box plot (right lower panel). Red lines 
indicate median; boxes include data between the 25th and 75th percentiles; whiskers extend to maximum values within 
1.5× the interquartile range; crosses represent outliers. 
I Individual cells were clustered into four cluster according to the SMAD7 RNA amount per cell 14h after 100pM TGFβ 
stimulation (left upper panel). Cluster are illustrated in the heat map (red line, left lower panel) matching with the 
corresponding nuc/cyto SMAD2 ratio trajectories. The distribution of the respective median nuc/cyto SMAD2 ratio of the 
four RNA cluster are shown in the right panel. 
3.2.2.2 Inhibition of transcription by DRB attenuates early adaptation 
Finally, to determine whether transcriptional negative feedback loops establish signal adaptation, I 
blocked these feedbacks by the general transcription inhibitor DRB (5,6-dichloro-1--D-
ribofuranosylbenzimidazole), which efficiently inhibits transcription at the early elongation stage by 
inhibiting CDK7, 8 and 9 kinases and preventing RNA polymerase II to proceed after initiation (Chodosh 
et al, 1989; Yamaguchi et al, 1998; Rickert et al, 1999). First, the efficiency of DRB on MCF10A cells was 
assessed by measuring SMAD7 expression at time points 0, 1.5 and 3h post TGFβ stimulation by RT-
PCR. DRB was added at different times before and after 100pM TGFβ treatment. DRB 0.25h prior TGFβ 
stimulus was sufficient to maintain basal level and to prevent accumulation of SMAD7 at its peak of 
1.5h to 3.47-fold and keep it constant around the basal level (Figure 19A). In addition, 3h value in 
DMSO control treated cells was 1.61-fold and with 0.25h prior DRB only 0.65-fold. Since DRB acts 
rather fast and transcription rates for SMAD7 were kept around the basal level and thus cellular 
changes and compensatory mechanisms are minimized, I added DRB 0.25h prior 100pM TGFβ 
stimulation for time-lapse microscopy experiments. As shown in Figure 19B, DRB alone had no effect 
on SMAD2 signaling. However, stimulating SMAD2 reporter with DRB prior to TGFβ stimulation, the 
amplitude was amplified, and adaptation was attenuated, as presented in boxplots for the ratio values 
1h and 3h post stimulation (Figure 19B and E). The longer duration of nuclear SMAD2 accumulation 
was particularly evident in the heat maps (Figure 19C). Since the cells started to die when adding DRB, 
only the first 6 hours of the response were analyzed. Furthermore, cells also showed an increased 
amplitude and slower adaptation when DRB was added 0.5 and 0.75h post TGFβ stimulation or slightly 
enhanced signaling 1.5h post stimulation (Figure 19D). The same results were obtained by treating 
cells 0.25h prior to 25pM and 5pM TGFβ. The amplitude was increased and the TGFβ response was 
boosted, but nevertheless early adaptation took place (Figure 19F, Appendix Figure A4 and A5). In 
conclusion these results indicate that transcriptional feedbacks like SMAD7 have an impact on the 
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early adaptation of SMAD2 signaling, but other regulatory mechanisms are apparently involved since 
early adaptation was attenuated and not prevented.  
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3.2.2.2 Figure 19. Inhibition of transcription by DRB attenuates early adaptation. 
A Expression of SMAD7 in MCF10A WT cells stimulated with 100pM TGFβ and treated with DRB (5,6-dichloro-1-beta-D-
ribobenzimidazole) at indicated time points (relative to TGFβ stimulation) were measured by RT-qPCR at indicated time 
points (0, 1.5h and 3h). DMSO was used for the control condition. β-Actin was used as an internal control. Error bars 
indicate standard deviation of technical triplicates. 
B Median nuc/cyto SMAD2 ratio of reporter cells stimulated with 100pM TGFβ and treated with DRB at indicated time 
points. DMSO was used for the control. Shaded area represent data between 25th and 75th percentiles. 
C Heat maps of SMAD2 translocation in individual cells over 24h. Cells were stimulated with 100pM TGFβ and treated with 
DMSO or DRB 0.25h pre TGFβ stimulus. Each horizontal line represents a single cell and the nuc/cyto ratio is shown as 
indicated in the legend. Cells were sorted by the time of the first division as indicated by red marks.  
D Median nuc/cyto SMAD2 ratio of reporter cells stimulated with 100pM TGFβ and treated with DRB at indicated time 
points post TGFβ stimulus. DMSO was used for the control. Shaded area represent data between 25th and 75th 
percentiles. 
E Signaling features for the SMAD2 reporter cells at 1.25h and 3.25h stimulated with 100pM TGFβ and treated with DRB 
at indicated time points. Red lines indicate median; boxes include data between the 25th and 75th percentiles; whiskers 
extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
F Median nuc/cyto SMAD2 ratio of reporter cells stimulated with 2.5 or 25pM TGFβ and treated with DRB at indicated 
time points. DMSO was used for the control. Shaded area represent data between 25th and 75th percentiles. 
3.2.2.3 SMAD7 knock out CRISPR Cas9 cell line 
In order to investigate the role of the reported main transcriptional negative feedback regulator 
SMAD7 more specifically (Yan et al, 2009), I aimed to generate a SMAD7 CRISPR Cas9 knockout cell line 
and perform live-cell imaging to determine how a complete knock out affects the dynamics of SMAD2.  
3.2.2.3.1 Generating clonal cell lines and validating selected clones by determining the 
mutation state of the SMAD7 gene locus  
For this purpose, a clonal SMAD2-YFP Cas9 reporter cell line was generated which additionally 
expresses the Cas9 gene after lentiviral infection and acts as a new control cell line. Furthermore, this 
cell line was transfected with an sgRNA targeting exon2 of the SMAD7 gene to create a polyclonal 
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SMAD7 knock out cell line (Shalem et al, 2014). No functional protein will be produced due to 
nonsense-mediated decay when missense mutations occur.  
The T7 endonuclease assay confirmed a high level of mutated genomic DNA (6.4). Therefore, 5 stable 
clonal cell lines (Clone 1, 6, 9, 12 and 16) were selected and the mutation state of the SMAD7 gene 
locus was determined by sequencing and validated by RT-PCR and Western Blot to identify the one 
with the most complete knock out. Sequencing results showed that clone 9 had the wild type SMAD7 
gene and clone 1, 6 and 16 only show heterozygous deletions leading to an open reading shift and an 
early stop codon. Fortunately, clone 12 showed a deletion on both alleles (22 and 7 base pairs), leading 
to an open reading frame shift and an early stop codon and therefore to a complete SMAD7 knock out 
(Figure 20A). In addition, RT-PCR data indicated that the basal SMAD7 mRNA level was reduced from 
Clon12 to 0.0095-fold compared to the SMAD2-YFP Cas9 reporter cell line. Furthermore, Western blot 
experiments revealed that 3h after 100pM TGFβ treatment clone 1, 6, 16 and in particular clone 12 
showed more pSMAD2 and more total SMAD2 (Figure 20B), which indicates a successful CRISPR CAS9 
knock out of SMAD7.  
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3.2.2.3.1 Figure 20. Generating clonal cell lines and validating selected clones by determining the mutation state of the 
SMAD7 gene locus. 
A Sequencing results for SMAD7 EXON 2 of MCF10A WT (parental) and SMAD7 CRISPR Cas9 knockout cell lines clone 1, 6, 
12 & 16. 
B Western blot analysis of SMAD2 activation in the control clonal SMAD2-YFP Cas9 reporter cell line (Cas9) and in the 
SMAD7 CRISPR Cas9 knockout cell lines clone 1, 6, 9, 12 & 16. Cells were stimulated with 100pM TGFβ and SMAD2 and 
SMAD2 phosphorylation was analyzed 3h post stimulus. GAPDH was used as a loading control. 
3.2.2.3.2 Sustained SMAD7 knock out affects SMAD2 dynamics  
Finally, the next step was to determine how SMAD7 knock out affects the TGFβ response of SMAD2 
measured by live cell imaging. For this purpose, the control cell line SMAD2-YFP Cas9, the partially 
SMAD7 knock out clones 1 & 16 and the complete knock out clone 12 were stimulated with 100 pM 
TGFβ and monitored for 21 hours. First of all, clone 1 and 16 show a slight increase in the basal nuclear 
and cytoplasmic values and they are extremely elevated for clone 12 (Figure 21A and B). Since the 
nuc/cyto ratio would be deceptive here, the focus was on the nuclear SMAD2 level (Figure 21C). The 
amplitudes of clone 1 and 16 were significantly increased and for clone 12 even doubled compared to 
the SMAD2-YFP Cas9 reporter cell line. Nonetheless, the early adaptation took place to a higher 
plateau level for all three clones. Clustering all cells of the experiment into 4 clusters revealed that the 
proportion of cells from cluster 4, with the strongest SMAD2 response, was increased for clone 1 and 
clone 16 and is approximately 50% of the cells of clone 12 (Figure 21D and E). Furthermore, the fraction 
of dividing cells from cluster 4 was reduced and the movement over the period of 21 hours was 
increased (Figure 21F and G). This confirms that a strong sustained SMAD2 response shift cells to 
migration, EMT and cell cycle arrest and is regulated by the negative feedback regulator SMAD7. 
Furthermore, to address the question how the SMAD7 knock out affects the TGFβ dose-response of 
SMAD2, clone 12 and SMAD2- YFP Cas9 cell line were stimulated with 25pM and 5pM TGFβ (Figure 
21H and I). As before, the amplitudes of clone 12 were increased and the early adaptation was 
weakened with a higher nuclear SMAD2 plateau level afterwards, which delayed the final adaptation 
to basal level (Appendix Figure A6). The resulting extended response of SMAD2 was particularly 
apparent in the heat maps (Appendix Figure A7).  
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3.2.2.3.2 Figure 21. Sustained SMAD7 knock out affects SMAD2 dynamics.  
A Basal nuclear level of the control clonal SMAD2-YFP Cas9 reporter cell line (Cas9) and for the SMAD7 CRISPR Cas9 
knockout cell lines clone 1, 12 & 16. Red lines indicate median; boxes include data between the 25th and 75th percentiles; 
whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
B Median cytoplasmic SMAD2 level of the control clonal SMAD2-YFP Cas9 reporter cell line (SMAD2-YFP Cas9) and for the 
SMAD7 CRISPR Cas9 knockout cell lines clone 1, 12 & 16 stimulated with 100pM TGFβ.  
C Median nuclear SMAD2 level of the control clonal SMAD2-YFP Cas9 reporter cell line (SMAD2-YFP Cas9) and for the 
SMAD7 CRISPR Cas9 knockout cell lines clone 1, 12 & 16 stimulated with 100pM TGFβ and tracked over 21h. Shaded area 
represent data between 25th and 75th percentiles. 
D Individual cells of the control clonal SMAD2-YFP Cas9 reporter cell line (SMAD2-YFP Cas9) and for the SMAD7 CRISPR 
Cas9 knockout cell lines clone 1, 12 & 16 stimulated with 100pM TGFβ  
were clustered into 4 signaling classes (cluster) according to their time-resolved nuclear SMAD2 level using dynamic time 
warping (DTW). Each line represents the median over all cells of the indicated cluster. Shaded area represent data between 
25th and 75th percentiles. 
E Distributions of signaling classes (cluster) on the different reporter cell lines.  
F Cell proliferation of reporter cells shown as fraction of dividing cells within 21h for the different signaling classes (cluster).  
G Motility of each cell as summed distance in pixel (pxl) covered 21h after stimulation with 100pM TGFβ. Cells were sorted 
according to signaling classes (cluster). Red lines indicate median; boxes include data between the 25th and 75th 
percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
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H Median nuclear SMAD2 level of the control clonal SMAD2-YFP Cas9 reporter cell line (SMAD2-YFP Cas9) and for the 
SMAD7 CRISPR Cas9 knockout cell line clone 12 stimulated with 5 or 25pM TGFβ and tracked over 24h. Shaded area 
represent data between 25th and 75th percentiles. 
I Individual nuclear SMAD2 trajectories for the control clonal SMAD2-YFP Cas9 reporter cell line (SMAD2-YFP Cas9) and for 
the SMAD7 CRISPR Cas9 knockout cell line clone 12 stimulated with 5 or 25pM TGFβ and tracked over 24h.  
3.2.2.3.3 Dependency of SMAD target genes on SMAD7 
In order to determine the effects of SMAD7 knock down on changes in downstream responses and 
possible compensation mechanisms, for example up regulation of further feedback loops, I analyzed 
target genes expression in Clone 12 by RT-PCR. SMAD6, another negative feedback loop, TIEG, the 
repressor of SMAD7 and SARA, a cofactor that interacts directly with SMAD2/ 3 and functions to recruit 
SMAD2/ 3 to the TGFβ receptor are not affected by SMAD7 knock out after treatment with 100pM 
TGFβ (Figure 22). In contrast, the peak of PAI1 at 3 hours was increased to nearly 20-fold compared to 
13.9-fold of the SMAD2-YFP Cas9 control cell line. Also, late expression at 14 and 24 hours was slightly 
increased. Since at 100pM TGFβ the expression could be already saturated, the PAI1 expression was 
examined with 5pM TGFβ and also showed a higher induction of 14.1-fold instead of 9-fold. In 
conclusion, SMAD7 knock out led not only to a stronger SMAD2 response, but also in case of PAI1 to 
an enhanced downstream response.  
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3.2.2.3.3 Figure 22. Dependency of SMAD target genes on SMAD7. 
Expression of TGFβ target genes in the control clonal SMAD2-YFP Cas9 reporter cell line (Cas9) and in the SMAD7 CRISPR 
Cas9 knockout cell line clone 12 stimulated with 5 or 100pM TGFβ were measured by RT-qPCR at indicated time points. β-
Actin was used as an internal control. Error bars indicate standard deviation of technical triplicates. 
3.2.2.4 Transient SMAD7 knock out affects SMAD2 dynamics 
Since the homozygous SMAD7 CRISPR Cas9 knock out clone 12 has a sustained knock out with possible 
compensatory mechanisms, it was crucial to investigate how a transient SMAD7 knock out affects 
SMAD2 dynamics. Thus, I used a clonal cell line (F10) with inducible shRNA expression for SMAD7 gene 
silencing in the background of the SMAD2-YFP cell line to investigate the role in shaping the different 
dynamics. The pTRIPZ lentiviral vector used provided inducible shRNA expression in the presence of 
doxycycline (Thermo Scientific Open Biosystems Expression Arrest TRIPZ Lentiviral shRNAmir). First, 
the efficiency of the TET-ON system after 48 and 72 hours of doxycycline treatment was tested by RT-
PCR, whereby in the medium the horse serum was replaced by BSA for all conditions. Results showed 
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a knock down of SMAD7 of the F10 clonal cell line to 19% after 48 hours of doxycycline compared to 
the SMAD2-YFP cell line and a knock down to 22% after 72 hours (Figure 23A). Therefore, an incubation 
time of 48 hours was used for all further experiments. First of all, it is obvious that doxycycline alone 
did not trigger translocation of SMAD2 in the control cell line SMAD2-YFP and in F10 (Figure 23B). 
Furthermore, the control cell line stimulated with 100pM TGFβ and with 100pM TGFβ and doxycycline 
showed the same known dynamics for the nuclear and cytoplasmic SMAD2, as well as for their ratio 
values. In contrast, the SMAD7 transient knock down cell line stimulated with doxycycline and 100pM 
TGFβ showed a lower amplitude and slightly less late signaling of SMAD2. However, the F10 cell line, 
as well as the SMAD7 CRISPR Cas9 knock out clone 12, showed changes in the basal nuclear and 
cytoplasmic SMAD2 levels. Focusing only on the nuclear values, its apparent that the amplitude was 
similar but the late SMAD response was amplified. The cytoplasmic levels were in particular elevated 
over the period of 24 hours. Furthermore, the high variabilities in the nuclear and cytoplasmic levels 
of the F10 cell line are noticeable, which presumably reflects the respective effectiveness of the TET-
ON system. In conclusion, the results are similar to clone 12, basal levels were increased, the amplitude 
of nuclear SMAD2 was not necessarily increased, but the early adaptation was weakened with a higher 
nuclear SMAD2 plateau level afterwards. Western results confirmed the time-lapse microscopy 
results. Biological triplicates showed that the transient F10 SMAD7 knockdown cell line after 
doxycycline treatment already exhibited more basal SMAD2 (Figure 23C). Furthermore, Western 
results revealed more SMAD4 and more phosphorylated SMAD2 for F10 stimulated with 100pM TGFβ 
and doxycycline (Figure 23D). 
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3.2.2.4 Figure 23. Transient SMAD7 knock out affects SMAD2 dynamics. 
A Expression of SMAD7 in SMAD2-YFP reporter cells and in the transient F10 SMAD7 knockdown 
cells (SMAD7 KD F10) after 48 or 72 hours of doxycycline at basal level. β-Actin was used as an internal control. Error bars 
indicate standard deviation of technical triplicates. 
B Median nuc/cyto SMAD2 ratio, median nuclear and cytoplasmic SMAD2 level of the SMAD2-YFP reporter cells stimulated 
with 100pM TGFβ or as an control stimulated with only doxycycline (doxy, left panels). Median nuc/cyto SMAD2 ratio, 
median nuclear and cytoplasmic SMAD2 level of the SMAD2-YFP reporter cells and the transient F10 SMAD7 knockdown 
cells (F10 SMAD7 KD) stimulated with 100pM TGFβ and 48h pretreated with doxycycline (doxy) or as an control F10 SMAD7 
KD cells only pretreated with doxycycline. Shaded area represent data between 25th and 75th percentiles. 
C Western blot analysis of biological triplicates of phosphorylated SMAD2 and total SMAD2 at basal level in the SMAD2-
YFP reporter cells 48h pretreated with or without doxycycline (doxy) and in the transient F10 SMAD7 knockdown cells 
(F10 SMAD7 KD)  48h pretreated with doxycycline (doxy). GAPDH was used as a loading control. 
D Western blot analysis of phosphorylated SMAD2 and total SMAD4 in the SMAD2-YFP reporter cells  
and in the transient F10 SMAD7 knockdown cells (F10 SMAD7 KD) 48h pretreated with doxycycline (doxy) and stimulated 
with 100pM TGFβ. GAPDH was used as a loading control. 
3.2.3 Inhibition of proteasomal degradation boost nuclear SMAD accumulation  
Receptor-regulated SMADs interact with SMURF2, the E3 Ubiquitin Ligase, that targets SMAD2 and 
SMAD4 for ubiquitination and proteasome-mediated degradation (Lin, 2000; Kavsak, 2000). To test 
whether Ubiquitin-dependent degradation plays a role in shaping the dynamics of SMADs I treated the 
cells with the proteasome inhibitor MG132. MG132 (carbobenzoxy-Leu-Leu-leucinal), a peptide 
aldehyde, reduces the degradation of ubiquitin-conjugated proteins by blocking the 26S complex (Lee 
& Goldberg, 1998). Treating the SMAD2-YFP cell line with MG132 45 minutes before TGFβ stimulation 
or at the same time highly boosted SMAD2 accumulation into the nucleus (Figure 24A and B, Appendix 
Figure A8). The maximum amplitude was increased, the time of the maximum amplitude was delayed 
and the length of the complete response and the mean value 5 hours after the first response were 
significantly increased (Figure 24C). Particularly for the nuclear levels it is noticeable that hardly any 
adaptation took place (Figure 24A). Also, treatment of MG132 0.75, 1.5 and 3 hours post TGFβ 
stimulation immediately enhanced SMAD2 accumulation into the nucleus (Figure 24A and C, Appendix 
Figure A8). The SMAD4-YFP cell line behaved essentially like the SMAD2-YFP cell line and revealed an 
extremely amplified SMAD4 signaling through MG132 (Appendix Figure A9 and A10). Here, the 
amplification of the amplitude, the delay of the maximum amplitude and the mean value 5 hours after 
the first response were even more obvious (Appendix Figure A11). Surprisingly, the SMAD2-YFP cell 
line stimulated only with MG132, showed already SMAD2 accumulation over time in the nucleus, 
which was also reflected in the ratio. The cytoplasmic SMAD2 level did not increase particularly (Figure 
24D). In order to verify the time-lapse microscopy results I performed Western Blot experiments and 
treated MCF10A wild type cells 45 minutes before 100pM TGFβ stimulation with MG132. Results 
revealed more phosphorylated SMAD2, total SMAD2 and SMAD4 (Figure 24E). In addition, I observed 
more TGFβ Receptor I if cells are prestimulated with MG132. Furthermore SMURF2 showed no 
changes and p21 is significantly enhanced. In addition, as expected enhanced SMAD2 and SMAD4 
accumulation into the nucleus through MG132 led to increased target gene expression, shown in 
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Figure 24F for Snail, SnoN and SARA. In conclusion inhibition of proteasomal degradation led to 
strongly enhanced TGFβ signaling due to enhanced pSMAD2 and SMAD4 levels in the nucleus and 
stabilized receptors. In detail treatment with the inhibitor prevented the early adaptation and shifted 
the adaptation to later time points. Therefore, proteasomal degradation plays a strong role for the 
adaptation process.  
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3.2.3 Figure 24. Inhibition of proteasomal degradation boost nuclear SMAD accumulation.  
A Median nuc/cyto SMAD2 ratio, median cytoplasmic and nuclear SMAD2 level of the SMAD2-YFP reporter cells stimulated 
with 100pM TGFβ and treated with the proteasome inhibitor 
MG132 at indicated time points. Shaded area represent data between 25th and 75th percentiles. 
B Exemplary individual nuc/cyto SMAD2 ratio trajectories (thin lines) for the SMAD2-YFP reporter cells stimulated with 
100pM TGFβ and treated with MG132 0.75h pre 100pM TGFβ compared to the median nuc/cyto SMAD2 ratio of the entire 
population (thick line). 
C Signaling features for the nuc/cyto SMAD2 ratio in the SMAD2 reporter cells stimulated with 100pM TGFβ and treated 
with MG132 at indicated time points. Red lines indicate median; boxes include data between the 25th and 75th 
percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
D Median nuclear SMAD2 level, median nuc/cyto SMAD2 ratio and cytoplasmic level of the SMAD2-YFP reporter cells 
stimulated with DMSO and 100pM TGFβ or with the proteasome inhibitor 
MG132 only. Shaded area represent data between 25th and 75th percentiles. 
E Western blot analysis of phosphorylated SMAD2, total SMAD4 and SMAD2, TGFβRI, SMURF2 and p21 in MCF10A WT 
cells stimulated with 100pM TGFβ and 0.75h pretreated with MG132. GAPDH was used as a loading control. 
F Expression of TGFβ target genes in MCF10A WT cells stimulated with 100pM TGFβ and 0.75h pretreated with MG132. 
β-Actin was used as an internal control. Error bars indicate standard deviation of technical triplicates. 
3.2.4 Receptor internalization and degradation: Endocytotic pathways 
Endocytosis of cell surface receptors is a major regulatory event in signal transduction (Baass et al, 
1995; Di Fiore & De Camilli, 2001; McPherson et al, 2001). TGFβ receptor signaling and turnover are 
regulated by distinct endocytic compartments to finally regulate SMAD2 activation (Di Guglielmo et al, 
2003). Clathrin-mediated endocytosis targets receptor proteins to the early endosome antigen-1 
3.2.4 Receptor internalization and degradation: Endocytotic pathways 
67 
 
(EEA1)- positive endosome, where the SMAD2 anchor SARA is enriched, and promotes TGFβ signaling 
through recycling or receptors enter the late endosome-lysosome for degradation (Di Guglielmo et al, 
2003; Hayes et al, 2002; Itoh et al, 2002; Panopoulou et al, 2002). The lipid raft- caveolar internalization 
pathway contains the SMAD7-SMURF2 bound receptor and is required for rapid receptor turnover and 
degradation. Hereby SMAD7 interacts with TGFβRI and recruits the E3 ligases SMURF1 and SMURF2, 
which direct ubiquitin-dependent degradation of the TGFβ receptor- SMAD7-complex. (Di Guglielmo 
et al, 2003; Ebisawa et al, 2001; Kavsak et al, 2000). Immunofluorescence experiments showed that 
TGFβ receptor II is stabilized in MCF10A WT cells 0.75h post 100pM TGFβ stimulation und subsequently 
degraded to less than the basal level (Figure 25A and B). To address the question how the distinct 
receptor internalization and degradation processes affect SMAD2 dynamics I inhibited the endocytic 
pathways with dynasore or nystatin respectively and performed time-lapse microscopy experiments. 
Dynasore is a newly identified cell- permeable inhibitor of dynamin GTPase activity, that facilitates the 
formation of coated pits in the process of clathrin-dependent endocytosis. Thus, dynasore is a potent 
enhancer of TGFβ signaling (Macia et al, 2006; Nankoe and Sever, 2006; Chen et al, 2009). Treatment 
with nystatin disrupts the lipid raft- caveolar endocytic pathway and shifts receptors into the non-raft 
compartment EEA1. Therefore, the inhibitor stabilizes the receptors and slightly enhances signaling 
and SMAD2 activation (Di Guglielmo et al, 2003). Monitoring living single cells treated with nystatin 
0.75h before 100pM TGFβ stimulation revealed an unchanged SMAD2 ratio (Figure 25C). However, 
the nuclear and cytosolic SMAD2 values were greatly increased (Figure 25C and Appendix Figure A12). 
Here, the time of the maximum amplitude, increase and the end time of the first response was 
unchanged, but inhibiting the caveolar endocytic pathway enhanced the maximum amplitude and the 
mean intensity within 5h after the first response (Appendix Figure A13). Therefore, SMAD2 
accumulated strongly into the nucleus, but with a clearly early adaptation and an extenuated late 
adaptation, so that SMAD2 remained at a high nuclear level. Interestingly, the increased nuclear 
SMAD2 values led to an increased mobility of the cells (Figure 25D). Inhibiting the clathrin-dependent 
endocytosis with dynasore 0.75h before 100pM TGFβ stimulation led to increased nuclear and 
cytosolic SMAD2 values, while the ratio was almost unchanged (Figure 25E and F). The maximum 
amplitude and the mean intensity within 5h after response were slightly increased, so that SMAD2 
accumulated slightly more into the nucleus, whereas the time of the maximum amplitude, increase 
and the end time of the first response remained unchanged (Appendix Figure A14). However, the 
mobility of the cells was not changed (Figure 25G). Taken together these results suggest that TGFβ 
receptor signaling and turnover play a huge role for the adaptation process of SMAD2 dynamics, 
especially for the late adaptation. Since early adaptation was attenuated and not prevented, other 
regulatory mechanisms are apparently involved. 
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3.2.4 Figure 25. Receptor internalization and degradation: Endocytotic pathways.  
A Fluorescence intensity of TGFβRII was measured in MCF10A WT cells stimulated with 100pM TGFβ by 
immunofluorescence. Black lines indicate median; boxes include data between the 25th and 75th percentiles; whiskers 
extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
B Exemplary pictures of fluorescence intensities of TGFβRII in MCF10A WT cells stimulated with 100pM TGFβ by 
immunofluorescence at indicated time points. Nuclear staining was carried out with Hoechst 33342. 
C Median nuc/cyto SMAD2 ratio, nuclear and cytoplasmic level of the SMAD2-YFP reporter cells stimulated with 100pM 
TGFβ and 0.75h pretreated with Nystatin. DMSO was used as a control. Shaded area represent data between 25th and 
75th percentiles. 
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D Motility of each cell as summed distance in pixel (pxl) covered 24h after stimulation with 100pM TGFβ and 0.75h 
pretreated with Nystatin. Median indicated as a thick line and shaded area represent data between 25th and 75th 
percentiles. 
E Median nuc/cyto SMAD2 ratio, nuclear and cytoplasmic level of the SMAD2-YFP reporter cells stimulated with 100pM 
TGFβ and 0.75h pretreated with Dynasore. DMSO was used as a control. Shaded area represent data between 25th and 
75th percentiles. 
F Exemplary individual nuclear SMAD2 trajectories (thin lines) for the SMAD2-YFP reporter cells stimulated with 100pM 
TGFβ and 0.75h pretreated with Dynasore compared to the median nuclear SMAD2 level of the entire population (thick 
line). 
G Motility of each cell as summed distance in pixel (pxl) covered 24h after stimulation with 100pM TGFβ and 0.75h 
pretreated with Dynasore. Median indicated as a thick line and shaded area represent data between 25th and 75th 
percentiles. 
3.2.5 TGFβ signaling shows a refractory period depending on signaling state due to 
adaptation mechanisms 
The refractory period is the recovery time of the signaling system to be ready for a second stimulus. In 
order to examine the refractory time and to understand which mechanism restricts reactivation of the 
pathway and constitute the refractory period, I performed time-lapse microscopy experiments of 
SMAD2 reporter cells stimulated repeatedly with different TGFβ concentrations at various time points. 
First, I measured SMAD2 dynamics upon 100pM re-stimulation after 3 and 6 hours, respectively, and 
at 3 and 6 hours by replacing the medium completely after 3 washing steps. As shown in Figure 26A 
and B within the monitored 24 hours the system was incapable of responding again to stimulation. To 
prove as a control experiment that cells can be stimulated at later times under our conditions, 
individual trajectories stimulated with 100pM TGFβ only at 3 or 6 hours are shown in the heat map 
(Figure 26B). In the next experiment, the reporter cells were stimulated with 5pM TGFβ and re- 
stimulated at 3 hours after 3 washing steps and medium change. As shown in Figure 26C and Appendix 
Figure A15 the SMAD2 ratio (nuclear dynamics are similar) was hardly changed and only a slight 
amplification of SMAD2 signaling can be observed. This is particularly evident by the similar SMAD2 
ratio values at 4 hours, 1 hour after re-stimulation (Appendix Figure A16). Interestingly, the cells re-
stimulated at 6 hours revealed a new peak at 7 hours but remained clearly below the first peak (Figure 
26C, Appendix Figure A15 and A16). Re-stimulation at 8 hours leads to a strong second response at 
9h. The amplitude remained slightly below the first response but is approximately equal with the 
response of the cells stimulated just once at 8 hours with 5pM TGFβ. Reasons for this could be the 
TGFβ molecules per cell, which decrease with increasing cell number, or the decreased TGFβ 
concentration of the stock solution, which was stored on ice during the experiment. Until now, it seems 
that cells can only be completely restimulated after the terminal adaptation has been completed. To 
determine if SMAD7 feedback contributes to the refractory period after stimulation I inhibited 
transcriptional feedback loops with DRB 0.25h pre TGFβ stimulation and repeated the stimulation 
experiments with 5pM TGFβ after 3 hours. SMAD7 expression is about 3-fold 3 hours post 5pM 
stimulation (3.1.3.1). The cells treated with DRB and re-stimulated with 5pM TGFβ showed a stronger 
3.2.5 TGFβ signaling shows a refractory period depending on signaling state due to adaptation 
mechanisms 
73 
 
signaling with increased first amplitude but without significant re-stimulation in the ratio data (Figure 
26D). However, the nuclear levels show a clear re-stimulation with a new peak at 7.5h on almost initial 
peak level (Figure 26D, E and Appendix Figure A17) In a control experiment, the cells were treated 
with DRB and stimulated only after 3 hours with 5pM TGFβ (Figure 26F). The response was similar to 
the re-stimulation peak. In conclusion complete re-stimulation was only possible when SMAD2 
shuttling into the nucleus is terminated and transcriptional negative feedback loops contribute to the 
refractory period of the system, at least for small concentrations.  
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3.2.5 Figure 26. TGFβ signaling shows a refractory period.  
A Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and restimulated with 
100pM TGFβ at indicated time points. Shaded area represent data between 25th and 75th percentiles. 
B Heat maps of SMAD2 translocation in individual cells over 24h. Cells were stimulated with 100pM TGFβ and restimulated 
with 100pM TGFβ at indicated time points. Cells were sorted by the time of the first division as indicated by red marks. 
C Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 5pM TGFβ and restimulated with 5pM 
TGFβ at indicated time points. Shaded area represent data between 25th and 75th percentiles. 
D Median nuc/cyto SMAD2 ratio, nuclear and cytoplasmic level of the SMAD2-YFP reporter cells stimulated with 5pM 
TGFβ and restimulated 3h post with 5pM TGFβ and 0.25h pretreated with DRB. DMSO was used as a control. Shaded area 
represent data between 25th and 75th percentiles. 
E Exemplary individual nuclear SMAD2 trajectories (thin lines) for the SMAD2-YFP reporter cells stimulated with 5pM TGFβ 
and restimulated 3h post with 5pM TGFβ and 0.25h pretreated with DRB compared to the median nuclear SMAD2 level 
of the entire population (thick line). 
F Median nuc/cyto SMAD2 ratio, nuclear and cytoplasmic level of the SMAD2-YFP reporter cells stimulated with 5pM TGFβ 
and 0.25h pretreated with DRB. DMSO was used as a control. Shaded area represent data between 25th and 75th 
percentiles. 
3.3 Source of variability 
Since the cellular state of the cell, like the refractory time, is crucial for the TGFβ response, the question 
generally came up which factors influence the enormous heterogeneity of the SMAD response. Why 
do individual and genetically identical cells react differently to a given TGFβ stimulus? To this end, I 
examined how the cell cycle state, cell density or cell location contribute to the observed 
heterogeneity in single cell responses, since these factors are suggested in previous studies to have 
impact on cell-to-cell variability (Loewer & Lahav, 2011; Snijder & Pelkmans, 2011).  
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3.3.1 Cell cycle state is not the main cause of heterogeneity 
In order to investigate if the variability in the signaling response is correlated to a specific cell cycle 
phase at stimulation, I imaged the SMAD2-YFP reporter cells 24 hours before stimulation with varying 
TGFβ concentrations (Figure 27A). When sorting cells according to the time of the last division before 
TGFβ stimulation or by the amplitude of the response, no obvious correlation between cell cycle phase 
and TGFβ response was observed for all different TGFβ concentrations. The heat map in Figure 27B 
indicates exemplary the results for 100pM TGFβ stimulation of more than 400 cells. To compare the 
distributions of cell divisions with the heterogeneous TGFβ response in detail, Marcel Jentsch mapped 
the SMAD signaling responses for each individual cell to the previously defined signaling classes (Figure 
27C). As shown in Figure 27D, there are no significant differences in the distributions of the cell 
divisions of the respective signaling classes. Furthermore, the influence of specific cell cycle phases 
was investigated by using specific inhibitors for the G2 (RO3306) and G0 / G1 arrest (Gefitinib). To 
prove the efficiency of the inhibitors, a fluorescent, ubiquitination-based cell cycle indicator (Fucci)- 
based MCF10A cell line was generated by Gitta Blendinger to monitor the proportion of arrested cells 
(Sakaue-Sawano et al, 2008). The authors harnessed the regulation of cell cycle-dependent 
ubiquitination in order to generate two antiphase oscillating indicators for cell-cycle progression. 
These fluorescent probes effectively label individual G1 phase nuclei red and those in S / G2 / M phases 
green (Figure 27E). Then by using the inhibitor RO3306, that inhibits effectively and reversible CDK1 
(Vassilev, 2006), the majority of the cells are arrested after 8 hours at G2 phase of the cell cycle (Figure 
27F). Therefore, I used RO3306 4 hours, where cells partially arrested, and 8 hours prior TGFβ 
stimulation, but cells arrested in G2 showed the same median response to 100pM TGFβ stimulation as 
freely cycling cells (Figure 27G). Moreover, using Gefitinib, an inhibitor that induces G0/ G1 arrest 
(Zhou, 2009), showed for the Fucci cell line a maximum of cells in G1 arrest at 19 hours of incubation 
with the inhibitor (Figure 27H). SMAD2-YFP reporter cells pretreated with Gefitinib 20,5 hours prior to 
100pM TGFβ stimulation showed only weak accumulation of SMAD2 into the nucleus (Figure 27I). 
Especially the heat maps showed clearly that there is hardly any pathway activity (Figure 27J). Since 
G1 arrest is also a known cell fate of TGFβ treatment (Hocevar & Howe, 1998), this could be a reason 
that cells in G1 are almost not reacting to TGFβ. 
In conclusion, cell cycle state is not the main cause of heterogeneity. Furthermore, synchronized cells 
in G2 with a CDK1 inhibitor showed no impact on the TGFβ response. An exception is already arrested 
cells in G0 / G1, which showed almost no SMAD2 response after 100pM TGFβ stimulation. 
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3.3.1 Figure 27. Cell cycle state is not the main cause of heterogeneity. 
A Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with varying TGFβ concentrations. Cells were 
imaged for 24 h before stimulation with TGFβ. Shaded area represent data between 25th and 75th percentiles. 
B Heat map of SMAD2 translocation in individual cells over time. Cells were imaged for 24 h before stimulation with 100pM 
TGFβ. The nuc/cyto SMAD2 ratio is shown as indicated in the legend. Time of cell division is indicated by white marks. Cells 
were sorted either by the time of the last division  
before stimulation (left panel) or by the amplitude of their response (right panel).  
C Mapping of SMAD2 translocation dynamics in individual cells to six signaling classes (cluster). Median nuc/cyto SMAD2 
ratios for resulting cluster are shown.  
D Time of last cell division before stimulus for each cluster. White lines indicate median; boxes include data between the 
25th and 75th percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent 
outliers.  
E A fluorescent, ubiquitination-based cell cycle indicator (Fucci)- based MCF10A cell line 
(Sakaue-Sawano et al, 2008). The authors generated two antiphase oscillating indicators for cell-cycle progression. These 
fluorescent probes effectively label individual G1 phase nuclei red and those in S / G2 / M phases green. 
F Green fluorescent protein nuc/cyto ratio of the Fucci- based MCF10A cell line treated with RO-3306. Shaded area 
represent data between 25th and 75th percentiles. 
G Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and pretreated with RO-
3306 at indicated time points. Shaded area represent data between 25th and 75th percentiles. 
H Red fluorescent protein nuc/cyto ratio of the Fucci- based MCF10A cell line treated with Gefitinib. Shaded area represent 
data between 25th and 75th percentiles. 
I Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 20.5h pretreated with 
Gefitinib. Shaded area represent data between 25th and 75th percentiles. 
J Heat maps of SMAD2 translocation in individual cells over 24h. Cells were stimulated with 100pM TGFβ and 20.5h 
pretreated with Gefitinib. Cells were sorted by the time of the first division as indicated by red marks. 
3.3.2 Local cell density is not sufficient to explain signaling heterogeneity 
Since the cell cycle status had no particular influence on the SMAD translocation, I next examined the 
cell density and the specific cell location with the neighboring cells. To investigate how the TGFβ 
response depends on cell density, I seeded a different number of cells 48 hours prior to 100pM TGFβ 
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stimulation (0.25, 0.5, 0.75, 1.5, 3, and 6 x 105 cells). For comparison, all other experiments were 
performed with a 2.5 x 105 cell seeding. As shown in Figure 28A, the SMAD2 ratio response looked 
quite similar. The basal ratio values were relatively constant and decreased only slightly with increasing 
cell number (Figure 28B), whereby the ratio amplitude increased only slightly with increasing cell 
number (Figure 28C). The exception here was the maximum seeded cell number of 6 × 105 with a lower 
amplitude and a stronger adaptation (Figure28A & C). However, the nuclear SMAD2 response was 
highly dependent on cell density (Figure 28D). Even the basal nuclear values depended on the cell 
density, the lower the cell number, the higher the nuclear level, with the exception of the maximum 
cell number of 6 × 105 cells (Figure 28E). Accordingly, the amplitude also decreased extremely with 
increasing cell density (Figure 28F). The late signaling also showed these differences, which becomes 
particularly clear in Figure 28G for the example trajectories for 0.25 and 6 x 105 seeded cells. 
Furthermore, the cytoplasmic levels decreased with increasing cell density, in particular the basal 
values (Figure 28H & I). These results can also be transferred to SMAD4, as shown for the nuclear 
SMAD4 values in Figure 28J. In summary, the ratio TGFβ response was largely independent of cell 
density, but the amount of SMADs in the nucleus increased with lower cell density. This applied to the 
basal level, amplitude and the late SMAD response. Cell contacts, cell volume, available number of 
receptors and most likely TGFβ molecules per cell could play a role. Since the cell density in this 
experimental setup is determined by too many factors, in another experiment I considered the 
influence of the local cell density with the neighboring cells on the TGFβ response. From the number 
and distance of neighboring cells, Marcel Jentsch calculated a density score for each individual cell, 
based on the weighted distance of cells in a 640 μm radius. The basis for this is the experiment of 
Figure 27C, where the cells were stimulated after 24 hours with 100 pM TGFβ and then sorted into six 
signaling classes. However, as shown in Figure 28K, the distributions for all signaling classes are 
overlapping and local cell density are not sufficient to explain signaling heterogeneity. 
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3.3.2 Figure 28. Local cell density is not sufficient to explain signaling heterogeneity. 
A Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells seeded with a different number of cells 48 hours prior 
to 100pM TGFβ stimulation. For comparison, all other experiments were performed with a 2.5 x 105 cell seeding. Shaded 
area represent data between 25th and 75th percentiles. 
B Basal nuc/cyto SMAD2 ratio of the SMAD2 reporter cells seeded with a different number of cells 48 hours prior. Red 
lines indicate median; boxes include data between the 25th and 75th percentiles; whiskers extend to maximum values 
within 1.5× the interquartile range; crosses represent outliers. 
C Nuc/cyto SMAD2 ratio of the SMAD2 reporter cells seeded with a different number of cells 48 hours prior to 100pM 
TGFβ stimulation at 1h time point. Red lines indicate median; boxes include data between the 25th and 75th percentiles; 
whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
D Median nuclear SMAD2 level of the SMAD2-YFP reporter cells seeded with a different number of cells 48 hours prior to 
100pM TGFβ stimulation. Shaded area represent data between 25th and 75th percentiles. 
E Basal nuclear SMAD2 level of the SMAD2 reporter cells seeded with a different number of cells 48 hours prior. Red lines 
indicate median; boxes include data between the 25th and 75th percentiles; whiskers extend to maximum values within 
1.5× the interquartile range; crosses represent outliers. 
F Nuclear SMAD2 level of the SMAD2 reporter cells seeded with a different number of cells 48 hours prior to 100pM TGFβ 
stimulation at 1h time point. Red lines indicate median; boxes include data between the 25th and 75th percentiles; 
whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
G Exemplary individual nuclear SMAD2 trajectories (thin lines) for the SMAD2-YFP reporter cells seeded with the indicated 
number of cells 48 hours prior to 100pM TGFβ stimulation compared to the median nuclear SMAD2 level of the entire 
population (thick line). 
H Median cytoplasmic SMAD2 level of the SMAD2-YFP reporter cells seeded with a different number of cells 48 hours prior 
to 100pM TGFβ stimulation. Shaded area represent data between 25th and 75th percentiles. 
I Basal cytoplasmic SMAD2 level of the SMAD2 reporter cells seeded with a different number of cells 48 hours prior. Red 
lines indicate median; boxes include data between the 25th and 75th percentiles; whiskers extend to maximum values 
within 1.5× the interquartile range; crosses represent outliers. 
J Median nuclear SMAD4 level of the SMAD4-YFP reporter cells seeded with a different number of cells 48 hours prior to 
100pM TGFβ stimulation.  
K Cell density for the experiment of Figure 27C, where the cells were stimulated after 24 hours with 100pM TGFβ and then 
sorted into six signaling classes. Density scores before stimulus for each signaling class represent a weighted sum of all 
neighboring cells within 640 μm radius. 
3.4 The activity of MAP kinases determines long-term dynamics of SMAD 
signaling 
I hypothesized that the dynamic response of SMADs may be influenced by crosstalk of non-canonical 
TGFβ signaling and other signaling networks. Crosstalk describes how signal integration from multiple 
inputs within a response network affects a common biological output (Vert & Chory, 2011). Cross-
signaling mechanisms between SMADs and MAPK (mitogen-activated protein kinase) pathways have 
been described recently, but how they influence the SMAD dynamics remains unexplained (Javelaud 
& Mauviel, 2005; Kolosova, 2011; Yumoto et al, 2013).   
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3.4.1 Inhibiting non- canonical activation of JNK has no influence on SMAD signaling 
The crosstalk between the JNK1 (c-Jun N-terminal kinase 1) and SMAD3 pathways in RPMCs (rat 
peritoneal mast cells) has been explored and they found that JNK1 was critical for the TGF-β1-induced 
SMAD3 phosphorylation and nuclear translocation in RPMCs (Liu, 2012). Nevertheless, the influence 
of the JNK on SMAD2 and SMAD4 dynamics is unclear. Therefore, I inhibited JNK1, 2 and 3 with 
different concentrations of the JNK inhibitor VIII (CAS 894804-07-0) and monitored SMAD2 and SMAD4 
translocation by time-lapse microscopy. Neither the nuclear nor cytoplasmic levels of SMAD2 and 
SMAD4 changed over the measured period in MCF10A cells (Figure 29A & B).  
 
3.4.1 Figure 29. Inhibiting non- canonical activation of JNK has no influence on SMAD signaling. 
A Median nuc/cyto SMAD2 ratio, nuclear and cytoplasmic level of the SMAD2-YFP reporter cells stimulated with 100pM 
TGFβ and treated with JNK Inhibitor VIII at indicated concentrations. DMSO was used for the control. Shaded area 
represent data between 25th and 75th percentiles. 
B Median nuc/cyto SMAD4 ratio of the SMAD4-YFP reporter cells stimulated with 100pM TGFβ and treated with 10μM 
JNK Inhibitor VIII. DMSO was used for the control. Shaded area represent data between 25th and 75th percentiles. 
3.4.2 Inhibiting non- canonical activation of p38 alters long-term SMAD dynamics 
To further analyze the influence of non-canonical TGFβ signaling on dynamic response of SMADs I 
focused on the p38 pathway. TGFβ receptors activate MAP3Ks (Mitogen-activated protein kinase 
kinase kinases or MEKKs) like TAK1 (Transforming growth factor beta-activated kinase 1 or MAP3K7), 
which in turn activates MKKs (Mitogen-activated protein kinase kinases) like 3, 4, 6 and finally 
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phosphorylate p38 (Figure 1B, Zhang, 2009). P38 signaling pathways are activated by stress stimuli and 
are involved in inflammation, cell cycle, cell death, development, cell differentiation, senescence and 
tumorigenesis in specific cell types (Zarubin & Han, 2005). I used p38 kinase inhibitors and investigated 
how dynamics of SMAD2 and SMAD4 change over time.  
3.4.2.1 Inhibition of p38 modulates the dynamics and localization of SMADs 
To increase p38 inhibition efficiency I combined two different inhibitors SB202190 und BIRB 796. 
SB202190 is widely used to inhibit p38α and p38β Isoforms. Pyridinyl imidazole inhibitors, including 
this compound, directly bind p38 MAP kinases in the ATP binding pocket (Davies et al, 2000; Frantz et 
al, 1998; Fox et al, 1998). BIRB 796 is an inhibitor of all isoforms of p38. Its binding induces a slow 
conformational change that locks the protein into an inactive conformation (Pargellis et al, 2002; Kuma 
et al, 2005). Indeed, I observed that inhibition of p38 activity with both inhibitors 0.75 hours pre 100pM 
TGFβ stimulation modulated the dynamics and localization of SMAD2 by slightly lowering the 
amplitude of the first peak (1.75h post experiment start) and preventing nuclear accumulation of 
SMAD2 at all later time points (Figure 30A). Thus, the ratio values at 5h showed a stronger adaptation 
of the p38 inhibitor pretreated and 100pM TGFβ stimulated cells and no further activation of the 
pathway took place, illustrated by the 15h value (Figure 30C). Cells treated only with the p38 inhibitors 
showed no change in basal SMAD2 activation (Figure 30A & C). That the p38 inhibitors prevented the 
late TGFβ response in almost all cells is particularly apparent in the heat maps (Appendix Figure A18).  
In Figure 30D, four example trajectories are presented for cells pretreated with the p38 inhibitors 
following 100pM TGFβ stimulation compared to the trajectories of non-inhibited but TGFβ stimulated 
cells. And in fact, most of the trajectories with the p38 inhibitors only showed the first peak compared 
to the variability of trajectories without inhibitors. Also, for lower TGFβ concentrations, such as 1, 2.5, 
5 and 25pM TGFβ, was the amplitude diminished and no late response was recognizable (Figure 30B, 
C and E). In order to show next that this is not a side effect of the combination of two inhibitors, I used 
both inhibitors individually with different concentrations (Figure 30F). With increasing concentrations 
of SB202190 and BIRB 796, the p38 effect increased on the late SMAD2 response respectively. For all 
further experiments the combination of both inhibitors in moderate concentrations were used. 
Moreover, to validate the time-lapse microscopy results, I performed immunofluorescence 
experiments and inhibited p38 kinase activity in MCF10A WT cells and stimulated the cells with 100pM 
TGFβ. An analysis of nuclear and cytoplasmic total SMAD2 levels of hundreds of cells also resulted in a 
stronger adaptation and a non-existent late response (Figure 30G). Representative cells for 1h and 8h 
post TGFβ stimulation of inhibited and non-inhibited cells are shown in Figure 30H. In addition, time-
lapse microscopy experiments of the SMAD4 reporter cell line also showed a reduced amplitude and 
3.4.2 Inhibiting non- canonical activation of p38 alters long-term SMAD dynamics 
84 
 
SMAD4 almost completely shuttled out of the nucleus at 5h with no further late response activation 
at 100pM TGFβ stimulation and p38 kinase inhibition (Appendix Figure A19, A20 and A22). 
Furthermore, p38 inhibitors alone did not show any change in SMAD4 activation (Appendix Figure A19 
and A22). Also, the ratio values of the SMAD4 reporter cell line stimulated with 2.5pM TGFβ confirmed 
the SMAD2 experiments (Appendix Figure A21 and A22). 
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3.4.2.1 Figure 30. Inhibition of p38 modulates the dynamics and localization of SMADs. 
A Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
p38 inhibitors (SB202190 & BIRB796). DMSO and only p38 inhibitors were used as controls. Shaded area represent data 
between 25th and 75th percentiles. 
B Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 2.5pM TGFβ and 0.75h pretreated with 
p38 inhibitors. Shaded area represent data between 25th and 75th percentiles. 
C Nuc/cyto SMAD2 ratio of the SMAD2 reporter cells stimulated with 2.5 or 100pM TGFβ and 0.75h pretreated with p38 
inhibitors at time points 1.75, 5 and 15h. White lines indicate median; boxes include data between the 25th and 75th 
percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
D Exemplary individual nuc/cyto SMAD2 trajectories for the SMAD2-YFP reporter cells stimulated with 100pM TGFβ (green 
lines) and additionally 0.75h pretreated with p38 inhibitors (red lines). 
E Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 1, 5 or 25pM TGFβ and 0.75h pretreated 
with p38 inhibitors. Shaded area represent data between 25th and 75th percentiles. 
F Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and treated with SB202190 
or BIRB796 at indicated concentrations. DMSO was used for the control.  
G Nuc/cyto SMAD2 ratio was measured in MCF10A WT cells stimulated with 100pM TGFβ and 0.75h pretreated with p38 
inhibitors by immunofluorescence at indicated time points. White lines indicate median; boxes include data between the 
25th and 75th percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent 
outliers. 
H Exemplary pictures of SMAD2 fluorescence intensities in MCF10A WT cells stimulated with 100pM TGFβ and 0.75h 
pretreated with p38 inhibitors by immunofluorescence at 1 and 8h. Nuclear staining was carried out with Hoechst 33342.  
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3.4.2.2 p38 inhibition causes specific termination of the late response 
In order to investigate whether the late response is specifically suppressed by the p38 inhibitors or 
whether the effect of the inhibitors is just delayed, I added them either 45min before, at the same 
time or one-hour post TGFβ stimulation. As expected, the late response was gone. More interesting 
adding the inhibitors 6 hours after TGFβ treatment terminated further activation fast (Figure 31A). 
Therefore, the late response is p38 kinase activity dependent. In order to examine the signaling 
termination more precisely, TGFβ receptors were inhibited in parallel in a further experiment. 
Obviously, termination with p38 inhibitors was slightly slower and not as strong as with TGFβ receptor 
inhibitors, as illustrated by the ratio values for 7, 8 and 15 hours (Figure 31B and C). Furthermore, I 
was able to observe the same effect for SMAD4 when I added the p38 inhibitors and the TGFβ receptor 
inhibitor 6 hours after 100pM TGFβ stimulation (Figure 31D and E). 
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3.4.2.2 Figure 31. p38 inhibition causes specific termination of the late response. 
A Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and p38 inhibitors 
(SB202190 & BIRB796) at indicated time points. Shaded area represent data between 25th and 75th percentiles. 
B Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 6h post p38 inhibitors 
or TGF-β RI Kinase inhibitor VI SB431542 (TGFβRi). Shaded area represent data between 25th and 75th percentiles. 
C Nuc/cyto SMAD2 ratio of the SMAD2 reporter cells stimulated with 100pM TGFβ and 6h post p38 inhibitors or TGF-β RI 
Kinase inhibitor VI SB431542 (TGFβRi) at time points 6, 7, 8 and 15h. White lines indicate median; boxes include data 
between the 25th and 75th percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses 
represent outliers. 
D Median nuc/cyto SMAD4 ratio of the SMAD4-YFP reporter cells stimulated with 100pM TGFβ and 6h post p38 inhibitors 
or TGF-β RI Kinase inhibitor VI SB431542 (TGFβRi). Shaded area represent data between 25th and 75th percentiles. 
E Nuc/cyto SMAD4 ratio of the SMAD4 reporter cells stimulated with 100pM TGFβ and 6h post p38 inhibitors or TGF-β RI 
Kinase inhibitor VI SB431542 (TGFβRi) at time points 6, 7, 8 and 15h. White lines indicate median; boxes include data 
between the 25th and 75th percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses 
represent outliers. 
3.4.2.3 p38 inhibition results in less phosphorylation of SMAD2 and SMAD3 
As a next step to decrypt the underlying mechanisms, I have done Western experiments. First, I tested 
the p38 inhibitors for their effectiveness by determining the phosphorylation status of HSP27, a target 
gene of p38 (Freshney et al, 1994; Cuenda et al, 1995). Inhibition of kinase activity 6 hours after TGFβ 
stimulation resulted in a strong reduction of phosphorylation of HSP27 0.5h post and hardly detectable 
amounts of pHSP27 one hour after inhibition, which indicated that inhibition was successful (Figure 
32). Furthermore, after inhibition SMAD2 was less phosphorylated while total SMAD2 level remained 
unchanged. Interestingly, SMAD3 was also less phosphorylated, whereas total SMAD3 was unchanged.  
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3.4.2.3 Figure 32. p38 inhibition results in less phosphorylation of SMAD2 and SMAD3. 
Western blot analysis of phosphorylated HSP27 (Ser82), phosphorylated SMAD2, total SMAD2, phosphorylated SMAD3 
and total SMAD3 in MCF10A WT cells stimulated with 100pM TGFβ and 6h post p38 inhibitors (SB202190 & BIRB796). 
GAPDH was used as loading controls. 
3.4.2.4 Dependency of SMAD target genes and cell fate on p38 kinase activity 
Consequentially I was interested in the impact of this dynamic remodeling on gene expression and cell 
fate. Therefore, I performed some RT-PCRs after inhibiting the kinase activity of p38 (Figure 33A). First, 
the SMAD2 expression remained more or less constant and unchanged by the inhibition. The negative 
feedback loops SnoN and SMAD7 were somewhat less expressed, while TIEG (TGF-beta inducible early 
gene) and SARA (SMAD anchor for receptor activation) remained unchanged. In addition, p21, which 
plays a role in proliferation and cell cycle arrest, was unaltered by p38 inhibition. But very exciting, 
Snail, a key regulator of TGF-β-induced epithelial-mesenchymal transition (EMT) (Naber et al, 2013), 
was clearly less expressed at later time points. Based on these observations, I measured the movement 
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of cells over 20 hours as covered distance in pixels. Cells treated with the inhibitors 0.75h before 
100pM TGFβ stimulation moved significantly slower and thus probably EMT was decreased (Figure 
33B). Therefore, p38 kinase activity is responsible for the second response of SMAD2 and SMAD4 and 
necessary probably for EMT. 
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3.4.2.4 Figure 33. Dependency of SMAD target genes and cell fate on p38 kinase activity. 
A Expression of TGFβ target genes in MCF10A WT cells stimulated with 100pM TGFβ and 0.75h pretreated with p38 
inhibitors (SB202190 & BIRB796). β-Actin was used as an internal control. Error bars indicate standard deviation of 
technical triplicates. 
B Motility of each cell as summed distance in pixel (pxl) covered 21h after stimulation with 100pM TGFβ and 0.75h 
pretreated with p38 inhibitors. Median indicated as a thick line and shaded area represent data between 25th and 75th 
percentiles. 
3.4.2.5 SMAD2 and SMAD4 dynamics are differentially affected by TAK1 inhibition 
Next, I was interested in the upstream components of p38 that influence the dynamics and localization 
of SMADs. As mentioned above, TGFβ receptors activate TAK1 (Transforming growth factor-β activated 
kinase-1), which in turn activates MKKs and p38. Therefore, I used the inhibitor (5Z)-7-Oxozeaenol, 
that inhibits both the kinase and the ATPase activity of TAK1 (Wu et al, 2013) and investigated how 
dynamics of SMAD2 and SMAD4 change. 
3.4.2.5.1 TAK1 Inhibition modulates the dynamics and localization of SMADs 
First, I investigated how SMAD2 dynamics depend on different inhibitor concentrations in time-lapse 
microscopy experiments. With increasing (5Z)-7-Oxozeaenol concentration 0.75h before 100pM TGFβ 
stimulation, I observed decreased SMAD2 translocation (Figure 34A). Especially the ratio values at 
1.75h compared to the control amplitude were reduced (Figure 34B). At later time points there was 
low SMAD2 activation probably due to degradation of the TAK1 inhibitor. At 4 μM TAK1 inhibitor 
concentration almost no SMAD2 translocation was observed, which can be seen particularly in the 
heat maps (Appendix Figure A23). For all further experiments 2 μM TAK1 inhibitor was used, in 
accordance with concentrations used in the literature. In the next experiment, it’s obvious that (5Z)-7-
Oxozeaenol alone led to no translocation of SMAD2 (Figure 34C). That the first response disappeared 
with TAK1 inhibition and 100pM TGFβ stimulation was also reflected in the nuclear and cytoplasmic 
values (Figure 34C and D). This also applied to cells, which have been inhibited and stimulated with 
smaller TGFβ concentrations as shown in Figure 34D and E for 2.5pM TGFβ. In order to validate the 
time-lapse experiments, immunofluorescence experiments were carried out by inhibiting TAK1 in wild 
type cells 0.75h pre 100pM TGFβ stimulation with (5Z)-7-Oxozeaenol. Measurement of the total 
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SMAD2 nuc/ cyto ratio confirmed the results of time-lapse microscopy, as seen in Figure 34F. The first 
response of SMAD2 activation disappeared, as shown for one hour and 3 hours post 100pM TGFβ 
stimulation for TAK1 inhibited compared to non-inhibited cells (Appendix Figure A24). The blockade 
of SMAD2 activation decreased at later time points, since presumably the effectiveness of the inhibitor 
decreased. Therefor as a conclusion TAK1 activity seems essential for SMAD2 signaling. 
Interestingly, it was quite different for SMAD4 when investigating the dynamics in time-lapse 
experiments with different (5Z) -7-Oxozeaenol concentrations 0.75h pre 100pM TGFβ. In comparison 
to the control, DMSO and 100pM TGFβ, SMAD4 accumulated strongly from the cytoplasm into the 
nucleus with increasing TAK1 inhibitor concentration (Figure 34G). However, after the increased 
amplitude an adaptation took place and SMAD4 signaling was normal at later time points, since 
presumably the inhibitor concentration was no longer sufficient. The fact that the SMAD4 response 
has been enormously increased is particularly evident in the heat maps (Appendix Figure A25). 
However, dynamics for low TAK1 inhibitor concentrations, 0.1 and 0.25 μM, did not show this effect 
and are presumably below a threshold. As for SMAD2, 2 μM TAK inhibitor was used for all further 
experiments. In Figure 34H, single cell trajectories are shown, in which one can recognize as well as in 
the median that at approx. 8 hours there was another peak of SMAD4 translocation. This was coupled 
to the slight SMAD2 activity at this time point. Unexpectedly, (5Z)-7-Oxozeaenol alone (without TGFβ) 
led to a strong translocation of SMAD4, as shown in comparison to the control (DMSO and 100pM 
TGFβ) and for single cell trajectories (Figure 34I and M). The enhanced SMAD4 response can also be 
observed in cells which have been inhibited and treated with smaller TGFβ concentrations, as shown 
in Appendix Figure A26 for 2.5pM TGFβ. And surprisingly adding (5Z) -7-Oxozeaenol 6 hours post 
100pM TGFβ stimulation resulted in an immediate import of SMAD4 with a larger amplitude (around 
11 hours) than the first TGFβ response (Figure 34K, Appendix Figure A27 and A28). The increased 
SMAD4 response was almost adapted to normal value after 15 hours (Appendix Figure A28). In 
conclusion TAK1 inhibition enhances SMAD4 signaling independent of SMAD2 and TGFβ. 
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3.4.2.5.1 Figure 34. TAK1 Inhibition modulates the dynamics and localization of SMADs. 
A Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
5Z-7-Oxozeaenol 
(TAKi) at indicated concentrations. Shaded area represent data between 25th and 75th percentiles. 
B Nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 5Z-7-
Oxozeaenol 
(TAKi) at indicated concentrations at time point 1.75h. Red lines indicate median; boxes include data between the 25th 
and 75th percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
C Median nuc/cyto SMAD2 ratio, nuclear and cytoplasmic level of the SMAD2-YFP reporter cells stimulated with 100pM 
TGFβ and 0.75h pretreated with 5Z-7-Oxozeaenol (TAKi). DMSO and only TAKi were used as controls. Shaded area 
represent data between 25th and 75th percentiles. 
D Nuc/cyto SMAD2 ratio of the SMAD2 reporter cells stimulated with 2.5 or 100pM TGFβ and 0.75h pretreated with 5Z-7-
Oxozeaenol (TAKi) at time point 1.75h. Red lines indicate median; boxes include data between the 25th and 75th 
percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
E Median nuc/cyto SMAD2 ratio, nuclear and cytoplasmic level of the SMAD2-YFP reporter cells stimulated with 2.5pM 
TGFβ and 0.75h pretreated with 5Z-7-Oxozeaenol (TAKi). Shaded area represent data between 25th and 75th percentiles. 
F Nuc/cyto SMAD2 ratio was measured in MCF10A WT cells stimulated with 100pM TGFβ and 0.75h pretreated with 5Z-
7-Oxozeaenol (TAKi) by immunofluorescence at indicated time points. White lines indicate median; boxes include data 
between the 25th and 75th percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses 
represent outliers. 
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G Median nuc/cyto SMAD4 ratio, nuclear and cytoplasmic level of the SMAD4-YFP reporter cells stimulated with 100pM 
TGFβ and 0.75h pretreated with 5Z-7-Oxozeaenol (TAKi) at indicated concentrations. Shaded area represent data between 
25th and 75th percentiles. 
H Exemplary individual nuc/cyto SMAD4 ratio trajectories (thin lines) for the SMAD4-YFP reporter cells stimulated with 
100pM TGFβ and 0.75h pretreated with TAKi compared to the median nuc/cyto SMAD4 ratio of the entire population 
(thick line). 
I Median nuc/cyto SMAD4 ratio, nuclear and cytoplasmic level of the SMAD4-YFP reporter cells stimulated with 100pM 
TGFβ and only 5Z-7-Oxozeaenol (TAKi). Shaded area represent data between 25th and 75th percentiles. 
J Exemplary individual nuc/cyto SMAD4 ratio trajectories (thin lines) of the SMAD4-YFP reporter cells treated only with 5Z-
7-Oxozeaenol (TAKi) compared to the median nuc/cyto SMAD4 ratio of the entire population (thick line). DMSO was used 
as a control. 
K Median nuc/cyto SMAD4 ratio of the SMAD4-YFP reporter cells stimulated with 100pM TGFβ and 6h post TAKi. Shaded 
area represent data between 25th and 75th percentiles. 
3.4.2.5.2 Underlying mechanisms of TAK1 inhibition 
To further confirm the microscopy results and detect underlying mechanisms, I performed western 
blot analysis. As shown in Figure 35A the first response of SMAD2 phosphorylation disappeared when 
TAK1 is inhibited 0.75h pre 100pM TGFβ stimulation. Later time points showed an increase in 
phosphorylation of SMAD2, since presumably the effectiveness of the inhibitor decreased. 
Furthermore, TAK1 inhibition enhanced early accumulation of SMAD4, which is especially apparent at 
time point 0 without TGFβ stimulation. Since TAK1 inhibition enhanced SMAD4 signaling independent 
of pSMAD2 and TGFβ, it was exciting to investigate how pSMAD3 behaves. In comparison to pSMAD2 
the effect was not so strong, however less SMAD3 was phosphorylated by TAK1 inhibition. Thus, the 
accumulation of SMAD4 is also independent of pSMAD3. To show that TAK1 acts upstream of p38, I 
investigated the phosphorylation status of the p38 target gene HSP27. As can be seen in Figure 35A, 
HSP27 was less phosphorylated and therefore p38 inhibition successful. Furthermore, TAK1 inhibition 
stabilized TGFβ receptors 1 suggesting a remodeling of the receptors so that pSMAD2 may not bind 
and phosphorylation is prevented.  
This assumption is supported by another time-lapse movie where cells are inhibited at 6 hours post 
100pM TGFβ stimulation with the TAKi inhibitor (5Z)-7-Oxozeaenol or TGFβR1 inhibitor. Inhibition of 
TAK1 and TGFβR1 showed the same signaling termination rates for SMAD2 translocation into the 
nucleus (Figure35B). The same ratio values are shown for 6, 7 and 10 hours in Figure 35C, while the 
(5Z)-7-Oxozeaenol efficiency probably decreased at 15 hours. 
Since SMAD4 translocated decoupled from pSMAD2, pSMAD3 and TGFβ into the nucleus, I 
investigated whether the BMP (Bone morphogenetic proteins) signaling pathway is involved. SMAD4 
acts as a shared partner for both TGFβ- specific and BMP- specific SMADs (Zhang et al, 1997). Three 
different inhibitors were used to inhibit BMP signaling: Noggin, LDN193189 and Dorsomorphin. 
Dorsomorphin inhibits selectively BMP type I receptor ALK2, ALK3 and ALK6, and thus blocks BMP-
mediated SMAD1, 5 and 8 phosphorylation. LDN193189 inhibits the activity of the BMP type I 
receptors ALK2 and ALK3 and therefor activation of SMAD1, 5 and 8 (Yu et al, 2008a&b). Noggin has 
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been shown to be a high-affinity binding protein to BMP and antagonizes BMP bio-activities (Groppe 
et al, 2002; Groppe et al, 2003). As shown in Figure 35D TAK1 inhibition enhanced SMAD4 signaling 
independent of BMP signaling since all three inhibitors have almost no effect on the accumulation of 
SMAD4 after TAK1 inhibition. In addition, inhibition of the receptors also showed no effect on the 
SMAD4 response after TAK1 inhibition, but the second small peak due to SMAD2 activation was 
prevented (Figure35E).  
In summary TAK1 inhibition prevents phosphorylation of SMAD2 and enhances early accumulation of 
SMAD4 independent of pSMAD2, pSMAD3, TGFβ and BMP signaling.  
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3.4.2.5.2 Figure 35. Underlying mechanisms of TAK1 inhibition.  
A Western blot analysis of phosphorylated SMAD2, total SMAD4, phosphorylated SMAD3, phosphorylated HSP27 and 
TGFβRI in MCF10A WT cells stimulated with 100pM TGFβ and 0.75h pretreated with 5Z-7-Oxozeaenol (TAKi). GAPDH was 
used as loading controls. 
B Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 6h post TAKi or TGF-β 
RI Kinase inhibitor VI SB431542 (TGFβRi). Shaded area represent data between 25th and 75th percentiles. 
C Nuc/cyto SMAD2 ratio of the SMAD2 reporter cells stimulated with 100pM TGFβ and 6h post TAKi or TGF-β RI Kinase 
inhibitor VI SB431542 (TGFβRi) at indicated time points. White lines indicate median; boxes include data between the 25th 
and 75th percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
D Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
BMP signaling inhibitors: Noggin, LDN193189 and Dorsomorphin. Shaded area represent data between 25th and 75th 
percentiles. 
E Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
5Z-7-Oxozeaenol (TAKi) and TGF-β RI Kinase inhibitor VI SB431542 (TGFβRi).  Shaded area represent data between 25th 
and 75th percentiles. 
3.4.2.5.3 Dependency of SMAD target genes on TAK1 activity 
Furthermore, I was interested in the impact of this dynamic remodeling on gene expression and cell 
fate. Therefore, I performed RT-PCRs after inhibiting TAK1 activity and 100pM TGFβ stimulation (Figure 
36). First, the SMAD2 and SMAD4 expression remained more or less constant and unchanged by the 
inhibition. However, the strong first response of the negative feedback loops SnoN and SMAD7 were 
gone and at later time points there was only a slight increase. Also, TIEG showed the same behavior. 
Nevertheless, SARA remained unchanged. Furthermore, even for Snail and PAI1 the extreme peaks 
were missing, and both were less expressed at later time points. This confirms that TAK1 activity is 
probably needed for EMT and although the SMAD4 response is enhanced, SMAD2 accumulation is 
essential for the TGFβ target genes.  
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3.4.2.5.3 Figure 36. Dependency of SMAD target genes on TAK1 activity. 
Expression of TGFβ target genes in MCF10A WT cells stimulated with 100pM TGFβ and 0.75h pretreated with 5Z-7-
Oxozeaenol (TAKi). β-Actin was used as an internal control. Error bars indicate standard deviation of technical triplicates. 
3.4.2.6 Underlying mechanisms of p38 and SMAD cross-talk 
Since TAK1-p38 pathway has an enormous impact on the dynamic remodeling of SMAD2 and SMAD4 
and affects TGFβ cell fate decisions, I was curious about the underlying mechanisms of this cross-talk. 
I focused on the downstream effect of p38 kinase activity inhibition. There are two possible 
mechanisms how inhibition of p38 effects SMAD signaling. First, less SMAD2 gets phosphorylated or 
second more pSMAD2 gets dephosphorylated.  
3.4.2.6.1 Knock down of SMAD7 does not alter the p38 effect on SMAD2  
A central role of regulating SMAD2 activity plays the negative regulator SMAD7. SMAD7 interacts with 
p38 and it has been reported that SMAD7 is important for TGFβ-induced activation of p38 and other 
upstream kinases (Edlund et al, 2003), suggesting a potential interface between p38 and SMAD2. To 
determine if p38 interact with SMAD7 to regulate long-term dynamics of SMAD2, I perturbed the 
signaling network using p38 inhibitors in the absence or presence of SMAD7. For this purpose, I used 
the SMAD7 CRISPR Cas9 knock out clone 12 (3.2.2.3) and the SMAD2-YFP Cas9 reporter cell line as a 
control cell line. As shown in Figure 37A, the effect of p38 inhibition was obvious in the SMAD2 ratio 
of the control cell line and in clone 12, although the response was stronger in the SMAD7 knock down 
cell line as expected. Furthermore, the p38 effect was also evident at the nuclear and cellular level and 
hence the late response disappeared (Figure 37B). In conclusion SMAD7 knock down had no Influence 
on the effect of p38 inhibition and therefore SMAD7 plays no or only a minor role in the mechanism. 
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3.4.2.6.1 Figure 37. Knock down of SMAD7 does not alter the p38 effect on SMAD2.  
A Median nuc/cyto SMAD2 ratio of the control SMAD2-YFP Cas9 reporter cell line and the SMAD7 CRISPR Cas9 knock out 
clone 12 stimulated with 100pM TGFβ and 0.75h pretreated with p38 inhibitorjls (SB202190 & BIRB796).  Shaded area 
represent data between 25th and 75th percentiles. 
B Nuclear and cytoplasmic SMAD2 level of the control SMAD2-YFP Cas9 reporter cell line and the SMAD7 CRISPR Cas9 
knock out clone 12 stimulated with 100pM TGFβ and 0.75h pretreated with p38 inhibitors. 
3.4.2.6.2 Inhibition of p38 does not shift receptors to degradation 
As a further approach I considered that SMAD2 is less phosphorylated due to modified receptor 
trafficking. Receptors are either internalized into early endosomes and recycled or internalized into 
Caveolin-positive vesicles and subsequently degraded (3.2.4). In order to test the hypothesis that 
inhibition of p38 kinase activity shifts the receptor trafficking more to degradation and thus, p38 
activity promotes recycling or prevent degradation, I used Nystatin. Nystatin causes disruption of the 
lipid raft- caveolar endocytic pathway and therefor inhibits the degradation pathway and stabilizes the 
receptors (Di Guglielmo et al, 2003). As shown in Figure 38A pretreatment with Nystatin and 100pM 
TGFβ stimulation resulted in stronger SMAD2 accumulation into the nucleus, although it was not so 
clearly indicated in the ratio, since more SMAD2 was also present in the cytoplasm. However, p38 
inhibition and Nystatin also showed the p38 effect, which is particularly evident in the heat maps 
(Figure 38A and B). The maximum amplitude was only marginally lower by p38 inhibition, the time of 
the maximum amplitude and the end time of the first response were the same, while the late response 
was lower, as can be seen in the mean intensity 5 hours after the first response and the final feature 
value (Figure 38C). In conclusion preventing lipid-raft mediated receptor degradation did not prevent 
the reduction of SMAD translocation by p38 inhibition.  
3.4.2 Inhibiting non- canonical activation of p38 alters long-term SMAD dynamics 
105 
 
 
 
3.4.2 Inhibiting non- canonical activation of p38 alters long-term SMAD dynamics 
106 
 
 
3.4.2.6.2 Figure 38. Inhibition of p38 does not shift receptors to degradation. 
A Median nuc/cyto SMAD2 ratio, nuclear and cytoplasmic level of the SMAD2-YFP reporter cells stimulated with 100pM 
TGFβ and 0.75h pretreated with p38 inhibitors and/or Nystatin. Shaded area represent data between 25th and 75th 
percentiles. 
B Heat maps of nuclear SMAD2 translocation in individual cells over 24h. Cells were stimulated with 100pM TGFβ and 
0.75h pretreated with p38 inhibitors and/or Nystatin. Cells were sorted by the time of the first division as indicated by red 
marks. 
C Signaling features for nuclear SMAD2 level in the SMAD2 reporter cells stimulated with 100pM TGFβ and 0.75h 
pretreated with p38 inhibitors and/or Nystatin. Red lines indicate median; boxes include data between the 25th and 75th 
percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
3.4.2.6.3 p38 effect is not mediated by alteration of the ubiquitin-dependent degradation  
Next, I investigated whether the p38 effect is due to ubiquitin-dependent degradation mediated by 
the proteasome. Inhibition of proteasome activity causes accumulation of key TGFβ signaling 
components and therefore modulates SMAD dynamics (3.2.3). In this process, SMURF2 acts as an 
ubiquitin E3 ligase mediating proteasome-dependent degradation of SMAD2 (Lin et al, 2000). Since 
SMAD7 binds to SMURF2 to form complexes that target the receptors and other TGFβ components for 
degradation (Kavsak et al, 2000), I hypothesized that the p38 kinase interferes with this complex and 
thus has an impact on the dynamic remodeling of SMAD2. As shown in Figure 39A pretreatment with 
the proteasome inhibitor MG132 and 100pM TGFβ stimulation resulted in a strong SMAD2 
accumulation into the nucleus. However, pretreatment with the p38 inhibitor and MG132 and TGFβ 
stimulation also showed the p38 effect, which is not only recognizable in the ratio, but also especially 
in the nuclear level (Figure 39A). Compared to treatment with MG132 and TGFβ, the amplitude was 
slightly reduced and the mean intensity within 5 hours after response was lower (Figure 39B). 
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Interestingly, the p38 effect was also evident when the cells were treated with the MG132 and the p38 
inhibitor compared to treatment with only MG132, hence independent of TGFβ stimulation. In 
conclusion the p38 effect is not mediated by alteration of the ubiquitin-dependent degradation (Figure 
39C). 
 
 
 
3.4.2.6.3 Figure 39. p38 effect is not mediated by alteration of the ubiquitin-dependent degradation.  
A Median nuc/cyto SMAD2 ratio, nuclear and cytoplasmic level of the SMAD2-YFP reporter cells stimulated with 100pM 
TGFβ and 0.75h pretreated with p38 inhibitors and/or MG132. Shaded area represent data between 25th and 75th 
percentiles. 
B Signaling features for nuc/cyto SMAD2 ratio of the SMAD2 reporter cells stimulated with 100pM TGFβ and 0.75h 
pretreated with p38 inhibitors and/or MG132. Red lines indicate median; boxes include data between the 25th and 75th 
percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
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C Median nuclear SMAD2 level, nuc/cyto SMAD2 ratio and cytoplasmic level of the SMAD2-YFP reporter cells treated with 
only p38 inhibitors or MG132. 
3.4.2.6.4 Inhibition of PP1 and PP2A does not alter the p38 effect on SMAD2 
Since p38 inhibition abrogates the MG132 effect independent of TGFβ, I hypothesized that the p38 
effect occurs independently of the receptors and the SMAD2 phosphorylation but could affect 
dephosphorylation. Thus, to understand the mechanism how the p38 kinase influences the long-term 
dynamics of SMADs, I focused on phosphatases. Phosphatases are grouped into three main classes 
based on sequence, structure and catalytic function. The largest class of phosphatases is the 
phosphoprotein phosphatase (PPP) family comprised of PP1, PP2A, PP2B, PP4, PP5, PP6 and PP7, and 
the protein phosphatase Mg2+- or Mn2+- dependent (PPM) family, comprised primarily of PP2C. The 
protein Tyr phosphatase (PTP) super-family forms the second group and the aspartate-based protein 
phosphatase the third (Moorhead et al, 2007). PP1 and PP2A are the major cellular phosphatases, 
which together account for more than 90% of protein phosphatase activity in eukaryotes (Virshup & 
Shenolikar, 2009). Therefore, I used first Okadaic acid, a phosphatase inhibitor particularly of type 1 
(PP1) and 2A (PP2A) (Bialojan & Takai, 1988), but also other types including 4, 5, and 2B (PP4, PP5, 
PP2B) (Louzao et al, 2005). The hypothesis is that p38 inhibition activates phosphatases and hence 
activated p38 inhibits directly or indirectly phosphatases. Since MCF10A cells died 6 hours after 
treatment of okadaic acid, I analyzed only the first 6 hours. As shown in Figure 40A pretreatment with 
the p38 inhibitors and 100pM TGFβ stimulation resulted in less SMAD2 accumulation into the nucleus. 
However, p38 inhibition and Okadaic acid 0.75 hours pre 100pM TGFβ stimulation, 1.5 hours post (data 
not shown) and 3 hours post TGFβ still revealed the observed p38 effect, which is particularly 
noticeable at 5 hours (Figure 40B). In conclusion using Okadaic acid I observed that inhibition of PP1 
and PP2A phosphatases did not influence the p38-mediated SMAD2 response.  
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3.4.2.6.4 Figure 40. Inhibition of PP1 and PP2A does not alter the p38 effect on SMAD2. 
A Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
p38 inhibitors and Okadaic acid at indicated time points. Shaded area represent data between 25th and 75th percentiles. 
B Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
p38 inhibitors and Okadaic acid at indicated time points. 
3.4.2.6.5 Inhibition of PP2C abrogates the p38 effect on SMADs 
To further investigate the hypothesis that phosphatases mediate the p38 effect, I specifically inhibited 
another phosphatase group PP2C with Sanguinarine chloride. Sanguinarine is a plant alkaloid, that 
shows selectivity for PP2C as compared with PP1, PP2A, and PP2B in vitro (Aburai et al, 2010). First, I 
treated MCF10A cells with different concentrations of Sanguinarine chloride and 100pM TGFβ. In 
accordance with the literature, I chose for all further experiments the final concentration of 1 μM, as 
at higher concentrations cells start to die and lower concentrations have little effect on the SMAD2 
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response (Figure 41A). As shown in Figure 41B cells pretreated with 1µM inhibitor and TGFβ showed 
a stronger accumulation of SMAD2 into the nucleus with similar amplitude and a prevented 
adaptation, as can be seen by the 5-hour value (Figure 41C). And surprisingly p38 and Sanguinarine 
chloride inhibitors and TGFβ abrogated the p38 effect (Figure 41B and C). In Figure 41D random cells 
for Sanguinarine pretreated and TGFβ stimulated cells with and without p38 inhibitors are plotted. The 
p38 effect disappeared and all cells showed a strong SMAD2 response, independent of p38 kinase 
inhibition. Also adding Sanguinarine 3 hours post stimulation in p38 pretreated cells immediately 
enhanced SMAD2 accumulation in the nucleus (Figure 41B and C). Furthermore, the p38 effect was 
also prevented for SMAD4, measured in the combined cell line E9 when the cells were treated with 
Sanguinarine chloride and p38 inhibitors (Figure 41E). In addition, the question arises whether 
inhibition with Sanguinarine chloride affected the inhibition of p38 and thus was the effect gone, since 
the PP2C family also acts on the p38 pathway. The phosphatase inhibition could also result in more 
pp38 and the p38 inhibitors could no longer function completely. To ensure that the kinase activity of 
p38 was still inhibited, I increased the concentrations of the inhibitors to 15μM SB202190 and 20μM 
BIRB. However, as can be seen in Figure 41F, the p38 effect disappeared with Sanguinarine chloride 
even at high p38 inhibitor concentrations. In conclusion inhibition of PP2C abrogated the p38- 
mediated SMAD response and therefore a PP2C family member was involved in the p38- SMAD-
crosstalk, but the link between activated p38 and the phosphatase remain unclear.  
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3.4.2.6.5 Figure 41. Inhibition of PP2C abrogates the p38 effect on SMADs. 
A Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
Sanguinarine chloride (SC) at indicated concentrations.  
B Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and p38 inhibitors and 
Sanguinarine chloride (SC) at indicated time points. Shaded area represent data between 25th and 75th percentiles. 
C Signaling features for nuc/cyto SMAD2 ratio of the SMAD2 reporter cells stimulated with 100pM TGFβ and p38 inhibitors 
and Sanguinarine chloride (SC) at indicated time points. White lines indicate median; boxes include data between the 25th 
and 75th percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
D Exemplary individual nuc/cyto SMAD2 ratio trajectories (thin lines) for the SMAD2-YFP reporter cells stimulated with 
100pM TGFβ and 0.75h pretreated with p38 inhibitors and/ or Sanguinarine chloride (SC) compared to the median 
nuc/cyto SMAD2 ratio of the entire population (thick line). 
E Median nuc/cyto SMAD4 ratio of the SMAD4-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
p38 inhibitors and/ or Sanguinarine chloride (SC). Shaded area represent data between 25th and 75th percentiles. 
F Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
a high concentration of p38 inhibitors (15μM SB202190 and 20μM BIRB796) and/ or Sanguinarine chloride (SC). Shaded 
area represent data between 25th and 75th percentiles. 
3.4.2.6.6 PPM1A is probably not involved in the p38-mediated TGFβ response 
As mentioned, PP2C family member belong to the Mn2+/Mg2+-dependent PPM family, where metal 
ions play a catalytic and central role through the activation of a water molecule for the 
dephosphorylation reaction (Shi, 2009). The PP2C family represents a large group of highly conserved 
protein phosphatases, with 16 distinct PP2C genes in the human genome that give rise to at least 22 
different isoforms (Lammers & Lavi, 2007). The different isoforms have distinct sequences and domain 
organizations. These PP2C isoforms also exhibit distinct functions, expression patterns, and subcellular 
localization. The primary function of PP2C appears to be the regulation of stress signaling, although it 
also plays a role in cell differentiation, growth, survival, apoptosis, and metabolism (Lu & Wang, 2008). 
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Some PP2C members, such as PP2Cα (PPM1A) and PP2Cβ are candidate tumor suppressor proteins, 
whereas others, such as PP2Cδ (Wip1), may contribute to oncogenic transformation (Shi, 2009). How 
these PP2C members are regulated during signaling remains largely unknown. Moreover, the PP2C 
family member that is involved in the p38- SMAD-crosstalk still needs to be clarified. Since PP2Cα 
(PPM1A) plays a critical role in terminating TGFβ signaling through direct dephosphorylation of 
SMAD2/SMAD3 (Lin et al, 2006), this phosphatase would be a good candidate. PPM1A promotes 
nuclear export of TGFβ-activated SMAD2/3. Ectopic expression of PPM1A abolishes TGFβ-induced 
antiproliferative and transcriptional responses, whereas depletion of PPM1A enhances TGFβ signaling 
in mammalian cells (Lin et al, 2006). Furthermore, PPM1A inhibited the activation of the p38 cascade 
(Takekawa et al, 1998). Thus, to understand the mechanism how the p38 kinase is linked to a PP2C 
family member to influence the long-term dynamics of SMADs, I knocked down PPM1A in time-lapse 
microscopy experiments. First, I did a knock down test 24, 48 and 72h after transfection of MCF10A 
WT cells with PPM1A siRNA. As seen in Figure 42A, PPM1A was down to 16% after 48h and even to 
10% after 72h. The control was carried out with scrambled RNA. To achieve the best knock down 
efficiency, I transfected the SMAD2 reporter cell line 48h prior to TGFβ treatment with PPM1A siRNA. 
Due to the prolonged growth period, the control response is somewhat reduced after 100 pM TGFβ 
stimulation (Figure 42B). Nonetheless, knockdown of PPM1A enhanced nuclear SMAD2 translocation. 
Already the first answer showed more SMAD2 in the nucleus, which can be seen especially in the heat 
maps (Figure 42C). As there was also more SMAD2 present in the cytoplasm, the ratio concealed the 
effects of the knockdown of PPM1A (Figure 42D and E). Furthermore, fewer cells divided due to 
enhanced SMAD2 activation (Figure 42F). The p38 effect in the nuclear control after treatment with 
the p38 inhibitors was also weaker, as shown in Figure 42G. However, the effect was clearly visible in 
the ratio and SMAD2 translocated after the first response from the nucleus back to the cytoplasm 
(Figure 42I and K). Nevertheless, even after PPM1A siRNA transfection and p38 inhibition, the p38 
effect was recognizable (Figure 42H, J and L). Therefore, PPM1A was probably not involved in the p38-
mediated TGFβ response. However, compensation mechanisms and incomplete knock down could 
conceal the function of PPM1A. 
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3.4.2.6.6 Figure 42. PPM1A is probably not involved in the p38-mediated TGFβ response. 
A Expression of PPM1A 24, 48 and 72h after transfection of MCF10A WT cells with PPM1A siRNA. The controls were carried 
out without transfection or scrambled RNA. β-Actin was used as an internal control. Error bars indicate standard deviation 
of technical triplicates. 
B Median nuclear SMAD2 level of the SMAD2-YFP reporter cells seeded 3 days prior and transfected 48h prior to 100pM 
TGFβ treatment with PPM1A siRNA. Shaded area represent data between 25th and 75th percentiles. 
C Heat maps of nuclear SMAD2 translocation in individual cells over 24h. Cells were transfected 48h prior to 100pM TGFβ 
treatment with PPM1A siRNA. Cells were sorted by the time of the first division as indicated by red marks. 
D Median cytoplasmic SMAD2 level of the SMAD2-YFP reporter cells transfected 48h prior to 100pM TGFβ treatment with 
PPM1A siRNA. Shaded area represent data between 25th and 75th percentiles. 
E Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells transfected 48h prior to 100pM TGFβ treatment with 
PPM1A siRNA. Shaded area represent data between 25th and 75th percentiles. 
F Cell proliferation of SMAD2 reporter cells shown as fraction of dividing cells within 24h. 
G Median nuclear SMAD2 level of the SMAD2-YFP reporter cells seeded 3 days prior to 100pM TGFβ stimulation and 0.75h 
pretreated with p38 inhibitors. Shaded area represent data between 25th and 75th percentiles. 
H Median nuclear SMAD2 level of the SMAD2-YFP reporter cells seeded 3 days prior and transfected 48h prior to 100pM 
TGFβ treatment with PPM1A siRNA and 0.75h pretreated with p38 inhibitors. Shaded area represent data between 25th 
and 75th percentiles. 
I Median cytoplasmic SMAD2 level of the SMAD2-YFP reporter cells seeded 3 days prior to 100pM TGFβ stimulation and 
0.75h pretreated with p38 inhibitors.  
J Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells transfected 48h prior to 100pM TGFβ treatment with 
PPM1A siRNA and 0.75h pretreated with p38 inhibitors. 
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K Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells seeded 3 days prior to 100pM TGFβ stimulation and 
0.75h pretreated with p38 inhibitors.  
L Median cytoplasmic SMAD2 level of the SMAD2-YFP reporter cells transfected 48h prior to 100pM TGFβ treatment with 
PPM1A siRNA and 0.75h pretreated with p38 inhibitors. 
3.4.3 Inhibition of ERK signaling alters long-term SMAD dynamics 
Inhibition of the p38 MAP kinase pathway results in modified other MAPK pathways like the 
extracellular-signal-regulated kinase (ERK) pathway (Hall & Davis, 2002). ERK is also another non-
canonical MAP Kinase pathway of TGFβ activation. TGFβ- can induce phosphorylation of the receptors 
I and II and on Shc, which leads to recruiting of Grb2/Sos to activate Erk 1/2 (pp44/pp42) through Ras, 
Raf, and MEK1 (Mitogen-activated protein kinase kinase 1) and 2 (Figure 1C, Zhang et al, 2009). 
Interestingly, inhibition of the kinase activity of p38 and stimulation with 100pM TGFβ led in MCF10A 
WT cells to enhanced ERK signaling measured by phosphorylated p42 (ERK2), as the target protein, in 
western blot analysis (Figure 43A). Since inhibition of p38 amplified ERK signaling, the question came 
up whether the effect of p38 was just a matter of proliferative and anti-proliferative triggers. 
Therefore, I initially inhibited MEK1 and 2 with AZD6244, a potent, selective, and ATP-uncompetitive 
inhibitor, and performed with and without p38 inhibitors in TGFβ-stimulated SMAD2 reporter cells 
time-lapse microscopy experiments (Davies et al, 2007). As can be seen in Figure 43B, the p38 effect 
at 2.5pM and 100pM TGFβ with MEK and p38 inhibitors was slightly lower but clearly recognizable. 
Inhibition with p38 inhibitors and Gefitinib, a tyrosine kinase inhibitor of the epidermal growth factor 
receptor (EGFR) (Tamura & Fukuoka, 2005), led to the same result (Figure 43C and Appendix Figure 
A29).  
In conclusion, inhibition of ERK signaling cannot abrogate the p38 effect. Nevertheless, I was interested 
in the impact of ERK signaling on SMAD dynamics. It is known that ERK signaling regulates target gene 
transcription through cofactors in conjunction with SMADs to control for instance EMT (Xie et al, 2004; 
Javelaud & Mauviel, 2005; Harish et al, 2015). 
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3.4.3 Figure 43. Inhibition of ERK signaling alters long-term SMAD dynamics. 
A Western blot analysis of phosphorylated ERK2 (pp42) in MCF10A WT cells stimulated with 100pM TGFβ and 0.75h 
pretreated with p38 inhibitors (SB202190 & BIRB796). GAPDH was used as a loading control. 
B Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 2.5 or 100pM TGFβ and 0.75h pretreated 
with p38 inhibitors and/ or AZD6244 (MEKi). Shaded area represent data between 25th and 75th percentiles. 
C Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
p38 inhibitors and/ or Gefitinib (Gef). Shaded area represent data between 25th and 75th percentiles. 
3.4.3.1 TGFβ response depends on EGF concentration 
In order to discover the impact of ERK signaling on the TGFβ response, I used different epidermal 
growth factor (EGF) concentrations in the media to vary the intensity of the signaling pathway. 
Normally 20 ng/ml EGF and horse serum, as well as insulin, cholera toxin and hydrocortisone were 
used in the medium (Debnath et al, 2003). To control the exact EGF concentrations in the media, I used 
0.3% BSA instead of horse serum, and insulin was omitted to not interfere with ERK signaling. I kept 
the cells overnight (approximately 14 hours) in these conditions and changed the media before the 
experiments. Considering the nuclear values, it became clear that cells without EGF in the media 
before stimulating with 100pM TGFβ showed extremely low SMAD2 activation (Figure 44A). This was 
reflected in a very low maximum amplitude and an absent second response, which was particularly 
evident in the heat maps and the final nuclear value (Appendix Figure A30 and A31). With increasing 
EGF concentrations the amplitude and the second response rose and reached saturation for SMAD2 
translocation into the nucleus at 10 ng/ml EGF (Figure 44A, Appendix Figure A30 and A31). 
Interestingly, already the basal nuclear and cytoplasmic SMAD2 levels increased with increasing EGF 
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concentrations (Appendix Figure A30) and therefore the EGF dependencies were somewhat less 
marked in the ratio than in the nuclear and cytoplasmic values (Figure 44B and C). Interestingly, 
without EGF only about 50% of the cells reacted to TGFβ at all, while about 90-95% reacted to TGFβ at 
1-20 ng/ml EGF concentration. Thus, the increasing TGFβ response by rising EGF concentrations was 
not due to a changed proportion of responders (Figure 44D). Moreover, the SMAD4 reporter cell line 
also showed comparable results and SMAD4 translocation and activation depends on ERK signaling 
(Appendix Figure A32). With rising EGF concentrations, the maximum amplitude and the long-term 
dynamics of SMAD4 increased (Appendix Figure A33). The basal nuclear and cytoplasmic SMAD4 levels 
were also increasing with rising EGF concentrations. Since more than 90% of the cells reacted at a 
concentration of 1-20 ng/ml EGF in the media to 100pM TGFβ, thus the strength of the TGFβ response 
depended on the EGF concentration (Appendix Figure A34).  
Western blot analysis with MCF10A WT cells also confirmed, that the TGFβ response depended on EGF 
signaling. If there was no EGF in the medium (0.3% BSA instead of horse serum and no insulin), only a 
very weak phosphorylation of SMAD2 and SMAD3 took place upon 100pM TGFβ stimulation compared 
to pSMAD2 and pSMAD3 with the normal medium of 20 ng/ml EGF (Figure 44E). 
Furthermore, I investigated whether the cell fate changes due to a modified crosstalk of TGFβ and ERK 
signaling. As shown in Figure 44F, cells without EGF almost never divided. But the different EGF 
concentrations had no influence on the proportion of dividing cells. Figure 44G shows the covered 
distance of the cells at varying EGF concentrations and 100pM TGFβ, and it is evident that cells were 
moving more with increasing EGF concentrations and therefore both ERK and TGFβ signaling may are 
important for EMT.  
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3.4.3.1 Figure 44. TGFβ response depends on EGF concentration. 
A Median nuclear SMAD2 level of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ at varying EGF (epidermal 
growth factor) concentrations. 
B Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ at varying EGF 
concentrations. 
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C Median cytoplasmic SMAD2 level of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ at varying EGF 
concentrations. 
D Responders in % of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ at varying EGF concentrations. 
E Western blot analysis of phosphorylated SMAD2 and SMAD3 in MCF10A WT cells stimulated with 100pM TGFβ at 0 or 
20ng/ml EGF. GAPDH was used as a loading control. 
F Cell proliferation of reporter cells shown as fraction of dividing cells stimulated with 100pM TGFβ at varying EGF 
concentrations. 
G Motility of each cell as summed distance in pixel (pxl) covered 24h after stimulation with 100pM TGFβ at varying EGF 
concentrations.  
3.4.3.2 Inhibition of the ERK cascade leads to a diminished late SMAD response 
To underline that SMAD signaling depends on the ERK signaling, I inhibited the ERK cascade at different 
points. First Gefitinib, the tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) 
(Tamura & Fukuoka, 2005), was used 0.75 hours before 100 pM TGFβ stimulation in time-lapse 
microscopy experiments. As shown in Figure 45A and C, inhibition of the EGF receptors led to reduced 
nuclear SMAD2 accumulation at later time points through an enhanced adaptation, while the 
amplitude of the initial response remained unchanged. In Figure 45B trajectories of random individual 
cells are shown. To exclude the possibility that Gefitinib would require a longer effective duration, cells 
were treated 2 hours before TGFβ stimulation with the inhibitor. But still the initial response remained 
unaffected and only the second response was modified (Figure 45A and C). Western blot analysis with 
MCF10A WT cells also confirmed the results. While total SMAD2 and total SMAD3 remain unchanged 
by treatment with gefitinib, the late phosphorylation of SMAD2 and SMAD3 was diminished (Figure 
45D). Even if the cascade was inhibited downstream of the receptors, such as the Raf kinase with the 
small molecular inhibitor Sorafenib (Wilhelm et al, 2004; Adnane et al, 2006) and MEK1 and 2 with 
AZD6244 (Davies et al, 2007), it confirmed the results with Gefitinib. ERK signaling was essential for 
late SMAD2 activation (Figure 45E and F). The results were also valid for SMAD4 and treatment with 
Gefitinib, AZD6244 and UO126, another dual MEK1 and MEK2 inhibitor (Favata et al, 1998), led to a 
diminished late response due to a stronger adaptation (Figure 45G).  
In conclusion, TGFβ response depends on ERK signaling.  
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3.4.3.2 Figure 45. Inhibition of the ERK cascade leads to a diminished late SMAD response. 
A Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ pretreated with Gefitinib 
at indicated time points. Shaded area represent data between 25th and 75th percentiles. 
B Exemplary individual nuc/cyto SMAD2 ratio trajectories (thin lines) for the SMAD2-YFP reporter cells stimulated with 
100pM TGFβ and 0.75h pretreated with Gefitinib compared to the median nuc/cyto SMAD2 ratio of the entire population 
(thick line). 
C Signaling features for nuc/cyto SMAD2 ratio of the SMAD2 reporter cells stimulated with 100pM TGFβ pretreated with 
Gefitinib at indicated time points. Red lines indicate median; boxes include data between the 25th and 75th percentiles; 
whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
D Western blot analysis of phosphorylated SMAD2, SMAD2, phosphorylated SMAD3 and SMAD3 in MCF10A WT cells 
stimulated with 100pM TGFβ and 0.75h pretreated with Gefitinib. GAPDH was used as loading controls. 
E Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
AZD6244. Shaded area represent data between 25th and 75th percentiles. 
F Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
Sorafenib. Shaded area represent data between 25th and 75th percentiles. 
G Median nuc/cyto SMAD4 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
Gefitinib, AZD6244 or UO126. Shaded area represent data between 25th and 75th percentiles. 
3.4.3.3 Dependency of SMAD target genes on ERK signaling 
I was also interested in the impact of this dynamic remodeling on gene expression and cell fate. 
Therefore, I performed RT-PCRs after Gefitinib treatment and 100pM TGFβ stimulation (Figure 46). 
While the gene expression of SMAD7 and SnoN were hardly changed, Gefitinib prevented the late 
activation of Snail from 6 hours on post TGFβ stimulation. This supports the hypothesis that the long-
term dynamics of SMAD2 are responsible for EMT and the balance between SMAD activation and ERK 
signaling defines cellular responses to TGFβ. 
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3.4.3.3 Figure 46. Dependency of SMAD target genes on ERK signaling. 
Expression of TGFβ target genes of MCF10A WT cells stimulated with 100pM TGFβ and 0.75h pretreated with Gefitinib. β-
Actin was used as an internal control. Error bars indicate standard deviation of technical triplicates. 
3.4.3.4 Mechanism of ERK inhibition 
Since ERK signaling had an enormous impact on the long-term dynamics of SMAD2 and SMAD4 and 
affected TGFβ cell fate decisions, I was curious about the underlying mechanisms of this cross-talk. 
3.4.3.4.1 Knock down of SMAD7 does not alter the Gefitinib effect on SMAD2 
To determine if ERK signaling interacts with SMAD7 to modulate the dynamics of SMAD2, I perturbed 
the signaling network using Gefitinib and TGFβ in the absence or presence of SMAD7. For this purpose, 
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I used the SMAD7 CRISPR Cas9 knock out clone 12 (3.2.2.3) and the SMAD2-YFP Cas9 reporter cell line 
as a control cell line. However, considering the ratio values, the gefitinib effect was recognizable in the 
control cell line and for clone 12 (Figure 47A). Also, the nuclear and cytoplasmic levels showed that 
the second response disappeared through gefitinib independent of SMAD7 (Figure 47B and C). 
Therefore, SMAD7 played no role in the mechanism. 
 
 
3.4.3.4.1 Figure 47. Knock down of SMAD7 does not alter the Gefitinib effect on SMAD2. 
A Median nuc/cyto SMAD2 ratio of the control SMAD2-YFP Cas9 reporter cell line and the SMAD7 CRISPR Cas9 knock out 
clone 12 stimulated with 100pM TGFβ and 0.75h pretreated with Gefitinib.  Shaded area represent data between 25th 
and 75th percentiles. 
B Median nuclear SMAD2 level of the control SMAD2-YFP Cas9 reporter cell line and the SMAD7 CRISPR Cas9 knock out 
clone 12 stimulated with 100pM TGFβ and 0.75h pretreated with Gefitinib.   
C Median cytoplasmic SMAD2 level of the control SMAD2-YFP Cas9 reporter cell line and the SMAD7 CRISPR Cas9 knock 
out clone 12 stimulated with 100pM TGFβ and 0.75h pretreated with Gefitinib. 
3.4.3.4.2 Inhibition of PP1 and PP2A does not alter the ERK effect on SMAD2 
Furthermore, I tested the hypothesis that ERK signaling leads finally to activated phosphatases and 
hence influences the long-term dynamics of SMADs. Therefore, I used Okadaic acid, a phosphatase 
inhibitor of the major cellular phosphatases PP1 and PP2A. As mentioned in 3.4.2.6.4 MCF10A cells 
were dying from 6 hours on, so I analyzed the first 7 hours after stimulation with Okadaic acid. As 
shown in Figure 48A pretreatment with Gefitinib and 100pM TGFβ stimulation resulted in less SMAD2 
accumulation into the nucleus, especially seen from 5 hours on. However, Gefitinib and Okadaic acid 
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0.75 hours pre 100pM TGFβ stimulation still revealed the known Gefitinib effect, which is particularly 
noticeable at 5 hours (Figure 48B). In conclusion, using Okadaic acid I observed that inhibition of PP1 
and PP2A phosphatases did not abrogate the modulated SMAD2 response due to inhibition of ERK 
signaling.  
 
 
3.4.3.4.2 Figure 48. Inhibition of PP1 and PP2A does not alter the ERK effect on SMAD2. 
A Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
Gefitinib and Okadaic acid (OA).  Shaded area represent data between 25th and 75th percentiles. 
B Nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with Gefitinib 
and Okadaic acid (OA) at 5h. Red lines indicate median; boxes include data between the 25th and 75th percentiles; 
whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
3.4.3.4.3 Inhibition of PP2C abrogates the ERK effect on SMADs 
Finally, I also investigated whether the phosphatase group PP2C interferes with ERK signaling to 
modulate the long-term dynamics of SMADs. Therefore, I pretreated the cells with 1µM Sanguinarine 
chloride and stimulated subsequently with 100pM TGFβ. As shown in Figure 49A, SMAD2 accumulated 
stronger into the nucleus with similar amplitude and less adaptation, as can be seen by the 5-hour 
value (Figure 49C). And surprisingly treatment with Gefitinib and Sanguinarine chloride inhibitors and 
TGFβ abrogated the effect of inhibition of the ERK cascade on SMAD2 (Figure 49B and C). In Figure 
49D random Sanguinarine pretreated and TGFβ stimulated cells with and without Gefitinib are plotted. 
The effect of Gefitinib disappeared and all cells showed a strong SMAD2 response, independent of 
inhibition of ERK signaling. Also adding Sanguinarine 3 hours post to Gefitinib pretreated cells 
immediately enhanced the SMAD2 accumulation into the nucleus (Figure 49E). Moreover, this also 
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applied to SMAD4, measured in the combined cell line E9, when the cells were treated with 
Sanguinarine chloride and Gefitinib (Figure 49F). In addition, the question arose whether inhibition 
with Sanguinarine chloride affected the efficiency of gefitinib and therefore was the effect gone, since 
the PP2C family also acts on ERK signaling. To ensure that the inhibitor worked efficiently, I examined 
the phosphorylation status of the target protein ERK2 (pp42) by Western blot analysis. As shown in 
Figure 49G, I proved that the ERK cascade was also interrupted when treated with Sanguinarine and 
Gefitinib and ERKs remained unphosphorylated. Furthermore, the Western results confirmed that the 
Gefitinib effect disappeared and that SMAD2 was just as phosphorylated when treated with 
Sanguinarine and Gefitinib compared to just Sanguinarine treatment. In conclusion inhibition of PP2C 
abrogated the effect of inhibition of the ERK cascade on SMAD response and therefore a PP2C family 
member is involved in the ERK- SMAD-crosstalk, but the link between ERK signaling and the 
phosphatase remain unclear.  
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3.4.3.4.3 Figure 49. Inhibition of PP2C abrogates the ERK effect on SMADs. 
A Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated 
with Gefitinib or Sanguinarine chloride (SC). Shaded area represent data between 25th and 75th percentiles. 
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B Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated 
with Gefitinib and Sanguinarine chloride (SC). Shaded area represent data between 25th and 75th percentiles. 
C Nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
Gefitinib and/or Sanguinarine chloride (SC). Red lines indicate median; boxes include data between the 25th and 75th 
percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
D Exemplary individual nuc/cyto SMAD2 ratio trajectories (thin lines) for the SMAD2-YFP reporter cells stimulated with 
100pM TGFβ and 0.75h pretreated with Gefitinib and/or Sanguinarine chloride (SC) compared to the median nuc/cyto 
SMAD2 ratio of the entire population (thick line). 
E Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated 
with Gefitinib and 3h post with Sanguinarine chloride (SC). Shaded area represent data between 25th and 75th 
percentiles. 
F Median nuc/cyto SMAD4 ratio of the SMAD4-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated 
with Gefitinib and/or Sanguinarine chloride (SC). Shaded area represent data between 25th and 75th percentiles. 
G Western blot analysis of phosphorylated ERK2 and phosphorylated SMAD2 in MCF10A WT cells stimulated with 100pM 
TGFβ and 0.75h pretreated with Gefitinib and/or Sanguinarine chloride (SC). GAPDH was used as a loading control. 
3.4.3.4.4 PPM1A is probably involved in the ERK-mediated TGFβ response 
As explained in 3.4.2.6.6, PPM1A (PP2Cα) is a PP2C family member and plays a critical role in 
terminating TGFβ signaling through direct dephosphorylation of SMAD2/SMAD3 (Lin et al, 2006). 
Furthermore, PPM1A negatively regulates ERK through direct dephosphorylation of pThr202 (Li et al, 
2013). Thus, to understand the mechanism of how ERK signaling is possibly linked to PPM1A 
influencing the long-term dynamics of SMADs, I knocked down PPM1A in time-lapse microscopy 
experiments as I did for the p38 inhibitor experiments (3.4.2.6.6). Therefore, I also transfected the 
SMAD2 reporter cell line 48h prior to TGFβ treatment with PPM1A siRNA. The Gefitinib effect was 
clearly visible in the control conditions and SMAD2 translocated from the nucleus back to the 
cytoplasm after the first response due to gefitinib inhibition (Figure 50A, B and C). Interestingly, after 
PPM1A siRNA transfection and gefitinib inhibition, the gefitinib effect was barely recognizable at the 
nuclear level and in the ratio and vanished for the cytoplasmic levels (Figure 50D, E and F). To gather 
evidence that PPM1A was involved in the ERK-mediated TGFβ response, I clustered on the first 45 
minutes of the cytoplasmic response to separate cells with a very good PPM1A knock down from those 
with worse or none knock down (Figure 50G). Subsequently, I considered only the cells of cluster 1, 
that represented a weak knock down, and cells of cluster 5 and 6, which represented a very good 
PPM1A knock down (Figure 50H and Appendix Figure A35). Presenting the nuclear levels of all cells 
from cluster 1, the gefitinib effect was recognizable in the control cells and in the PPM1A siRNA-treated 
cells (Figure 50I & J). Interestingly, the Gefitinib effect was recognizable only in the control cells from 
clusters 5 and 6, and PPM1AsiRNA and Gefitinib-treated cells showed the same or even stronger 
response after TGFβ addition (Figure 50K & L). This means that without PPM1A the Gefitinib effect 
disappeared and thus late SMAD2 nuclear translocation was PPM1A-dependent. Therefore, I 
continued to study the expression of PPM1A in RT-PCR experiments after Gefitinib and 100pM TGFβ 
treatment in WT cells. Gefitinib slightly increased the expression of PPM1A (Figure 50M). However, 
this was only slightly reflected in Western experiments, and the PPM1A level was only mildly elevated 
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by Gefitinib (Figure 50N). Therefore, modifications of PPM1A must be investigated in further 
experiments. 
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3.4.3.4.4 Figure 50. PPM1A is probably involved in the ERK-mediated TGFβ response. 
A Median nuclear SMAD2 level of the SMAD2-YFP reporter cells seeded 3 days prior to 100pM TGFβ stimulation and 0.75h 
pretreated with Gefitinib. Shaded area represent data between 25th and 75th percentiles. 
B Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells seeded 3 days prior to 100pM TGFβ stimulation and 
0.75h pretreated with Gefitinib. Shaded area represent data between 25th and 75th percentiles. 
C Median cytoplasmic SMAD2 level of the SMAD2-YFP reporter cells seeded 3 days prior to 100pM TGFβ stimulation and 
0.75h pretreated with Gefitinib. Shaded area represent data between 25th and 75th percentiles. 
D Median nuclear SMAD2 level of the SMAD2-YFP reporter cells seeded 3 days prior and transfected 48h prior to 100pM 
TGFβ treatment with PPM1A siRNA and 0.75h pretreated with Gefitinib. Shaded area represent data between 25th and 
75th percentiles. 
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E Median nuc/cyto SMAD2 ratio of the SMAD2-YFP reporter cells seeded 3 days prior and transfected 48h prior to 100pM 
TGFβ treatment with PPM1A siRNA and 0.75h pretreated with Gefitinib. Shaded area represent data between 25th and 
75th percentiles. 
F Median cytoplasmic SMAD2 level of the SMAD2-YFP reporter cells seeded 3 days prior and transfected 48h prior to 
100pM TGFβ treatment with PPM1A siRNA and 0.75h pretreated with Gefitinib. Shaded area represent data between 25th 
and 75th percentiles. 
G Clustering on the first 45 minutes of the cytoplasmic SMAD2 level of the SMAD2-YFP reporter cells seeded 3 days prior 
and transfected 48h prior to 100pM TGFβ treatment with PPM1A siRNA and 0.75h pretreated with Gefitinib to separate 
cells with a very good PPM1A knock down from those with worse or none knock down. Individual cells were clustered into 
six cluster and the corresponding median nuclear SMAD2 level over 24h is shown. 
H Individual cells were clustered into six cluster (Figure 50 G) and the corresponding median cytoplasmic SMAD2 level 
over 24h is shown. 
I Median nuclear SMAD2 level of cells from Cluster 1 seeded 3 days prior 100pM TGFβ treatment and 0.75h pretreated 
with Gefitinib. 
J Median nuclear SMAD2 level of cells from Cluster 1 seeded 3 days prior and transfected 48h prior to 100pM TGFβ 
treatment with PPM1A siRNA and 0.75h pretreated with Gefitinib. 
K Median nuclear SMAD2 level of cells from Cluster 5 and 6 seeded 3 days prior 100pM TGFβ treatment and 0.75h 
pretreated with Gefitinib. 
L Median nuclear SMAD2 level of cells from Cluster 5 and 6 seeded 3 days prior and transfected 48h prior to 100pM TGFβ 
treatment with PPM1A siRNA and 0.75h pretreated with Gefitinib. 
M Expression of PPM1A at indicated time points of MCF10A WT cells transfected 48h prior to 100pM TGFβ treatment with 
PPM1A siRNA and 0.75h pretreated with Gefitinib. β-Actin was used as an internal control. Error bars indicate standard 
deviation of technical triplicates. 
N Western blot analysis of PPM1A in MCF10A WT cells stimulated with 100pM TGFβ and 0.75h pretreated with Gefitinib. 
GAPDH was used as a loading control. 
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4 DISCUSSION 
4.1 Dynamics and variability of SMAD signaling in single cells 
The TGFβ pathway is a multi-functional signaling system regulating many fundamental cellular and 
developmental processes, including cell cycle arrest, differentiation, morphogenesis and apoptosis, as 
well as cancer progression (Massagué, 1998; Whitman, 1998, Piek et al, 1999, Siegel & Massagué, 
2003). The underlying mechanisms of these wide range of physiological effects to TGFβ have not been 
elucidated in detail. Since there has been growing evidence that the temporal dynamics of SMAD 
proteins are important for their functioning (Schmierer et al, 2008, Warmflash et al, 2012), I focused 
specifically on how the strength of the extracellular input is encoded in temporal patterns of SMADs. 
Moreover, I explored how signaling dynamics influence cellular outcomes and how specific dynamical 
patterns are both shaped and interpreted by the structure of molecular networks. In this context, I 
emphasized regulatory and adaptive mechanisms as well as cross-talk with non-canonical signaling 
pathways. 
In this thesis, I provided a quantitative understanding of how cells encode and decode information 
about the identity and quantity of a TGFβ stimulus. I investigated SMAD2 and SMAD4 dynamics and 
followed pathway activation at the single-cell level by monitoring the translocation of SMADs from the 
cytoplasm to the nucleus with high temporal and spatial resolution, by combining fluorescent reporter 
cell lines with live-cell microscopy and automated image analysis. Specifically, I established stable 
clonal reporter cell lines for SMAD2 and SMAD4. Initially SMADs were predominantly located in the 
cytoplasm, followed by strong accumulation into the nucleus after TGFβ treatment until the regulatory 
and adaptation mechanisms stopped the pathway activation and SMADs shuttled back to the 
cytoplasm.  
Clarke et al reported that cells respond to the absolute number of bioavailable TGFβ molecules in their 
environment. They developed a bioassay that enables them to count precisely the number of bioactive 
TGFβ molecules present in the medium (Clarke et al, 2009). Ligand molecules per cell is the input 
variable to which the cells respond, and ligand number per cell is the best predictor of signaling 
responses (Zi and Klipp, 2007a; Clarke et al, 2009).  Like the majority of published studies we did the 
experiments with concentrations, but left other conditions like growth area, cell number, culturing 
time before stimulation, etc. the same. Additionally, we only compared results between conditions of 
the experiment and always used internal controls. The TGFβ pathway is a particularly interesting 
system for testing for fold-change detection and thus consider also the basal level because it is known 
that the expression levels of its components vary considerably from cell to cell (Zieba et al, 2012).  
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However, the average response of our single-cell measurements match with biochemical analyses in 
previous studies  (Inman et al, 2002b; Clarke et al, 2009; Zi et al, 2011; Vizán et al, 2013). Currently 
CRISPR/ Cas9-mediated gene knock-in would be used to prevent any influence of SMAD 
overexpression in our reporter cells. However, validation experiments showed comparable dynamics 
of endogenous and tagged proteins and our system did not alter the cellular response to TGFβ 
stimulus. Therefore the SMAD2 and SMAD4 reporter faithfully represents the activity of the pathway. 
Moreover, as expected the TGFβ response of the reporter cell lines was at all time points receptor-
dependent and corresponded with studies using the inhibitor SB431542 (Inman et al, 2002a). The 
authors showed that inhibiting the pathway at the receptor level causes export of both R-SMADs and 
SMAD4 (Inman et al, 2002a).  
Furthermore, the average SMAD2 and SMAD4 dynamics in MCF10A cells were TGFβ dose dependent, 
since I observed that a decrease in the TGFβ concentration lowered the peak amplitude, rendered 
signaling more transient and led to rapid adaptation to the pre-stimulus level. This is consistent with 
experimental and modeling analyses that showed that SMAD signal amplitude gradually increases with 
the increments of TGFβ doses (Chung et al, 2009; Melke et al, 2006; Goumans et al, 2002). More in 
detail, Zi et al showed that TGFβ signaling responses display different sensitivities to ligand doses at 
different time scales (Zi et al, 2011). Modeling simulations and experimental results showed that while 
short-term P-SMAD2 is graded, long-term P-SMAD2 response is switch-like to changes in TGFβ doses, 
since a small change of TGFβ dose within a certain range results in a large change in P-SMAD2 response. 
In contrast to other signaling pathways such as NF-κB that display binary on/off responses (Tay et al, 
2010) the TGFβ response was graded. The linear relationship between receptor activity and nuclear 
ERK activity is lost during several enzymatic amplification steps, also ERK signaling can elicit a binary, 
switch-like response. It seems that the ERK activation amplitude is a non-linear function of active EGF-
receptor levels (Schoeberl et al, 2002). Obviously, the kinetic pathways of ERK signaling and SMAD 
signaling have differing properties. ERK signaling peaks very sharp and fades within an hour (Schmierer 
& Hill, 2007). Nevertheless, long-term response of ERK signaling has been reported in MCF10A cells 
(Albeck et al, 2013).  
By analyzing the median nuc/cyto SMAD2 and SMAD4 ratio of the cell population, one synchronous 
initial response of SMAD translocation at 1h, followed by adaptation and a second signaling phase with 
temporally less defined periods of nuclear translocation could be monitored. However, our results 
conflict with a previous study in single cells that reported a different behavior of SMAD2 nuclear 
accumulation upon TGFβ stimulation using a clonal cell line of mouse myoblast C2C12 cells stably 
expressing an RFP-SMAD2 fusion protein (Warmflash et al, 2012). SMAD4 reveals similar results. The 
response to ligand was detectable within 10 min and peaked at 1–2 h, followed by adaptation. But, 
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Warmflash et al observed sustained SMAD2 accumulation, since SMAD2 exhibits stable nuclear 
accumulation upon continuous TGFβ1 stimulation without early adaptation. In addition to cell-type 
differences, a noticeable distinction in the experimental setup that may explain the contrasting results 
is the higher level of overexpression of tagged SMAD2 in the previous study (> 2× vs. 0.5× compared 
to endogenous levels) (Strasen et al, 2018). Furthermore, the reported cells were analyzed only 10 -12 
hours by live cell imaging. In addition, this data also contradicts their data shown in the Western Blot, 
where clearly a peak at 1h and subsequent adaptation was shown. Furthermore, only a few timepoints 
in immunofluorescence were shown, and especially the time points after the peak were omitted. Their 
model postulates that the duration of SMAD4 nuclear localization is independent of that for R-SMADs 
and the model in which activated, nuclear-localized R-SMADs are synonymous with pathway activation 
need to be refined. My results, which are backed up by additional studies from the literature, point in 
another direction. The prevailing model is that R-SMADs carry pathway information with SMAD4 
mirroring their activity (Schmierer & Hill, 2005; Liu et al, 1997). Nevertheless, future studies should 
include more cell lines to exclude cell type specific differences. A recent study using proximity ligation 
assay in fixed cells revealed that the levels of SMAD3/4 and SMAD2/4 complexes vary by more than 
40-fold across cells (Zieba et al, 2012). Moreover I showed that SMAD2 and SMAD4 dynamics were 
coupled and co-regulated using fluorescent reporter cell lines simultaneously visualizing the response 
of both SMADs.  
Moreover, as published, R-SMAD phosphorylation is necessary for the nuclear accumulation and 
transcriptional activity of both the R-SMADs and SMAD4 (Schmierer & Hill, 2005; Liu et al, 1997). I 
could show that the expression of TGFβ target genes were dose-dependent like the median response 
in the time-lapse data. While the first peak of target genes appeared to be strongly TGFβ 
concentration-dependent in a graded manner, the enhanced induction with increasing TGFβ 
concentration at later time points slightly diminished over time. Thus, target gene expression 24h after 
the 100pM TGFβ stimuli showed clear differences in comparison to lower doses. In particular PAI-1 
represented a more switch-like behavior. However, Warmflash et al also examined the kinetics of 
endogenous target gene expression by qRT-PCR in unmodified C2C12 cells. The response of all three 
target genes they studied was transient, rising over the first 2 h after stimulation and returning to 
baseline within 4–6 h. But they have only looked at the first 12 hours and PAI1, SMAD7 and TIEG in my 
experiments were well above baseline at 14h and 24h with high TGFβ concentrations. Zi et al supports 
my results since they also found that the short-term SMAD7 gene expression is graded and induction 
of PAI-1 expression by TGFβ is considerably delayed and can be measured at 24 h post TGFβ treatment 
and is switch- like (Zi et al, 2011). However, a general switch-like response for TGFβ induced long-term 
gene expression should be validated carefully with further concentrations in between and more target 
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genes in future experiments. In addition, I observed that target genes were not only TGFβ quantity but 
also stimulation period dependent. Cells reacted to the current TGFβ state and needed long-term 
stimulation and continued SMAD signaling to achieve full target gene transcription 24 hours post TGFβ. 
Many studies focused on signaling responses to continuous TGFβ stimulations, thus  little is known 
about cell responses to short pulses of TGFβ stimulations. Zi et al showed in model simulations that 
short-term TGF-β pulse stimulation results in transient P-Smad2, whereas serial pulses result in 
sustained P-Smad2, similar to that seen with continuous stimulation (Zi et al, 2011). The functional 
significance of pulses of TGFβ has yet to be shown in vivo, but is theoretically occurring within tissues, 
where the extracellular volume and local secretion of TGFβ is extremely small in magnitude, resulting 
in a largely noisy extracellular level of TGFβ (Zi et al, 2012).  
However, median trajectories only monitor average dynamics across the population. Analysis of the 
SMAD2 and SMAD4 reporter cell lines revealed, that the extent and duration of SMAD nuclear 
accumulation was highly variable and cells showed a broad variability of dynamics, although they were 
genetically identical. These complex and heterogeneous dynamics were not limited to saturating TGFβ 
concentrations, as I also noticed pronounced variability when treating the cells with lower ligand 
concentrations. Likewise, Warmflash et al observed that in low-density cultures, nuclear localization 
of SMADs was heterogeneous, treatment with TGFβ1 did not synchronize the cells and SMAD4 
remained heterogeneous. Zi et al questioned whether there are oscillations in TGFβ network because 
no oscillations of TGFβ signaling have yet been observed in cells (Zi et al, 2012). Averaging signaling 
dynamics at cell population levels can mask dynamic signaling mechanisms within individual cells 
(Spiller et al, 2010). The suspected oscillatory responses may appear at the single cell level in a variety 
of cell lines and culture conditions upon TGFβ stimulation. Oscillations of signaling responses have 
been observed in some pathways with negative feedbacks, for example, NF-κB, p53 and ERK systems 
(Shankaran et al, 2009; Hoffmann et al, 2002; Geva-Zatorsky et al, 2006). However, only few examples 
showed oscillatory SMAD dynamics in MCF10A cells. One reason could be that the negative feedback 
regulations of TGFβ network may not be strong enough at the endogenous level. Moreover, the time-
delay between negative feedback and SMAD activation might not be coupled in a proper time scale (Zi 
et al, 2012).  
In collaboration with Marcel Jentsch I extracted single cell features to analyze the complex 
heterogeneous dynamics in detail. We detected features that are robust, change in a dose and time 
dependent manner, and those that vary across individual cells. Mainly the length of the first increase 
was robust over all conditions, as well as the time of the maximum amplitude. However, the maximum 
amplitude increased with rising TGFβ concentrations and showed saturation for 25pM ligand 
concentration. Furthermore, the mean ratio value 5 hours after the first response increased until 25pM 
4.1 Dynamics and variability of SMAD signaling in single cells 
136 
 
TGFβ and only for 100pM TGFβ was the final value 24 hours of imaging significantly above the basal 
level. Interestingly, almost all SMAD2 reporter cells treated with 5pM - 100pM TGFβ ligand reacted to 
the stimulus, which underlines that it is not a binary on/ off system and cells sensitively respond to 
extracellular TGFβ concentration with SMAD specific dynamics. The variability in the level of SMAD 
proteins from cell to cell raises the question as to how cells and tissue can reliably sense information 
about their external environment through the TGFβ pathway (Frick et al, 2017). Some of the ideas that 
have been proposed are integration of responses from multiple signaling pathways (Cheong et al, 
2011), compensate via cross-talk with other pathways (Uda et al, 2013), average responses across 
neighboring cells (Cheong et al, 2011), use negative feedbacks (Voliotis et al, 2014), or measuring signal 
dynamics (Selimkhanov et al, 2014) and interpreting signaling relative to background by detecting fold 
changes (Goentoro et al, 2009). Indeed, Frick et al, analyzed the response distributions across doses 
and found that measuring fold change in SMAD3 confers higher information transduction capacity to 
the TGFβ pathway. The fact that the fold change relative to background is the driving factor here also 
means that a high level of nuclear Smad complex alone does not necessarily indicate a high level of 
signaling. This finding may have implications for understanding the context-dependent outcomes of 
the TGFβ pathway (Frick et al, 2017). However, displaying the absolute nuc/cyto ratio fluorescent 
intensities revealed stable dynamics.  
To understand how phenotypic responses and cell fates of TGFβ signaling can be specifically encoded 
by SMAD dynamics we used a clustering approach to achieve a better separation in more homogenous 
groups. Marcel Jentsch established a method based on dynamic time warping as a tool for non-linear 
alignment of time series data. Cells were re-sorted in six clusters of signaling classes according to their 
dynamic behavior, which provided a better separation than sorting to different TGFβ ligand 
concentration. Although signaling classes represented mathematically identifiable clusters of time 
courses, it is important to note that SMAD dynamics in each class were not sharp but rather gradual 
(Strasen et al, 2018). The definition of six classes is a heuristic choice to classify the observed 
heterogeneity. In future studies, it may be interesting to use other approaches established in the 
context of single-cell sequencing such as diffusion maps to reduce dimensionality of their high-
dimensional observations (Haghverdi et al, 2016). Interestingly, a recent study proposed that the 
response of MCF10A cells to extracellular ATP can be similarly grouped in three classes corresponding 
to distinct cellular states (Yao et al, 2016). Moreover, phenotypic responses and cell fate decisions 
were correlated with signaling classes of distinct dynamic behavior. Interestingly, this data suggests 
that migration and proliferation may be controlled by different aspects of the dynamical SMAD 
signaling response. Migration tended to be affected by a transient peak of SMAD translocation, 
whereas the anti-proliferative effects seemed to require sustained SMAD signaling. It needs to be 
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highlighted that a clear shift to migration, EMT and cell cycle arrest required a strong and sustained 
second signaling phase rather than a high first amplitude. Therefore, signaling classes of distinct long- 
term dynamic behavior determine the cell fate. Thus, cells are able to translate various dynamics of 
the same signaling molecule into specific outcomes.  
Previous studies indicated that cellular responses to TGFβ superfamily ligands depend on the quantity 
to which the cells are exposed. In development, TGFβ superfamily members form morphogen 
gradients to determine the fates of cells (Rogers and Schier, 2011). Cells read the TGFβ concentration 
with high precision, as they can distinguish subtle differences in the concentration gradients and 
orchestrate different cell fates (Green et al, 1992). Strict regulation of the duration and strength of the 
morphogenic signal itself, but also of the response evoked, are key for embryonic pattern formation 
(Schmierer & Hill, 2007). In addition to its role in development, TGFβ is dysregulated in a variety of 
cancers (Padua & Massagué, 2009), and the timing of signaling also plays an important role. For 
example, TGFβ is transiently upregulated in metastasizing breast cancer cells (Giampieri et al, 2009) 
and consistent with our findings, transient SMAD activation in cancer cell lines was sufficient to alter 
cellular motility and induce EMT–like processes, while sustained signaling was required to influence 
proliferation (Nicola  ́s & Hill, 2003; Giampieri et al, 2009). Moreover, Zi et al found that most cell fate 
decisions regulated by TGFβ-related molecules are switch-like and irreversible (e.g. cell differentiation 
and apoptosis) (Zi et al, 2011).  Some of the most common and well-characterized ‘all-or-none’ 
responses are found in the mitotic trigger and the MAP kinase signaling cascade during Xenopus oocyte 
maturation (Ferrell, 2008). Positive and double negative feedback loops are critical for the irreversible 
switch of these processes (Ferrell, 2008). 
Interestingly, He et al identified TIF1g, also known as Ectodermin, as a transcriptional partner of 
activated R-SMADs in competition with SMAD4 (He et al, 2006). Whereas the R-SMAD/TIF1g complex 
stimulates erythrocyte differentiation, the R-SMAD/SMAD4 complex inhibits hematopoietic stem cell 
proliferation. Thus, the balance between R-SMAD/TIF1g- and R-SMAD/ SMAD4-mediated TGFβ 
signaling in hematopoietic stem cells is critical for cell fate. TIF1g acts as an inhibitor of SMAD4 function 
by inducing ubiquitin-induced SMAD4 degradation (Dupont et al, 2005).  
Furthermore, the role of the transcription factor SMAD3 and its complex binding with SMAD4 is 
unclear. Although structurally similar, SMAD2 and SMAD3 affect distinct genes (Brown et al, 2007), 
and it is also known that SMAD3 can bind directly to DNA, whereas the predominant isoform of SMAD2 
does not (Gaarenstroom et al, 2014).  
Dynamic information encoding thus may be conserved from the level of cell lines to the level of 
heterogeneous single-cell signaling. It reflects regulatory potential of the pathway: The sensitivity to 
TGFβ inputs of individual cells can be adjusted within tissue (Strasen et al, 2018). 
4.1 Dynamics and variability of SMAD signaling in single cells 
138 
 
A better understanding of how signaling dynamics are regulated and how they affect cellular responses 
may provide new insights for manipulating them in a controlled way, like modulating the levels or 
enzymatic activities of selected proteins to switch the response from EMT-like processes to 
proliferation control. In turn, this may enable new pharmacological strategies for altering cell fate in 
cancer therapies. 
However, changes in downstream responses are not just triggered by dynamics, but by a combination 
of additional factors such as posttranslational modifications, spatial localization or identity and 
strength of other pathway components. Thus, dynamics represent only one layer of regulation within 
a complex signaling response that leads to different cellular outcomes. In fact, different dynamical 
patterns arise because of differences in network structure or the kinetics of individual molecular 
interactions (Purvis & Lahav, 2013).  
When considering the functional role of dynamics, the question how cell fate is encoded in these 
different dynamical patterns arises. Identifying the mechanisms that are necessary to detect time-
dependent features and translate these patterns into distinct phenotypic responses remains one of 
the most challenging goals for the field.  
For example, ERK dynamics are decoded by a finely tuned spatiotemporal network controlling cell fate 
decisions with a persistence detector for the duration of ERK activation. Thus, when ERK activation is 
transient, gene products such as c-Fos are induced but then undergo rapid degradation. When ERK 
levels are persistent, however, newly synthesized c-Fos is directly phosphorylated by the still-active 
kinase, which stabilizes c-Fos in the nucleus (Purvis & Lahav, 2013, Murphy et al, 2002, 2004). 
Decoding mechanisms promise to provide critical answers about the function of temporal signals 
because they represent the link between signal patterns and functional cellular outcome (Behar and 
Hoffmann, 2010). In order to gain a better understanding of the decoding of SMAD dynamics on the 
RNA level, I correlated the single-cell target gene expression of PAI- 1 with single- cell SMAD signaling 
by combining 3 hours and 14 hours live- cell imaging of the SMAD2- reporter cell line stimulated with 
25pM TGFβ with subsequent smFISH. First of all, the absolute RNA counts per cell at basal level, 3 
hours and 14 hours post TGFβ stimulation showed pronounced cell-to- cell variability. The 
heterogeneous SMAD2 dynamics were not correlated with PAI-1 expression 3 hours post stimulation. 
However, considering 14 hours of individual SMAD signaling, I observed correlation of long-term 
SMAD2 dynamics to the PAI-1 target gene expression. This fits with experimental and computational 
population studies by Zi et al. They showed a switch- like long-term PAI-1 gene expression connected 
with long-term growth inhibitory response (Zi et al, 2011). To determine how different dynamics of 
the same molecule are interpreted by downstream components, a detailed analysis of the dynamic 
features is necessary. Also Frick et al observed variability in the mRNA expression of the target genes, 
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which may be due to variability in cell size, chromatin state, cell-cycle phase, other extrinsic variables, 
or stochastic noise. Using also smFISH, they observed that expression of SMAD3 target genes (ctgf, 
snai1, and wnt9a) correlated more strongly with the fold change, rather than the level, of nuclear 
SMAD3. They suspected some target genes sense SMAD3 levels relative to background, as a strategy 
for coping with cellular noise. However, no features of long-term dynamics were evaluated. Moreover, 
Hill and Levy identified in large-scale microarray analysis two populations of TGFβ- target genes that 
are distinguished by their dependency on SMAD4, since some genes absolutely require SMAD4 for 
their regulation, while others do not. Functional analysis also indicates a differential SMAD4 
requirement for TGFβ -induced cell fates. Moreover, the intrinsic DNA affinity of SMADs is relatively 
low and SMADs themselves are not sufficient to drive transcription. They require other DNA-binding 
transcription factors to efficiently bind to promoters and recruit transcriptional co-activators. Thus, 
interfering with SMAD–DNA binding or the recruitment of co-activators or co-repressors has an effect 
on specific SMAD-induced gene responses. For example, SMAD partner C/EBPb plays a critical role in 
TGFβ-induced activation of cell cycle inhibitor p15INK4b promoter, a pivotal target gene in the 
cytostatic response to TGFβ (Itoh & ten Dijke, 2007). 
My results demonstrate that SMAD dynamics play a functional role in driving cellular responses, but 
further research is needed to answer the question of how dynamics are interpreted at the molecular 
level.  
4.2 Regulatory and adaption mechanisms 
In the next step I investigated how dynamics are regulated and analyzed what molecular mechanisms 
give rise to specific dynamical patterns. I studied the dynamics of signaling molecules by inhibiting key 
components through either small molecule inhibitors or genetic manipulation. Through these 
perturbation experiments I showed several molecular mechanisms that contribute to the observed 
dynamics.  
I investigated how complete adaptation of the signaling pathway is connected to TGFβ ligand depletion 
by cellular uptake and lysosomal degradation. By measuring extracellular TGFβ ligand concentration, 
we concluded that the full ligand depletion mainly affected signaling termination in time-lapse imaging 
experiments. As long as extracellular TGFβ was present, SMADs accumulated into the nucleus. 
Computational analyzes by Zi et al indicated that the half-life of TGFβ in the medium was also dose 
dependent. The low doses of TGFβ stimulations had shorter half-lives and were depleted over time, 
resulting in very low levels of long-term cellular responses. On the other hand, when the TGFβ dose is 
above a certain threshold, the half-life of TGFβ in the medium is significantly increased and the TGFβ 
remaining in the medium after long time periods led to a saturated response (Zi et al, 2011). Indeed, 
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we found that the estimated ligand decay of an initial TGFβ concentration of 25pM was completed 
within 20 hours with a half-life of around 6 hours. These findings corresponded with the complete 
adaptation of the signaling pathway to basal pre-stimulation level in the microscopy experiments. 
Furthermore, cells stimulated with 100pM TGFβ revealed an extracellular ligand concentration of 
around 20pM after 24 hours, which corresponded to a half- life around 9 hours. This agreed with the 
non-complete adaptation to basal level for 100pM TGFβ stimulation within 24 hours. Interestingly, 
theoretical approaches found that ligand depletion speed is affected by LRC formation, which is 
proportional to the concentration of ligand and cell surface receptors. The rate of ligand depletion can 
be adjusted by varying the volume of the media while keeping the ratio of TGFβ molecule per cell 
constant (Zi et al, 2011). Their model simulation predicts that slowing down ligand depletion by 
increasing medium volume should decrease the ultrasensitivity of long-term P-SMAD2 dose response 
with 24h treatment. Their modeling and experimental analyses also suggest that ligand depletion is an 
important mechanism for terminating transient signaling and generating a long-term switch-like 
response, since the rate of ligand depletion controls the duration of SMAD2 phosphorylation (Zi et al, 
2011). Also predominant hypothesized mechanisms for terminating the response are loss of SMAD2 
function through negative feedback and phosphorylated SMAD2 degradation, promoted by secondary 
phosphorylation of SMAD2 in the nucleus (Alarcón et al, 2009, Itoh & ten Dijke, 2007). Receptors are 
downregulated at the cell surface in the presence of TGFβ (Wakefield et al, 1987, Zwaagstra et al, 
1999). Receptors are constitutively degraded via the lysosomal and ubiquitin-proteosome pathways, 
depending on whether the receptors are internalized in clathrin-coated pits or caveolae (Di Guglielmo 
et al, 2003; Kavsak et al, 2000; Mitchell et al, 2004). 
In accordance with our results that the complete adaptation is mainly due to ligand depletion, Clarke 
et al concluded that TGFβ depletion principally determines SMAD signal kinetics. TGFβRII defective, 
but not TGFβRI defective, cell lines lost their ability to deplete TGFβ from the medium, thus TGFβ 
depletion most likely occurs through TGFβRII-mediated endocytosis (Clarke et al, 2009). In this aspect, 
TGFβ degradation shares many similarities with EGF or TGFα (Reddy et al, 1996; Shankaran et al, 2009). 
The ligand-induced endocytosis does not merely serve as a mechanism for “down- regulation” of 
signaling, but also provides a mechanism whereby the receptor can continuously track the changes in 
the secretion of TGFβ by nearby cells. 
Furthermore, negative feedback in a signal transduction cascade is one of the major mechanisms for 
desensitization of sustained ligand stimulation and generation of transient, sometimes oscillating 
signaling outputs (Brandman & Meyer, 2008). Negative feedback in the TGFβ superfamily signaling 
pathways is mediated by induction of the inhibitory SMADs (I-SMADs) SMAD6 and SMAD7, and is 
thought to function in signal termination. SMAD7, a TGFβ-inducible early response gene (Nakao et al, 
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1997; Hayashi et al, 1997), antagonizes TGFβ signaling through multiple mechanisms, both in the 
cytosol and the nucleus. Despite the complex mechanisms, the question remains what is the role of 
negative feedback loops in regulating TGFβ dynamics? I systematically investigated the role of 
feedback loops in shaping SMAD dynamics by combining smFISH of SMAD7 with time-lapse imaging of 
the SMAD2-reporter 1.5h and 14h post 100pM TGFβ stimulation. Obviously, the first peak amplitude 
of SMAD2 dynamics was correlated to the absolute RNA amount. Thus, early SMAD7 transcription 
reflected strongly SMAD2 signaling, but for long-term dynamics the correlation was not obvious. 
Further experiments are needed to get conclusive results. Finally, I showed that transcriptional 
negative feedback loops attenuated early adaptation, by blocking these feedbacks by the general 
transcription inhibitor DRB, which efficiently inhibits transcription at the early elongation stage by 
inhibiting CDK7, 8 and 9 kinases and preventing RNA polymerase II to proceed after initiation. The 
amplitude was increased and the TGFβ response was amplified, but nevertheless early adaptation took 
place. In conclusion these results indicate that transcriptional feedbacks like SMAD7 have an impact 
on the early adaptation of SMAD2 signaling, but other regulatory mechanisms are apparently involved 
since early adaptation was attenuated and not prevented. Moreover, Vizán et al showed that the TGFβ 
pathway fully attenuates even in the presence of protein synthesis inhibitors, such as cycloheximide 
indicating that the mechanism governing attenuation relies on proteins constitutively present in the 
cells before they receive the signal (Vizán et al, 2013; Pierreux et al, 2000). 
This is in contrast to Warmflash et al, who showed that inhibiting protein synthesis decreased the 
duration of SMAD2 nuclear accumulation but prolonged SMAD4 nuclear accumulation without early 
adaptation. Therefore, they concluded that SMAD4 adaptation requires new protein synthesis, and 
transcriptional dynamics correlate with SMAD4 but not SMAD2 nuclear accumulation. Since I question 
the SMAD2 cell line from Warmflash et al, I would conclude that early adaptation is only limitedly 
depended on transcriptional negative feedback loops and other regulatory mechanisms are involved.  
In order to investigate the role of the main transcriptional negative feedback regulator SMAD7 on the 
dynamics of SMAD2 more specifically, I generated a SMAD7 CRISPR Cas9 knockout cell line. First, I 
made clonal cell lines and validated selected clones by determining the mutation state of the SMAD7 
gene locus. Fortunately, clone 12 showed a deletion on both alleles, leading to an open reading frame 
shift and an early stop codon and therefore to a complete SMAD7 knock out.  
Next, I determined how SMAD7 knock out affects the SMAD2 dynamics measured by live cell imaging. 
The amplitude was significantly increased compared to the control cell line. In accordance with my 
DRB experiments, the early adaptation rose to a higher plateau level. Furthermore, the fraction of 
dividing cells was reduced and the movement over the period of 21 hours was increased. This 
confirmed that a strong sustained SMAD2 response shifted cells to migration, EMT and cell cycle arrest 
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and was regulated by the negative feedback regulator SMAD7. Thus, SMAD7 knock out led not only to 
a stronger SMAD2 response, but also in case of PAI1 to an enhanced downstream response. Since the 
homozygous SMAD7 CRISPR Cas9 knock out clone 12 had a sustained knock out with possible 
compensatory mechanisms, I investigated how a transient SMAD7 knock out affected the SMAD2 
dynamics. 
In conclusion, the results were similar to clone 12, basal levels were increased, the amplitude of 
nuclear SMAD2 was not necessarily increased, but the early adaptation was weakened with a higher 
nuclear SMAD2 plateau level afterwards. Using Western blot experiments, I was able to confirm live 
cell imaging results. Interestingly, SMAD7 is affected by post-translational modifications, which could 
affect SMAD dynamics. SMAD7 interacts with the transcriptional co-activator p300, which can 
stimulate the acetylation of two lysine residues in the N-terminus of SMAD7, the same residues 
targeted by SMURF1-induced ubiquitination (Itoh & ten Dijke, 2007). Importantly, acetylation prevents 
SMAD7 ubiquitination and protects SMAD7 from degradation [ten Dijke & Hill, 2004]. Interestingly, 
post-translational modifications are reversible processes. Class 1 HDAC1 and class III histone 
deacetylase SIRT1 can reverse p300- mediated SMAD7 acetylation and thereby accelerate SMAD7 
ubiquitination and degradation (Simonsson et al, 2005; Kume et al, 2007). The deubiquitinating 
enzyme UCH37/UCHL5 interacts with SMAD7 and counteracts the SMURF2-induced ubiquitination of 
TGFβ type I receptor (Wicks et al, 2005). As our experimental study was limited to SMAD7, it would be 
interesting to investigate the contribution of the remaining negative feedbacks on SMAD dynamics. 
Furthermore, TGFβ binding to its receptors initiates the degradation of several key components of the 
signaling pathway. The degradation of these components, including both positive and negative 
transducers, is mediated by the ubiquitin-proteasome system. Inhibition of the proteasome activity 
controls the levels of SMADs posttranslationally and modulates TGFβ signaling in a time-dependent 
and gene-specific manner (Zi et al, 2012). 
R-SMADs have been found to be ubiquitinated and targeted for proteasomal degradation by various 
classes of ubiquitin ligases (Itoh & ten Dijke, 2007). This ensures low basal levels of non- activated 
SMADs, thereby decreasing cellular competence to sense TGFβ family members. Degradation of 
activated SMADs leads to attenuation or termination of signaling responses. The HECT family E3 
ubiquitin ligases, SMURF1 and SMURF2, antagonize TGFβ family signaling by interacting with R-SMADs 
and targeting them for degradation (Arora & Warrior, 2001). While SMURF1 specifically targets 
SMAD1/5, thereby affecting BMP responses, whereas SMURF2 interacts more broadly with different 
R-SMADs, allowing interference with BMP and TGFβ signaling (Zhu et al, 1999; Arora & Warrior, 2001; 
Zhang et al, 2001; Bonni et al, 2001, Izzi et al, 2004). Interestingly, while SMURF2 binds to both SMAD2 
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and 3, it does not degrade SMAD3 (Lin et al, 2000), instead it induces the degradation of proteins such 
as SnoN that interact with the SMAD3–SMURF2 complex (Bonni et al, 2001).  
SMURF-like molecule WWP1/Tiul1 binds SMAD2 in a TGFβ-dependent manner, and interaction of 
Tiul1/WWP1 with TGIF is required for poly-ubiquitination and degradation of SMAD2 (Seo et al, 2004; 
Komuro et al, 2004). Furthermore, the SMURF-like protein NEDD4-2 polyubiquinate SMAD2 and 
induces SMAD2 proteasomal degradation (Kuratomi et al, 2005; Bai et al, 2004]. The C-terminus of 
Hsc70 interacting protein (CHIP), which belongs to the U-box E3 ligase family, mediates ubiquitination 
and degradation of SMAD3 independently of TGFβ stimulation (Xin et al 2005). Alternatively, SMAD3 
can be downregulated by the SCF/Roc1 ubiquitin ligase complex (ten Dijke et al, 2004; Izzi et al, 2004].  
SMAD4 can be polyubiquinated and proteasomally degraded by direct binding of the E3 ligases 
SCFbTrCP1, Jab1 or CHIP (ten Dijke et al, 2004; Izzi et al, 2004; Li et al, 2004; Wan et al, 2004). In 
addition, SMURF1 and 2, Tiul1/WWP1 and NEDD4-2 also have the ability to degrade SMAD4 via a 
SMAD7-mediated interaction (Morén et al, 2005). In general proteasomal degradation also regulates 
the R-SMAD levels after translocation into the nucleus. Thus, C-terminally phosphorylated SMAD2 can 
undergo ubiquitination, and inhibition of proteasomal degradation enhances its nuclear accumulation 
(Lo et al, 1999). However, only a small fraction of SMAD2 and SMAD3, in the absence or presence of 
TGFβ, is ubiquitinated. Thus, the bulk of nuclear SMAD2 or SMAD3 is not targeted for degradation, but 
dephosphorylated and relocated to the cytoplasm (Inman et al, 2002b; Xu et al, 2002). Moreover, 
SMURF1 and 2 also mediate ubiquitination of activated TGFβ- receptors, leading to their degradation 
in the proteasome (Ebisawa et al, 2001; Tajima et al, 2003). Thus, to test whether Ubiquitin-dependent 
degradation plays a role in shaping the dynamics of SMADs I treated the cells with the proteasome 
inhibitor MG132. Inhibition of proteasomal degradation led to strongly enhanced TGFβ signaling due 
to enhanced SMAD2 and SMAD4 levels in the nucleus and stabilized receptors. Treatment with the 
inhibitor prevented the early adaptation and shifted the adaptation to later time points. Therefore, 
proteasomal degradation plays a strong role for the adaptation process. Western Blot experiments 
verified the time-lapse microscopy results and revealed more phosphorylated SMAD2, total SMAD2, 
SMAD4, TGFβ Receptor I and interestingly p21 was significantly enhanced. 
In addition, as expected enhanced SMAD2 and SMAD4 accumulation into the nucleus through MG132 
led to increased target gene expression, shown for Snail, SnoN and SARA. In particular, SARA 
contributes to the adaptation process. If there is less SARA, fewer R-SMADs are guided to the 
receptors. SnoN antagonizes TGFβ- signaling through direct interactions with SMAD4 and the R-SMADs 
(Liu et al, 2001; Wang et al, 2000). SnoN-mediated negative regulation on the SMAD proteins is 
removed during TGFβ- signaling by at least two distinct ways. In the presence of TGFβ- signaling, 
SMAD2 interacts with both SnoN and SMURF2, allowing the HECT domain of SMURF2 to target SnoN 
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for ubiquitin-mediated degradation by the proteasome (Bonni et al, 2001). SMAD2 and SMAD3 can 
also recruit the E3 ubiquitin ligase anaphase promoting complex (APC), resulting in the ubiquitination 
and degradation of SMAD bound SnoN (Stroschein et al, 2001; Wan et al, 2001). 
My result matches observations in population studies where ubiquitin-dependent degradation has 
been shown to modulate the extent of SMAD2 retention in the nucleus (Lo & Massagué, 1999). Also 
Vizán et al suggested that pSMAD2 was not directly degraded, but that rather receptor turnover was 
affected by MG132 (Vizán et al, 2013). Warmflash et al showed that after inhibition of the proteasome 
with MG132 the amount of SMAD2 in the cell nucleus increased throughout the period of observation 
(15 h). However, it had very little effect on the dynamics of SMAD4 nuclear localization and did not 
prolong the time of expression of TGFβ target genes. These differences could be due to the different 
cell types or different experimental setup. The accelerated degradation of TGFβ signaling components 
via the proteasome system has been found in a number of tumors, indicating that dysregulated 
proteasomal degradation is a novel pathway how tumor cells silence TGFβ signaling (Zi et al, 2012). 
Thus, Dupont et al identified a RING-type E3 ubiquitin ligase Ectodermin that catalyzes poly-
ubiquitination of SMAD4, which leads to SMAD4 degradation. Importantly, Ecto is overexpressed in 
intestinal tumors and thus may play a role in attenuating the antiproliferative effects of SMAD4 in 
tumor cells (Dupont et al, 2005).  
Endocytosis of TGF receptors and its kinetics are expected to be important for sensing the duration 
and strength of signaling, and thus for reading and interpreting gradients of TGF superfamily members 
(Schmierer & Hill, 2007). The level of nuclear SMAD complexes must not only increase upon increasing 
receptor activity, but must also decrease as soon as receptor activity falls (when the receptors are 
degraded and/or dephosphorylated) (Kavsak et al, 2000; Shi et al, 2004). Balancing SMAD activation 
and SMAD inactivation ensures that the level of active nuclear SMADs is strictly proportional to 
receptor activity (Schmierer & Hill, 2007). Receptor internalization and degradation are a major 
regulatory event in signal transduction and are regulated by two distinct, competing routes (Baass et 
al, 1995; Di Fiore & De Camilli, 2001; McPherson, Kay & Hussain, 2001, Di Guglielmo et al, 2003). 
Clathrin-dependent internalization targets receptor proteins to the early endosome antigen-1 (EEA1)- 
positive endosome, where the SMAD2 anchor SARA is enriched, and promotes TGFβ signaling through 
recycling or receptors enter the late endosome-lysosome for degradation (Di Guglielmo et al, 2003; 
Hayes et al, 2002; Itoh et al, 2002; Panopoulou et al, 2002). Whereas the clathrin-independent, lipid 
raft- caveolar internalization pathway contains the SMAD7-SMURF2 bound receptor and is required 
for rapid receptor turnover and degradation. The I-SMAD–SMURF complex is first formed in the 
nucleus and is subsequently targeted to lipid raft vesicles via the C2 domains of SMURFs. Upon 
association of the SMAD7–SMURF2 complex with an active TGFβ receptor, both SMAD7 and the 
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receptor are ubiquitinated and destined for proteasomal and lysosomal degradation (Di Guglielmo et 
al, 2003; Ebisawa et al, 2001; Kavsak et al, 2000).  SMURF1- deficient mice do not show any 
enhancement of TGFβ signaling (Yamashita et al, 2005), probably because of the redundant functions 
of SMURF1 and 2 in TGFβ signaling. My immunofluorescence experiments showed that TGFβ receptor 
II is stabilized in MCF10A WT cells 0.75h post 100pM TGFβ stimulation und subsequently degraded to 
less than the basal level. An early study from Wrana et al shows that the phosphorylation of TGFβRI in 
the receptor complex peaks at about 2 minutes after TGFβ stimulation (Wrana et al, 1994). The signal 
is relayed to the activation of SMAD proteins, which arrive at their maximal levels in about 30-60 
minutes. The time delay between ligand receptor complex and R-SMAD activation may be due to 
intermediate processes, including receptor endocytosis, the recruitment of SMADs to receptor 
complex and SMAD activation (Zi et al, 2012). After 30-60 minutes, the phosphorylation of SMADs 
correlates with the degree of TGFβ-receptor complex level, which might be due to continuous 
nucleocytoplasmic shuttling of the SMADs, but this shuttling fails to explain why there is a prominent 
delay following receptor activation and prior to SMAD phosphorylation (Schmierer et al, 2008; Inman 
et al, 2002a & b).  
To address the question how the distinct receptor internalization and degradation processes affect 
SMAD2 dynamics I inhibited the endocytic pathways with dynasore or nystatin respectively and 
performed time-lapse microscopy experiments. Treatment with nystatin disrupts the lipid raft-
caveolar endocytic pathway and shifts receptors into the non-raft compartment EEA1. Therefore the 
inhibitor stabilizes the receptors and slightly enhances signaling and SMAD2 activation (Di Guglielmo 
et al, 2003). I showed that inhibiting the caveolar endocytic pathway enhanced the maximum 
amplitude and the mean intensity within 5h after the first response. Thus, SMAD2 accumulated 
strongly into the nucleus, but with an early adaptation and an extenuated late adaptation, so that 
SMAD2 remained at a high nuclear level. Interestingly, the increased nuclear SMAD2 values led to an 
increased mobility of the cells. Therefore, receptor internalization and degradation play a crucial role 
in the cell-fate decision. 
Inhibiting clathrin-dependent endocytosis with dynasore 0.75h before 100pM TGFβ stimulation led to 
increased nuclear and cytosolic SMAD2 values, while the ratio is almost unchanged. The maximum 
amplitude and the mean intensity within 5h after response were slightly increased, so that SMAD2 
accumulated slightly more into the nucleus, whereas the time of the maximal amplitude, increase and 
the end time of the first response remained unchanged. 
Taken together these results suggest that TGFβ receptor signaling and turnover play a huge role for 
the adaptation process of SMAD2 dynamics, especially for the late adaptation. Since early adaptation 
was attenuated and not prevented, other regulatory mechanisms are apparently involved. Even 
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though there is little debate about whether the TGFβ receptors undergo endocytosis, the precise role 
of receptor endocytosis in signaling remains controversial (Chen, 2009). Several lines of evidence 
support a positive role of endocytosis on R-SMAD phosphorylation (Di Guglielmo et al, 2003; Penheiter 
et al, 2002; Runyan et al, 2005; Hayes et al, 2002), while there are several reports describing SMAD 
activation immediately at the cell surface without need of receptor endocytosis (Lu et al, 2002, Zhou 
et al, 2004; Meyer et al, 2011).   
In addition, currently unknown regulatory mechanisms are likely to exist that target TGFβ receptors 
preferentially to one or the other endocytic compartment, thus promoting either signaling or receptor 
degradation (Schmierer & Hill, 2007). Interfering with one route inhibits or shifts the internalization 
towards the other route, respectively, indicating that partitioning is a dynamic and balanced process. 
The varying impact of receptor trafficking on signaling could be attributed to different experimental 
systems and cell types, which may have different ratio of clathrin-dependent to clathrin-independent 
endocytosis. In addition, in cells that are deficient in caveolin, TGFβ signaling can occur in the absence 
of clathrin-dependent endocytosis (Lu et al, 2002). Moreover, the inhibitors of endocytosis may not be 
very specific and could have some off-target effects. Multiple protein interactions are likely to control 
subcellular receptor localization and cell-surface receptor availability.  
Thus, like SMURFs, TGIF interacting ubiquitin ligase (Tiul)1/WWP1 and NEDD4-2 also associate with 
SMAD7 and can promote degradation of activated TGFβ type I receptors (Seo et al, 2004; Komuro et 
al, 2004; Kuratomi et al, 2005). Dapper2, a PDZ-binding protein, inhibits mesoderm formation by 
promoting lysosomal degradation of TGFβ receptors in mammals (Su et al, 2007). Furthermore, protein 
phosphatase PP1a was shown to be recruited in a SMAD7-dependent manner to ALK1 in endothelial 
cells and to target ALK1 for dephosphorylation (Valdimarsdottir et al, 2006). In addition to the positive 
role it plays in signaling by recruiting SMAD2 and 3 to the activated TGFβ receptor, the assembly of 
PP1c with SMAD7–GADD34 complex in mammalian cells is enhanced by SARA, resulting in more 
efficient dephosphorylation of the TGFβ type I receptor (Shi et al, 2004). Moreover, receptor and SMAD 
kinetics are influenced by SARA. At steady state, the bulk of SARA and SARA bound SMAD2 are located 
in early endosomes. Receptor-mediated phosphorylation of SARA bound SMAD2 occurs at the plasma 
membrane but is more efficient in SARA-rich early endosomes to which the activated receptor complex 
is internalized via clathrin-coated pits (Di Guglielmo et al, 2003; Hayes et al, 2002; Lu et al, 2002). All 
these different parameters may in turn control the duration of SMAD phosphorylation and activation, 
and thus give rise to qualitatively different responses resulting from different signaling thresholds. 
Despite the variable effects of receptor endocytosis on SMAD phosphorylation, activation of non-
SMAD signaling pathways by TGFβ appears to require receptor internalization (Meyer et al, 2011; Zuo 
et al, 2009).  
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Since TGFβ is not recycled, internalization of TGFβ by endocytosis is the primary means of removing 
active TGFβ from the cell surface, and lysosomal degradation is the primary means of termination of 
TGFβ signaling (Clarke et al 2009; Zi et al, 2011). In agreement with my results, TGFβ signaling 
amplitude and duration can be regulated through the control of receptor trafficking (Zi et al, 2012). 
However in contrast, it has also been shown that receptors are internalized constitutively with similar 
efficiencies in the absence and presence of a signal (Di Guglielmo et al, 2003).Thus, TGFβ does not 
appear to alter TGFβ receptor trafficking. The latter is compatible with the action of TGFβ family ligands 
as morphogens that allow a cell to continuously sense the concentrations of active ligand. In addition, 
studies in Xenopus have shown that the retention of activated activin receptors within the endocytic 
pathway is required for cellular memory of activin signaling. Such memory is needed for correct cell 
fate decisions by morphogens (Jullien et al, 2005).  To understand the role of receptor endocytosis on 
TGFβ signaling, diverse mathematical models were established. Vilar et al assumed that TGFβ signaling 
activity is proportional to the level of ligand-receptor complexes in the internalized endosomes. In 
addition, ligand-receptor complexes between type I and type II receptors have the same constitutive 
degradation rate. However, the model lumps the processes including non-clathrin dependent 
internalization, recycling and the degradation of the receptors into one reaction as “the ligand-induced 
receptor degradation from plasma membrane” (Zi et al, 2012). Thus, Zi and Klipp developed a 
mathematical model, including two major types of TGFβ receptor endocytosis (Zi & Klipp, 2007b). In 
agreement with my results, the model simulations suggest that SMAD activation is regulated by the 
balance between clathrin dependent endocytosis and caveolar/lipid-raft mediated (clathrin- 
independent) endocytosis. If clathrin-dependent internalization is dominant, SMAD activation 
becomes a sustained response. On the other hand, if clathrin- independent endocytosis is dominant, 
SMAD activation displays a transient response. Interestingly, the simulation results suggest that 
changing the balance between the two branches of endocytosis has relatively little effect on the early 
SMAD signal, and has larger effect in reshaping long term SMAD activity. In addition, Vizán et al found 
that TGFβ binding triggered the rapid depletion of signaling-competent receptors from the cell surface, 
with the type I and type II receptors exhibiting different degradation and trafficking kinetics (Vizán et 
al, 2013). A computational model of TGFβ signal transduction from the membrane to the nucleus that 
incorporates their experimental findings predicts that autocrine signaling, such as that associated with 
tumorigenesis, severely compromises the TGFβ response. They showed that the long-term signaling 
behavior of the TGFβ pathway is determined by receptor dynamics, but does not require TGFβ–
induced expression of feedback regulators. In the future, a detailed systems biology approach can be 
useful to clarify this issue by combining mathematical models with quantitative experimental data of 
receptors and SMAD kinetics. In further studies, systematic analysis of the dynamic receptor 
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localization according to different input strengths and duration would be necessary. Combined live-
cell reporters for SMAD translocation and receptor localization may provide deeper insights regarding 
the molecular mechanisms of pathway activation. Moreover, inhibition of both endocytic pathways 
would provide information about the entire role of receptor endocytosis in TGFβ signaling. As the 
downregulation of TGFβ levels and/or TGFβ responsiveness has been implicated in other disease 
processes, such as autoimmune disease, potent TGFβ- enhancers such as dynasore or dynasore-like 
compounds are potential therapeutic compounds for treating such diseases (Li and Flavell 2008). 
Finally, receptor internalization and slow recovery of the receptor at the surface, in conjunction with 
increased receptor degradation upon TGFβ stimulation, could influence both signal attenuation and 
the refractory behavior (Vizán et al, 2013). I showed that TGFβ signaling revealed a refractory period 
depending on the signaling state due to adaptation mechanisms. I examined the refractory time to 
understand which mechanisms restrict reactivation of the pathway and constitute the refractory time, 
by performing time-lapse microscopy experiments of SMAD2 reporter cells stimulated repeatedly with 
different TGFβ concentrations at various time points. Within the monitored 24 hours the system 
stimulated with high TGFβ concentrations (100pM TGFβ) was incapable of responding again to 
stimulation. In conclusion cells could only be completely re-stimulated after the terminal adaptation 
has been completed. Transcriptional negative feedback loops contributed to the refractory period of 
the system, at least for small concentrations. This is in accordance with Vizán et al, who also showed 
a period in which cells are unresponsive to further acute ligand stimulation. Such as different concepts 
for the terminal adaptation of TGFβ signaling are discussed, there are different concepts how the 
refractory period is influenced. In particular, the TGFβ strength and duration must be considered. Thus, 
Vizán et al assumed that cells enter a refractory state because surface receptors were rapidly occupied 
and internalized, whereas replenishment of the receptors at the cell surface was very slow. The 
refractory state was induced by TGFβ binding to receptors, but depended not on receptor activity and 
did not require negative feedback through TGFβ target genes. However, SMAD7 and other negative 
feedback loops also affect receptor endocytosis and indirectly TGFβ binding to receptors. In further 
experiments, the restimulation behavior should be investigated together with inhibition of the distinct 
receptor endocytosis pathways. Cell-dependent depletion of TGFβ from the medium (Clarke et al, 
2009) was essential for the ability of the cells to regain response competence after the refractory 
period (Vizán et al, 2013). In accordance with my results, once the ligand was depleted or consumed, 
cell surface receptor levels were slowly restored and the cells became once more fully competent to 
respond to an acute stimulation (Vizán et al, 2013). For example, this concept is in contrast with 
signaling downstream of the erythropoietin receptor (EpoR). The amount of unoccupied cell surface 
EpoR recovers very quickly after ligand stimulation and the system never reaches a refractory state 
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(Becker et al, 2010). In conclusion, ligand activation mechanisms may be important in vivo to limit the 
exposure of cells to high concentrations of mature TGFβ that would provoke a refractory state (Vizán 
et al, 2013). Indeed, high TGFβ exposure is associated with disease states, for example, during wound 
healing, fibrosis, or in tumorigenesis (Blobe et al, 2000; Massagué, 2008). The consequence of 
exposure to high concentrations of TGFβ is not only acute pathway activation but also desensitization. 
Therefore, a tumor that receives a constant supply of TGFβ, for instance because of autocrine signaling, 
would maintain only a low level of signaling. 
Thus, taken together, the results reported in this section suggest that adaptation mechanisms are a 
combinatorial effect of ligand degradation, proteasomal degradation, receptor endocytosis and 
feedback strength, which act at different time scales and doses. Positive and negative signals are 
equally important in controlling TGFβ signaling responses. Moreover a designation of TGFβ signaling 
components as having either negative or positive effects on signaling is often too simplistic. The future 
focus must be on how the various adaptation mechanisms change SMAD dynamics, and how this 
correlates precisely with cell fate. Thus, a balance between all regulatory mechanisms guarantees that 
the level of nuclear SMAD complexes reflects receptor activity at any time throughout the signaling 
period. The dynamically maintained concentration of nuclear SMAD complexes will then determine 
which SMAD target genes are activated, according to promoter binding-site affinity, co-repressors, co-
activators, but also through more complex mechanisms (Schmierer & Hill, 2007).  
4.3 Source of variability 
Next, I investigated which sources influence the heterogeneity of the SMAD response to a given TGFβ 
stimulus in individual and genetically identical cells. To this end, I examined how the initial state of the 
cell, such as cell cycle state, cell density or cell location, contribute to the observed heterogeneity in 
dynamical behavior (Loewer & Lahav, 2011; Snijder & Pelkmans, 2011). However, cell cycle state was 
not the main cause of heterogeneity. No obvious correlation between cell cycle phase and TGFβ 
response was observed for all different TGFβ concentrations. In addition, there were no significant 
differences in the distributions of the cell divisions of the respective signaling classes. Furthermore, 
synchronized cells in G2 showed no impact on the TGFβ response.  
By seeding a different number of cells 48 hours prior to 100pM TGFβ stimulation, I examined how the 
individual TGFβ response depends on cell density. However, the ratio TGFβ response was largely 
independent of cell density, but the amount of SMADs in the nucleus increased with lower cell density. 
This applied to the basal level, amplitude and the late SMAD response. The question is what is critical 
for the cellular outcome, ratio SMAD2 level or the absolute nuclear level? In addition, what are the 
triggering factors that the nuclear and cytoplasmic basal levels were already altered by varying cell 
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density? Since the cell density in this experimental setup determined by many factors, like cell 
contacts, cell volume, available number of receptors and/or TGFβ molecules per cell, in another 
experiment Marcel Jentsch and I considered the influence of the local cell density on the TGFβ 
response. However, local cell density was not sufficient to explain signaling heterogeneity. In summary, 
the cell density explains minor differences between different experiments, but not the heterogeneity 
within the cells in one experiment. This is also supported by a paper demonstrating that activation of 
the cell density sensing YAP/TAZ pathway does not attenuate SMAD signaling (Nallet-Staub et al, 
2015). Furthermore, a mathematical model has shown that cell density affects signaling dynamics in 
response to the same concentration of ligand. Cells have distinct signaling durations and signaling 
persists longer when cell density is decreased (Zi & Klipp, 2007b). Thus the authors argued, that the 
key parameter for experimental design cannot be “concentration of ligand”, but rather must be 
“molecules of ligand per cell”, which takes into account the number of cells in the experiment. 
Therefore, we kept the cell number, time of TGFβ stimulation, size of dishes or medium volume 
constant for all experiments.  
Interestingly, recent single-cell transcriptomic studies revealed that cell volume contribute to 
phenotypic and functional cell heterogeneity even in monoclonal cell lines (Buettner et al, 2015; 
Padovan-Merhar et al, 2005). How cell volume influences SMAD heterogeneity could be investigated 
in future experiments. Moreover, subcellular structures and organelle size, shape and distribution 
contribute to phenotypic heterogeneity (Rafelski and Marshall, 2008; Marshall, 2011; Chan and 
Marshall, 2010). 
In addition, the stochastic nature of gene expression can lead to highly variable behaviors across 
genetically identical populations of cells, commonly referred to as noise. Expression noise can be 
disadvantageous, by affecting the precision of performing biological functions, but it may also be 
advantageous by enabling heterogeneous stress-response programs to environmental changes (Eldar 
& Elowitz, 2010). Importantly, gene expression is a multi-step process and the stochasticity of its 
individual steps, including transcription and translation, contributes to the resulting variability. In 
addition, protein level variations represent a combination of fluctuations caused by the stochastic 
nature of biochemical reactions (Bar-Even et al, 2006; Pedraza & Paulsson, 2008; Lestas et al, 2010), 
cell-specific activity of regulatory processes (Colman-Lerner et al, 2005) and influences from 
population microenvironment (Snijder et al, 2009; Snijder & Pelkmans, 2011). Thus, individual cells are 
likely to express different amounts of receptors at the cell surface. Model simulations indicated that 
signaling responses are regulated by the ratio of ligand to cell surface receptor number (Zi & Klipp, 
2007b). When all cells are exposed to the same amount of ligand, the ratio of ligand to cell surface 
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receptor number in each cell will be different, which might cause heterogeneous signaling responses 
at single cell level. Number of receptors could also be correlated with cell volume.  
To further test whether protein level variations may cause SMAD signaling heterogeneity and 
decomposition into signaling classes, we developed a modeling approach in cooperation with Stefan 
Legewie and Uddipan Sarma (Strasen et al, 2018). The modeling simulations provide evidence that 
feedback expression is a main determinant of signaling classes. In addition to stochastic gene 
expression, cell-specific activation of signaling pathways controlling SMAD7 expression could 
contribute to the observed cell-to-cell variability. Such pathways may include IFN-c/ Stat1 (Ulloa et al, 
1999), PKC (Tsunobuchi et al, 2004), hepatocyte growth factor (Shukla et al, 2009) or mir21 (Li et al, 
2013). Further experiments are needed to clarify sources of heterogeneous feedback expression.  
The question of the mechanisms and consequences of intercellular heterogeneity is not purely 
academic since cell-to-cell heterogeneity is a major driver of cancer evolution, immune responses and 
disease progression. The treatment of many diseases is complicated by heterogeneity that renders 
some cells more resistant to treatment than others. Furthermore, it has been argued that neglecting 
cell heterogeneity is one of the major causes of error in disease classification (Marko et al, 2011). 
4.4 The activity of MAP kinases determines long-term dynamics of SMAD 
signaling  
The TGFβ/SMAD pathway does not function in isolation, but is part of a signaling network in which 
cross-talk between pathways occurs. Therefore, it is interesting to investigate how coordinate 
regulation of multiple pathways is achieved by changes in activity of common pathway components. 
Especially noncanonical signaling pathways including the mitogen-activated protein kinase (MAPK), 
NF-κB or PI3 kinase/ AKT pathways, can either be induced by TGFβ, or can modulate the outcome of 
TGFβ-induced SMAD signaling (Massague  ́and Chen, 2000; Lutz and Knaus, 2002; Derynck and Zhang, 
2003). SMAD proteins are also capable of physically interacting with transcription factors, themselves 
substrates of MAPKs, adding more complexity to the intricate relationship between MAPKs and the 
SMAD pathway. Although the canonical pathway tends to be treated as the more important, recent 
studies suggest that the SMAD-independent TGFβ signaling plays a more significant role in vivo than 
previously thought (Holm et al, 2011; Iwata et al, 2012). In a mouse model of Marfan’s syndrome in 
which TGFβ signaling is elevated, the aortic aneurysm phenotypes are made worse by reducing the 
canonical pathway component SMAD4, and the phenotypes are made less severe by attenuation of 
noncanonical pathways (Holm et al, 2011). These results show not only that the noncanonical pathway 
is of importance in disease mechanisms but also that the two pathways somehow interact with one 
another. Indeed, evidence exists for a tight integration of SMAD signaling within a complex network of 
4.4 The activity of MAP kinases determines long-term dynamics of SMAD signaling 
152 
 
cross-talks with noncanonical TGFβ pathways that largely contribute to modify the initial SMAD signals 
and allow the pleiotropic activities of TGFβ (Javelaud & Mauviel, 2005). Therefore, we investigated 
systematically how the dynamic response of SMADs is influenced by cross-talk of non-canonical TGFβ 
signaling and other signaling networks.  
First of all, I examined the influence of the JNK pathway on SMAD2 and SMAD4 dynamics in MCF10A 
cells. Crosstalk between the JNK1 and SMAD pathways in RPMCs has been described as JNK–mediated 
phosphorylation of SMAD3 enhances its activation and nuclear translocation (Liu, 2012). In addition, 
the JNK pathway may contribute to regulate autocrine TGFβ1 expression, as JNK-deficient fibroblasts 
constitutively express TGFβ1, an expression that can be repressed by complementation of the cells 
with JNK (Ventura et al, 2004). Nevertheless, using JNK inhibitors neither the nuclear nor cytoplasmic 
levels of SMAD2 and SMAD4 have changed in time-lapse microscopy experiments. Clearly, the 
crosstalk between these two pathways depends on the physiological cell context, a general theme in 
TGFβ signaling. 
Further on, I investigated how the p38 pathway influences SMAD2 and SMAD4 dynamics. TGFβ 
receptors activate MAP3Ks (MEKKs) like TAK1, which in turn activates MKKs like 3, 4, 6 and finally 
phosphorylate p38 (Zhang, 2009, Figure 2A). Interestingly a study by Gui et al showed that prolonged 
and sustained activation of the p38 MAPK pathway requires SMAD signaling, which is observed in 
hepatocytes, osteoblasts and pancreatic carcinoma cells. SMAD activation induces the expression of 
GADD45β, an upstream activator of MKK4, and thus promotes the prolonged activation of p38 MAPK 
(Gui et al, 2012). Additionally, treatment of JEG-3 cells with a p38 MAPK inhibitor (SB203580) 
attenuated TGFβ1-induced SMAD3 protein expression and suppressed the activation of SMAD3 (Xu et 
al, 2013). These results suggested that there is crosstalk between p38 MAPK and SMAD3 through TGFβ 
signaling in human choriocarcinoma. Indeed, I observed that inhibition of p38 activity with p38 
inhibitors BIRB 796 and SB202190 modulated the dynamics and localization of SMAD2 upon TGFβ 
stimulation by diminishing the amplitude of the first peak and preventing nuclear accumulation of 
SMAD2 at all later time points. The results were also transferable for lower TGFβ concentrations. 
Increasing concentrations of SB202190 and BIRB 796 also increased the p38 effect on the late SMAD2 
response, respectively. Immunofluorescence experiments confirmed the microscopy results. In 
addition, SMAD4 showed no long-term dynamics, too. Interestingly, adding the inhibitors 6 hours after 
TGFβ treatment terminated further activation fast, but obviously termination was slightly slower and 
not as strong as with TGFβ receptor inhibitors. In conclusion long-term dynamics of SMAD2 and SMAD4 
were p38 kinase activity dependent. Furthermore, p38 inhibition resulted in less phosphorylation of 
SMAD2 and SMAD3 while total SMAD2 and total SMAD3 levels remained unchanged. Inhibition 
efficiency was demonstrated by the phosphorylation status of HSP27. Evidence of cross-talk between 
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SMADs and p38 has been controversial, some studies previously demonstrated that loss of p38 activity 
decreased SMAD2/3 nuclear localization in the presence of TGFβ (Hayes et al, 2003), and knockout of 
SMAD3 showed decreased phosphorylation of p38 by TGFβ (Li et al, 2010). Also, inhibition of p38 
MAPK with a specific inhibitor, SB202190, abolished TGFβ-inducible activation of SMAD-dependent 
promoter and decreased SMAD2 phosphorylation. This suggests an interaction between SMAD and 
p38 MAPK pathways in TGFβ1-induced signaling in T98G glioblastoma cell (Dziembowska et al, 2007). 
In addition, p38 MAPK inhibitors can attenuate TGFβ1-induced SMAD3 transcriptional levels (Tan et 
al, 2014).  
While other studies have shown that inhibition of p38 was not required to phosphorylate SMAD2 
(Zhang et al, 2006), and over-expression of dominant negative SMAD3 did not inhibit TGFβ mediated 
activation of p38 (Yu et al, 2002). Likewise, TGFβ1-dependent phosphorylation of SMAD2/3 was 
unaffected by the inhibitor of p38 MAP kinase SB203580 in confluent growth-arrested HK-2 cells and 
SB203580 had no effect on the phosphorylation of SMAD2 and SMAD3 in rat peritoneal mesothelial 
cells stimulated with TGFβ1 (Wang et al, 2013). However, only short time periods were considered. 
Thus, I investigated the impact of this late SMAD dynamic remodeling on gene expression and cell fate. 
The negative feedback loops SnoN and SMAD7 were somewhat less expressed, while TIEG and SARA 
remained unchanged. In addition p21, which plays a role in proliferation and cell cycle arrest, was 
unaltered by p38 inhibition. Interestingly, Snail, a key regulator of TGFβ-induced EMT (Naber et al, 
2013), was clearly less expressed at later time points and in accordance with this finding, cells moved 
significantly slower and thus probably EMT was decreased. In conclusion, p38 kinase activity was 
necessary for the second response of SMAD2 and SMAD4 as well as for inducing probably EMT. This 
could be exploited by therapeutic approaches to cancer, so that the protective TGFβ-induced cell cycle 
arrest persists, but EMT is suppressed and cancer progression, invasion, and tumor metastasis is no 
longer supported. Wu et al also showed that using the p38 inhibitor SB203580 resulted in decreased 
metastasis, indicating that p38 inhibitors can be used as potential treatment for advanced breast 
cancer. In addition, Bakin et al considered this pathway as a potential target of therapeutic 
interventions in neoplastic and inflammatory disorders associated with TGFβ-mediated EMT. They also 
found, in accordance with my results, evidence that the p38 MAPK pathway is required for TGFβ-
mediated EMT and cell migration in NMuMG mouse mammary epithelial cells. Inhibition of the p38 
MAPK pathway affected TGFβ-mediated phosphorylation of ATF2, but did not inhibit phosphorylation 
of SMAD2. The SB202190 inhibitor impaired TGFβ-mediated changes in cell shape and reorganization 
of the actin cytoskeleton. In addition, dominant-negative Rac1N17 blocked TGFβ-induced activation of 
the p38 MAPK pathway and EMT, suggesting that Rac1 mediates activation of the p38 MAPK pathway 
(Bakin et al, 2002). Furthermore, also a study by Daroqui et al demonstrated that p38 MAPK and MEK 
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contribute to TGFβ stimulation of cell motility and invasion by analyzing signal transduction mediators 
(Daroqui et al, 2012). A study by Ohshima showed that mutant TGFβI did not affect activation of the 
SMAD pathway, but retained signaling via the MAP kinase pathway (Ohshima & Shimotohno, 2003). 
They also suggested that TGFβ receptor-activated p38 is involved in TGFβ-induced apoptosis but not 
growth arrest in mouse mammary gland epithelial cells. In accordance with this, it was published that 
TGFβ-induced apoptosis is mediated by SMAD-dependent expression of GADD45b through p38 
activation. They demonstrated that ectopic expression of GADD45b in AML12 murine hepatocytes is 
sufficient to activate p38 and to trigger apoptotic cell death, whereas antisense inhibition of Gadd45b 
expression blocks TGFβ-dependent p38 activation and apoptosis. Previous studies have shown that 
transcriptional activation of target genes by TGFβ, including the collagenase-3 and biglycan genes, 
requires the activation of both the MAP kinase and SMAD pathways (Leivonen et al, 2002; Ungefroren 
et al, 2003). Moreover, it was shown that TGFβ-mediated phosphorylation and stabilization of Sox9 
are dependent on p38 activity in chondrocytes. Wang et al showed that, TGFβ1 significantly 
upregulated the expression of MCP-1 at both the protein and mRNA level in a time-dependent manner 
and SB203580 markedly inhibited the expression in rat peritoneal mesothelial cells (Wang et al, 2013).  
Next, in order to examine the upstream components of the p38 pathway that influences the dynamics 
and localization of SMADs in more detail, I focused on TAK1. Therefore I used the inhibitor (5Z)-7-
Oxozeaenol, that inhibits both the kinase and the ATPase activity of TAK1 (Wu et al, 2013) and 
investigated how dynamics of SMAD2 and SMAD4 change. It is known that there are notable 
differences in the mechanism of SMAD2/3 and TAK1 activation. TGFβ1-induced TAK1 activation occurs 
independent of TGFβRI kinase activity, whereas activation of SMAD2/3 involves recruitment and 
phosphorylation by TGFβRI and requires kinase activity of TGFβRI (Wu et al, 2000; Chen et al, 1998; 
Kim et al, 2009; Sorrentino et al, 2008). I could show that with increasing inhibitor concentration 
SMAD2 translocation decreased and the first response disappeared. (5Z)-7-Oxozeaenol alone did not 
lead to translocation of SMAD2. Immunofluorescence experiments confirmed the results of time-lapse 
microscopy. As a conclusion, TAK1 activity seemed essential for SMAD2 signaling. I could show that 
SMAD4 accumulated strongly from the cytoplasm into the nucleus with increasing TAK1 inhibitor 
concentration. Furthermore, (5Z)-7-Oxozeaenol alone led to a strong translocation of SMAD4. And 
surprisingly adding (5Z) -7-Oxozeaenol 6 hours post TGFβ stimulation resulted in an immediate import 
of SMAD4. In conclusion TAK1 inhibition enhanced SMAD4 signaling independent of SMAD2 and TGFβ. 
These observations suggest that TAK1 might be the point of convergence in various signaling pathways 
activated by a variety of stimuli and play a pivotal role in regulating cellular responses (Choi et al, 2012). 
Nevertheless, another MAP3K, MEKK4 (MAP3K4), has also been proposed to mediate the TGFβ-
induced phosphorylation of p38 MAPK through SMAD-dependent expression of GADD45b, which 
4.4 The activity of MAP kinases determines long-term dynamics of SMAD signaling 
155 
 
associates with and activates MAP3K4 (Takekawa et al, 2002). Also, the depletion of MLK2 (MAP3K10) 
in cells with homozygous knock-in of catalytically inactive MEKK4 (MAP3K4) results in a complete loss 
of the TGFβ-induced phosphorylation of p38 MAPK, implying that MEKK4 and MLK2 mediate the TGFβ-
induced phosphorylation and activation of p38 MAPK in MEFs and HaCaT keratinocytes. However, 
many reports implying a role for TAK1 in mediating the TGFβ-induced phosphorylation of p38 MAPK 
(Kim et al, 2009; Yamaguchi et al, 1995; Walsh et al, 2008). More recent reports have focused mainly 
on TRAF6 as an upstream activator of TAK1 (Sorrentino et al, 2008; Yamashita et al, 2008). It is 
therefore likely that TRAF6 could mediate the TGFβ-induced phosphorylation of p38 MAPK through 
another MAP3K (Sapkota, 2013).  
In addition I confirmed the microscopy results and assumed underlying mechanisms. I showed in 
western blot experiments that the first response of SMAD2 and SMAD3 phosphorylation disappeared 
when TAK1 was inhibited. Thus, the accumulation of SMAD4 was also independent of pSMAD3. 
Furthermore, TAK1 inhibition stabilized TGFβ receptor 1 suggesting a remodeling of the receptors so 
that pSMAD2 may not bind and phosphorylation was prevented. This assumption is supported by 
another time-lapse movie, where cells inhibited 6 hours post TGFβ stimulation with the (5Z)-7-
Oxozeaenol or TGFβR1 inhibitor showed the same signaling termination rates for SMAD2 translocation 
into the nucleus. Furthermore, although SMAD4 translocated into the nucleus decoupled from 
pSMAD2, pSMAD3 and TGFβ, I proved that the accumulation was also independent of BMP signaling. 
Studies indicate that TAK1 can regulate TGFβ-induced activation of SMAD signaling by inducing SMAD7 
expression (Dowdy et al, 2003). Interestingly, a study by Yumoto et al showed that TAK1 is required 
for appropriate activation of both the noncanonical p38 pathway and canonical SMAD pathway in the 
neural crest-derived craniofacial ecto-mesenchyme. They show that TAK1 deficiency results in 
attenuated TGFβ R-SMAD linker region phosphorylation (SMAD2 at Thr-220, which has been shown to 
be critical for full transcriptional activity of SMAD2) and that TAK1 kinase mediates both distinct and 
overlapping agonist-induced transcriptional responses (Yumoto et al, 2013). Linker regions in R-SMADs 
are Ser/ Thr-rich and are known to be phosphorylated by several different kinases, e.g. GSK, MAPKs, 
and CDKs, and it has been suggested that these post-translational modifications have both activatory 
and inhibitory regulatory functions in TGFβ signaling. More research in this direction is necessary. My 
western blot experiments did not yield any clear results. Nevertheless, in conclusion TAK1 mediates 
both canonical and noncanonical arms of the TGFβ signaling and affects SMAD2 and SMAD4 dynamics. 
Furthermore, I could show that this dynamic remodeling had an impact on gene expression. The strong 
first response of SnoN, SMAD7, TIEG, Snail and PAI1 were gone and they were less expressed at later 
time points. This confirmed that TAK1 activity was probably needed for EMT and although the SMAD4 
response was enhanced, SMAD2 accumulation was essential for the expression of TGFβ target genes. 
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In addition to the role of TAK1 in the regulation of SMAD function, there is cross-talk between the 
SMAD and downstream targets of TAK1 such as ATF2 in regulation of certain TGFβ1 target gene 
expression (Hanafusa et al, 1999; Sano et al, 1999; Abécassis et al, 2004). 
TGFβ activates the TAK1-MKK6-p38 kinase cascade leading to the phosphorylation of ATF-2, and ATF-
2 associates with SMAD4 in response to TGFβ. Therefore, SMAD complexes and phosphorylated ATF-
2 may interact in a nucleoprotein complex that associates with DNA and activates transcription of 
TGFβ-responsive genes (Hanafusa et al, 1999). In accordance with my results, knocking down TRAF6 
expression also inhibits TGFβ-mediated EMT (Yamashita et al, 2008). Thus, activation of the TRAF6-
TAK1-p38 pathway is another obligatory requirement for TGFβ-induced EMT. Also, the TRAF6-TAK1-
p38 pathway is essential for TGFβ- induced apoptosis. Overexpression of TAK1 caused cells or Xenopus 
embryo to undergo apoptosis, whereas cells expressing the kinase-inactive TAK1 were protected from 
TGFβ-induced apoptosis (Shibuya et al, 1998; Kimura et al, 2000; Edlund et al, 2003). As well abrogation 
of TAK1 activation inhibits TGFβ-induced apoptosis in embryonic fibroblasts, prostate cancer cells, and 
AML12 liver cells, indicating that TAK1 also acts as a mediator of apoptosis (Sorrentino et al, 2008; 
Yamashita et al, 2008). In contrast knockdown of TAK1 expression or inhibition of TAK1 activation 
augments cell apoptosis induced by TGFβ1 in various cell types in vitro and in vivo, including the kidney, 
indicating that TAK1 is required for prevention of apoptosis and plays a role as a cell survival factor 
(Ma et al, 2011; Omori et al, 2010).  Moreover, TGFβ-induced fibronectin expression in fibroblasts is 
mediated by TAK1 through MKK4-JNK signaling cascade and TAK1-deficient fibroblasts exhibited 
reduced profibrotic response to TGFβ1 stimulation (Shi-wen et al, 2009; Hocevar et al, 2005). In vitro 
studies show that TAK1 mediates TGFβ-induced expression of types I and IV collagens and fibronectin 
in cultured mesangial cells (Ono et al, 2003). In conclusion, a combination of the canonical and non-
canonical signaling outputs, as well as context-dependent crosstalk inputs from other signaling 
networks, probably define the nature of cellular responses to TGFβ ligands. 
In order to investigate the underlying mechanisms of p38 activity and SMAD cross-talk, I focused first 
on the participation of SMAD7. TAB1 (TGFβ-activated kinase-binding protein-1) is able to associate 
with SMAD7, a phenomenon that may lead to inhibition of TAK-1-dependent p38 activation (Edlund et 
al, 2003). Alternatively, it has also been suggested that SMAD7 could act as a scaffolding protein to 
provide structural support for MKK3/p38 activation by TAK1 (Edlund et al, 2003). Additionally, the 
ability of SMAD7 to interact with TGFβR1 using two modes—a three-finger-like structure in the MH2 
domain and a basic groove in the MH2 domain, in contrast to only one mode for SMAD6, the other I-
SMAD, suggests a dual role for SMAD7: inhibition of TGFβ-SMAD signaling and promotion of TGFβ-
induced activation of p38 MAPK pathway. Nevertheless, using a SMAD7 knock out cell line with p38 
inhibitors did not show an SMAD7 influence on the effect of p38 inhibition of long-term SMAD 
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dynamics. Interestingly, it was shown recently that SMAD6 is immediately induced in response to 
TGFβ1 in AML-12 and primary hepatocytes and inhibits TGFβ1-induced TRAF6 polyubiquitination 
through recruiting the A20 deubiquitinating enzyme, thereby suppressing subsequent TAK1-p38 
MAPK activation (Jung et al, 2013). In future experiments, the role of SMAD6 could be examined in 
more detail. As a further approach I considered that SMAD2 is less phosphorylated due to modified 
receptor trafficking. However, by using Nystatin and p38 inhibitors I showed that p38 inhibition did 
not shift receptors to degradation. Interestingly, a study from Tan et al showed that p38 MAPK 
inhibitors can attenuate TGFβ1-induced TGFβRI and TGFβRII transcriptional levels. They assumed that 
the blockade of the p38 MAPK pathway can downregulate the activated TGFβRI and TGFβRII (Tan et 
al, 2014). Correlation of receptor activation and p38 activity in future experiments would be 
interesting. Next, by using the proteasome inhibitor MG132, I showed that the p38 effect was not 
mediated by alteration of the ubiquitin-dependent degradation. Interestingly, the p38 effect was also 
evident when the cells were treated with MG132 and p38 inhibitor compared to treatment with only 
MG132, hence independent of TGFβ stimulation. 
To further understand the mechanism how the p38 kinase influences the long-term dynamics of 
SMADs, I focused on phosphatases. By using Okadaic acid, a phosphatase inhibitor particularly of type 
1 (PP1) and 2A (PP2A), and p38 inhibitors I showed that inhibition of PP1 and PP2A did not alter the 
p38-mediated SMAD2 response. But inhibiting another phosphatase group PP2C with Sanguinarine 
chloride abrogated the p38 effect on SMAD2 and SMAD4 dynamics. Since phosphatase inhibition could 
also result in more pp38 and the p38 inhibitors function possibly incompletely, I could also show that 
the p38 effect disappeared with Sanguinarine chloride even at high p38 inhibitor concentrations. In 
conclusion inhibition of PP2C abrogated the p38- mediated SMAD response and therefore a PP2C 
family member is involved in the p38- SMAD-crosstalk. But the link between activated p38 and the 
phosphatase remain unclear. 
Since PPM1A (PP2Cα) was identified as a nuclear R-SMAD phosphatase that directly dephosphorylates 
C-terminal phosphorylated SMAD1, 2 and 3, I focused on this candidate. PPM1A limits the activation 
state of SMAD2/3 and promotes nuclear export and depletion of cellular PPM1A expression enhances 
TGFβ responses. PPM1A is not specific for SMADs but has many other substrates like 
phosphatidylinositol-3 kinase, axin, CDK2 and CDK6 (Lin et al, 2006; Duan et al, 2006; Yoshizaki et al, 
2004; Strovel et al, 2000; Cheng et al, 2000). Interestingly, PPM1A is not induced by TGFβ signaling, 
neither in terms of activity nor in terms of subcellular distribution (Lin et al, 2006). In accordance I 
could show that knockdown of PPM1A enhanced nuclear SMAD2 translocation in microscopy 
experiments. Nevertheless, even after PPM1A siRNA transfection and p38 inhibition was the p38 effect 
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recognizable. Therefore, PPM1A is probably not involved in the p38-mediated TGFβ response. 
However, compensation mechanisms and incomplete knock down can obscure the result.  
Interestingly as an outlook, the p38 pathway is involved in the control of posttranslational modification 
of SMADs. Specifically, it has been demonstrated that p38 regulates the sumoylation of SMAD4 by 
proteins of the PIAS family of E3 ligases, contributing to an enhancement of SMAD4-dependent 
transcription. Sumoylation of SMAD4 mainly occurs at lysine 159, located in the linker region (Ohshima 
and Shimotohno, 2003). In another exciting study Zhang et al demonstrated, that inhibition of p38 
MAP kinase inhibited de novo TGFβ1 protein synthesis without interfering with SMAD activation 
(Zhang et al, 2006). What that has to do with changing SMAD dynamics needs to be explored in future 
experiments. A useful approach would be to use kinase translocation reporters (KTRs), which enable 
multiplexed measurements of the dynamics of kinase activity at single-cell level (Regot, 2014). This 
would allow to track p38 kinase activity and SMAD dynamics in the same cell. These KTRs are composed 
of an engineered construct in which a kinase substrate is fused to a bipartite nuclear localization signal 
(bNLS) and nuclear export signal (NES), as well as to a fluorescent protein for microscopy-based 
detection of its localization. The relative cytoplasmic versus nuclear fluorescence of the KTR construct 
(the C/N ratio) is used as a proxy for the kinase activity in living, single cells (Kudo et al, 2018). 
Unfortunately, microscopy experiments with an established KTR cell line resulted in a weak p38 signal 
after TGFβ stimulation. Which role substrates of p38, such as MAPK-activated protein kinase 2 (MK2) 
play could also be investigated in further experiments. 
Numerous small molecule inhibitors of p38 MAPK, including VX745, have been developed and have 
entered clinical trials. Given the critical roles of p38 MAPK in mediating TGFβ-induced CREB 
phosphorylation and transcription, as well as EMT (Bakin et al, 2002) and cell death (Yoo et al, 2003; 
van der Heide et al, 2011), the use of these inhibitors in a clinical context may have consequences on 
the TGFβ responses as well. Depending on different biological contexts, p38 MAPK inhibitors may 
prove to be useful as inhibitors of TGFβ-induced metastasis or may prove less useful by promoting 
tumor proliferation through blocking TGFβ-induced apoptosis (Sapkota, 2013). 
Finally I investigated the influence of the ERK pathway, another non-canonical MAP Kinase pathway of 
TGFβ activation, on SMAD dynamics. According to a study by Huang and Chen, TGFβRII alone is able to 
mediate TGFβ signaling to ERK1/2, and differences in the level of TGFβRII expression determine 
whether or not TGFβ activates or inhibits ERK1/2 (Huang & Chen, 2012). The kinetics of ERK 
phosphorylation induced by TGFβ varies with cell types and culture conditions. The ShcA/Grb2/Sos 
complex is capable of activating Ras at the plasma membrane, leading to sequential activation of c-
Raf, MEK, and ERK (Zhang, 2009). I showed that inhibition of the kinase activity of p38 and TGFβ 
stimulation led to enhanced ERK signaling in MCF10A WT cells. However, inhibition of ERK signaling 
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could not abrogate the p38 effect. Nevertheless, I examined the impact of ERK signaling on SMAD 
dynamics in live cell time-lapse microscopy experiments.  
With increasing EGF concentrations the maximum amplitude and the second response rose. Thus, cells 
without EGF in the media before stimulating with TGFβ showed extremely low SMAD2 activation. 
Interestingly, already the basal nuclear and cytoplasmic SMAD2 levels increased with increasing EGF 
concentrations. In addition, the increasing TGFβ response by rising EGF concentrations was not due to 
a changed proportion of responders. With Western blot analysis I confirmed the results, as without 
EGF only a very weak phosphorylation of SMAD2 and SMAD3 has been measured. Furthermore, cells 
without EGF almost did not divide. But the different EGF concentrations had no influence on the 
proportion of dividing cells. But I found that cells moved more with increasing EGF concentrations and 
therefore both ERK and TGFβ signaling may important for EMT. 
Moreover, inhibiting the ERK signaling through Gefitinib, a tyrosine kinase inhibitor of the epidermal 
growth factor receptor (EGFR), led to reduced nuclear SMAD2 accumulation at later time points 
through an enhanced adaptation, while the amplitude of the initial response remained unchanged. 
Western blot analysis also confirmed the results and the late phosphorylation of SMAD2 and SMAD3 
was diminished. Even if the cascade was inhibited downstream of the receptors, such as the Raf kinase 
with Sorafenib (Wilhelm et al, 2004; Adnane et al, 2006), MEK1 and 2 with AZD6244 and UO126, 
another dual MEK1 and MEK2 inhibitor (Davies et al, 2007) a diminished late SMAD2 and SMAD4 
response due to a stronger adaptation was observed which confirmed the results with Gefitinib.  
Furthermore, I analyzed the impact of this dynamic remodeling on gene expression and cell fate. I 
showed that Gefitinib prevented the late activation of Snail. This supports the hypothesis that the long-
term dynamics of SMAD2 are probably responsible for EMT and the balance between SMAD activation 
and ERK signaling defines cellular responses to TGFβ. ERK1/2 activation has been linked to a number 
of TGFβ-regulated cellular events, including CKIs p21Cip1 and p27Kip1 gene expression and growth 
arrest (Hartsough et al, 1996; Frey and Mulder, 1997), EMT (Zavadil et al, 2001) and breast cancer cell 
motility (Dumont et al, 2003). Moreover, activation of ERK was necessary for TGFβ induced fibroblast 
replication (Hough et al, 2012). Finally, ERK substrates, such as AP-1 family members, can interact and 
function in conjunction with SMADs to regulate gene expression (Davies et al, 2005; Zhang et al, 1998; 
Hall et al, 2003). Interestingly, it was shown that in HK2 cells TGFβ1 mRNA autoinduction was inhibited 
by the ERK MAP kinase inhibitor PD98059 (Zhang et al, 2006). In addition, Zhang et al, showed that 
TGFβ1 activates NF-κB via ERK MAP kinase and that this is also required for transcriptional 
autoinduction of TGFβ. An alternative signaling pathway was described, where by activating 
phosphotidylinositol 3-kinase (PI3K), TGFβ stimulates p21-activated kinase2 (Pak2) to phosphorylate 
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c-Raf, ultimately resulting in ERK activation. The TGFβ/PI3K/Pak2/Raf/MEK/ERK pathway regulates 
SMAD signaling and is critical for TGFβ-induced growth (Hough et al, 2012).  
Furthermore, since ERK signaling had an enormous impact on the long-term dynamics of SMAD2 and 
SMAD4 and affected TGFβ cell fate decisions, I investigated the underlying mechanisms of this cross-
talk.  
First of all, by using the SMAD7 CRISPR Cas9 knock out cell line I showed that SMAD7 played no role 
for the gefitinib effect. In addition, by using Okadaic acid, I observed that inhibition of PP1 and PP2A 
phosphatases did not abrogate the modulated SMAD2 response due to inhibition of ERK signaling. 
Finally, I found out that the phosphatase group PP2C interfered with ERK signaling to modulate the 
long-term dynamics of SMADs. Inhibition of PP2C with Sanguinarine chloride abrogated the effect of 
inhibition of the ERK cascade on SMAD2 and SMAD4 and all cells showed a strong SMAD response. 
Also I demonstrated that adding Sanguinarine chloride 3 hours post stimulation to Gefitinib pretreated 
cells immediately enhanced the SMAD2 accumulation into the nucleus. Moreover I confirmed that 
Gefitinib worked efficiently and the ERK cascade was also interrupted when treated with Sanguinarine 
and Gefitinib and ERKs remained unphosphorylated in Western blot analyzes. In conclusion a PP2C 
family member was involved in the ERK- SMAD-crosstalk, but the link between ERK signaling and the 
phosphatase remains unclear. Thus, I investigated that after PPM1A siRNA transfection and gefitinib 
inhibition, the gefitinib effect was almost gone. By clustering on the first 45 minutes of the cytoplasmic 
response to separate cells with a very good PPM1A knock down from those with worse or none knock 
down, I gathered evidence that PPM1A was involved in the ERK-mediated TGFβ response. Gefitinib-
treated cells with a very good PPM1A knock down showed the same or even stronger response after 
TGFβ addition. In conclusion, without PPM1A the Gefitinib effect disappeared and thus late SMAD2 
nuclear translocation was PPM1A-dependent. In addition, Gefitinib slightly increased the expression 
of PPM1A, but this was only slightly reflected in Western experiments. Therefore, modifications of 
PPM1A must be investigated in further experiments. Because the receptor kinase is located in the 
membrane compartment and R-SMAD phosphatases such as PPM1A are nuclear, the dynamic 
equilibrium between phosphorylation and dephosphorylation must be closely coupled to the 
nucleocytoplasmic transport of SMADs (Schmierer & Hill, 2007). 
In addition to C-terminal phosphorylation at a conserved SSXS sequence, more recent research has 
shown that R-SMADs can also be phosphorylated in the linker region between their Mad homology 
domains, which is important for both full activation and cessation of activation (Alarcón et al, 2009; 
Matsuzaki et al, 2009). ERK phosphorylates the linker region of nuclear localized SMADs, resulting in 
increased half-life of C-terminal pSMAD2 and 3 (Ser465/467) and increased duration of SMAD target 
gene transcription (Hough et al, 2012). ERK signaling has also been proposed to inhibit TGFβ signaling 
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since ERK phosphorylates serine or threonine residues in the PX(S/T)P or (S/T)P motif of the linker 
regions in receptor SMADs (SMAD1,2,3,5,8) which then cannot migrate into the nucleus, thus 
inhibiting TGFβ-SMAD signaling (Kretzschmar et al, 1999). This mechanism might explain why in some 
cells with hyperactive Ras signaling the response to TGFβ is inhibited (Calonge et al, 1999; Kretzschmar 
et al, 1999). But other studies have not reported impaired nuclear translocation of SMADs in Ras-
transformed cells or in cells with activated MAP kinase signaling (Engel et al, 1999; Lehmann et al, 
2000). 
Thus, Ras and TGFβ-signals act cooperatively as well as antagonistically during development and in 
oncogenesis. Although TGFβ can override the proliferative effects of EGF and other Ras-activating 
mitogens in normal epithelial cells, oncogenic activation of Ras suppresses the cytostatic effects of 
TGFβ. As Ras has diverse effectors and targets in the cell, its interplay with TGFβ- signaling is likely to 
occur at multiple levels, many of which involve indirect molecular interaction. Oncogenic Ras also 
appeared to induce degradation of SMAD4 (Saha et al, 2001). Interestingly, Ras/MAP kinase signaling 
also induces expression of TGFβ1 thereby amplifying the TGFβ response and inducing secondary TGFβ 
responses and thus may explain the often-observed increase in expression of TGFβ1 by tumor cells. 
(Yue & Mulder, 2000b; Owen et al, 1990; Geiser et al, 1991; Van Obberghen-Schilling et al, 1988). 
Thus, in the context of cancer, the crosstalk between ERK, TGFβRs and SMADs has been shown to 
directly and indirectly promote cancer growth in the early stages of cancer resulting in metastasis (Corn 
et al, 2008; Fu et al, 2009; Giehl et al, 2007).  
Also here, kinase translocation reporters (KTRs) could help to shed light on the cross-talk between 
SMAD and ERK signaling. Unfortunately, microscopy experiments with an established KTR cell line 
resulted in only a weak ERK signal after TGFβ stimulation. An evaluation was not possible. Furthermore, 
in future experiments the impact of PPM1A on the ERK-mediated SMAD2 response could be validated 
with a CRISPR/ CAS9 PPM1A knock out cell line. In addition, PPM1A is one of the phosphatases 
responsible for the removal of phosphate residues from cyclin dependent protein kinases (Cheng et al, 
2000). Since CDKs are also involved in the linker phosphorylation of R-SMADs, one could examine the 
link in further experiments. Moreover, PPM1A dephosphorylates RanBP3 to enable efficient nuclear 
export of SMAD2 and SMAD3. PPM1A directly interacts with and dephosphorylates RanBP3 at Ser 58 
in vitro and in vivo. Dephosphorylation of RanBP3 at Ser 58 promoted its ability to export SMAD2/3 
and terminate TGFβ responses (Dai et al, 2011). In contrast RSKs (ribosomal S6 kinases) phosphorylate 
Serine 58 of RanBP3 (Yoon et al, 2008). Since activated ERKs phosphorylate and activate downstream 
RSKs, in further experiments one could investigate the link between SMAD dynamics, RanBP3, RSK and 
PPM1A.  
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In addition, at present, modeling efforts have been focused on the canonical TGFβ signaling cascade, 
but it is imperative to develop mathematical models that comprise also non-canonical pathways in 
order to accurately predict overall TGFβ signaling and cellular outcome. Interestingly, in an automated 
high-throughput interaction mapping, more than 100 proteins associated with the TGFβ receptor 
complex were identified (Barrios-Rodiles et al, 2005). Many of these proteins are either themselves 
signaling molecules or are signaling adaptors, which suggest a tremendous extent of cross-talk. In 
conclusion, further clarification of the mechanisms of the cross-talk between the TGFβ, MAPK 
pathways and other signaling pathways may offer novel breakthroughs and potential applications in 
the field of therapeutic approaches.
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5 CONCLUSION AND OUTLOOK 
In this study, I provided a quantitative understanding of how cells encode and decode information 
about the identity and quantity of a TGFβ stimulus. I followed pathway activation at the single-cell 
level by monitoring the translocation of SMADs from the cytoplasm to the nucleus with high temporal 
and spatial resolution. By analyzing the median nuc/cyto SMAD2 and SMAD4 ratio of the cell 
population with live-cell microscopy, one synchronous initial response of SMAD translocation at 1h, 
followed by adaptation and a second signaling phase with temporally less defined periods of nuclear 
translocation could be monitored. Adaptation mechanisms are a combinatorial effect of ligand 
degradation, proteasomal degradation, receptor endocytosis and feedback strength, which act at 
different time scales and doses. The future focus must be on how the various adaptation mechanisms 
change SMAD dynamics, and how this correlates precisely with cell fate. Analysis of the SMAD2 and 
SMAD4 reporter cell lines revealed, that the extent and duration of SMAD nuclear accumulation was 
highly variable and cells showed a broad variability of dynamics, although they were clonal cells. I 
showed that phenotypic responses and cell fate decisions were correlated with distinct dynamic 
behavior. One of the most challenging goals will be identifying the molecular mechanisms that are 
necessary to translate the different dynamical patterns into distinct phenotypic responses. 
Furthermore, the TGFβ/SMAD pathway does not function in isolation, but is one part of a signaling 
network in which cross-talk between pathways occurs. Indeed, the dynamic response of SMADs is 
influenced by cross-talk of non-canonical p38 and ERK MAPK signaling and especially the long-term 
dynamics define the nature of cellular responses to TGFβ ligands . The dynamic remodeling of SMADs 
through the impact of p38 and ERK signaling is mediated by phosphatases of the PP2C family member. 
Future research should focus on the link between p38 or ERK signaling and the phosphatases. 
Moreover, I gathered evidence that PPM1A is involved in the ERK-mediated TGFβ response. Thus, 
modifications of PPM1A must be investigated in further experiments. In general, future studies should 
include more cell lines to exclude cell type specific differences. In conclusion, further clarification of 
the mechanisms of the cross-talk between the TGFβ, MAPK pathways and other signaling pathways 
may offer novel breakthroughs and potential applications in the field of therapeutic approaches. 
Modeling simulations could help uncover these mechanisms.
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6 MATERIALS AND METHODS 
6.1 Cloning 
6.1.1 Genomic DNA isolation 
For the isolation and purification of genomic DNA from cultured MCF10A cells, the QIAamp Mini DNA 
Kit (Qiagen) was used. The isolation was performed according to the manufacturers protocol. The DNA 
was eluted with 200μl elution buffer (EB, Qiagen).  
6.1.2 Polymerase chain reaction 
The polymerase chain reaction (PCR) is a method to amplify DNA fragments using specific primers. Taq 
(NEB), Phusion High-Fidelity (NEB) or Q5 High-Fidelity DNA polymerase (NEB) were used with the 
following reaction setup and programs (Table 1 and 2): 
 
Phusion High-Fidelity DNA polymerase 
10 μl 5× GC-Buffer 
1 μl dNTP mix (10 mM) 
1.5 μl Forward primer (10 pmol/μl)  
1.5 μl Reverse primer (10 pmol/μl)  
10 µl Betaine 
0.5 μl Phusion DNA polymerase 
10-200 ng Template 
up to 50μl ddH2O 
 
Q5 High-Fidelity DNA polymerase:  
10 μl 5× Q5-Buffer 
1 μl dNTP mix (10 mM) 
1 μl Forward primer (10 pmol/μl)  
1 μl Reverse primer (10 pmol/μl)  
0.5 μl Q5 DNA polymerase 
10-200 ng Template 
up to 50μl ddH2O  
 
Taq DNA polymerase:  
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5 μl 10× Taq-Buffer 
1 μl dNTP mix (10 mM) 
1 μl Forward primer (10 pmol/μl)  
1 μl Reverse primer (10 pmol/μl)  
0.5 μl Taq DNA polymerase  
 10 ng Template 
up to 50 μl dd H2O 
 
Step  Temperature Time Cycles  
Initial denaturation 98 °C 1.50 min 1 
Denaturation 98 °C  10s 15 
Annealing 65 °C  30s 15 
Elongation 72 °C 1.05 min 15 
Denaturation 98 °C 10s 20 
Annealing 60 °C  30s 20 
Elongation  72 °C 1.05 min 20 
Final elongation  72 °C 7.00 min 1 
Table 1. Program used for Phusion or Q5 polymerase. 
Step  Temperature Time Cycles  
Initial denaturation 95 °C 5.00 min 1 
Denaturation 95 °C 10 s 35 
Annealing 60 °C 30 s 35 
Elongation  72 °C 1.05 min 35 
Final Elongation 72 °C  7.00 min 1 
Table 2. Program used for Taq polymerase. 
6.1.3 DNA analysis and purification by agarose electrophoresis 
For separation and purification of DNA fragments, 1% - 2% agarose gel with ethidium bromide (EtBr, 
1:20000, ROTH) were prepared. For a 1% (w/v) agarose gel, 1 g of agarose was dissolved in 100 ml 1× 
TAE buffer by heating in a microwave, until the solution appeared totally clear. EtBr was added after 
the solution had cooled down to approximately 40°C. Gel was loaded with either 3 μl (for DNA 
verification) or total sample volume (for later DNA extraction) mixed with respective volume of 6× DNA 
loading dye, along with 5μl 2-log DNA ladder mix (NEB). Running time was dependent on gel size and 
preferred degree of separation, as well as used voltage (approximately 40 - 70 min/80-100 V). For 
purification after detection, DNA bands were cut out of the gel and Gel Extraction kit (Qiagen) was 
used according to manufacturers manual. DNA was eluted in 30 μl elution buffer (EB, Qiagen) and 
concentration was measured with Nanodrop 2000c Spectrophotometer (Thermo Fisher Scientific).  
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-1xTAE buffer: 
40 mM Tris, 20 mM Acetic Acid, 1 mM EDTA  
-2Log DNA Ladder mix: 
1/6 2Log DNA Ladder (NEB), 1/6 TriTrack DNA loading dye, 4/6 H2O  
6.1.4 Electroporation and chemical transformation of Escherichia coli  
Cloning of plasmid constructs was carried out either in chemical (DH5α E.coli, NEB) or electro 
competent cells (Top10 E.coli, Thermo Fisher Scientific). Shortly before transformation cells were 
thawed on ice and either 15 μl of chemical competent or 50 μl of electro competent cells were gently 
mixed with 1 μl plasmid solution. Electro competent cells were then transferred to an electro-shock 
cuvette (ROTH) and electroporation (Eppendorf) was carried out. LB or SOC medium (1 ml) was used 
for resuspending the cells and transferring them to a new tube for incubation at 37°C/250 rpm for 1 
hour. To grow single colonies, 30 μl of the cells were spread on LB-Kanamycin plates (50 μg/ml, 
AppliChem) or LB-Ampicillin plates (100 μg/ml, AppliChem) and placed in an incubator at 37°C over 
night. The mix of chemical competent cells and plasmid was incubated on ice for 30 minutes, before 
heat-shock was applied. Thus the cells were incubated at 42°C for 45 seconds and quickly placed on 
ice for 2 minutes. 200 μl prewarmed LB or SOC media was added and cells were incubated 1 hour at 
37°C and 250 rpm. Finally 70 μl of the cell suspension was spread on LB-Kanamycin plates or LB-
Ampicillin plates and incubated over night at 37°C. The next day single colonies were picked, 
transferred to 4 ml LB-medium containing either Kanamycin or Ampicillin and incubated at 
37°C/200rpm overnight. Cells from overnight cultures were then pelleted in new 2 ml tubes by 
centrifuging 5 minutes at 6000 rpm and discarding the supernatant. Pellets were resuspended in 250 
μl buffer P1, mixed (by inverting) with 250 μl Buffer P2 and incubated for 5 minutes. Addition of 250 
μl buffer P3 was followed by vortexing the solution and incubation for 10 minutes on ice. To separate 
cell debris from DNA, centrifugation was carried out for 20 minutes at 13000 rpm/4°C and supernatant 
was mixed with 80% sample volume of isopropyl alcohol. After incubation of 5 minutes, a second 
centrifugation step of 20 minutes was performed to pellet plasmid DNA. Supernatant was discarded 
and the pellet washed with 500 μl 70% ethanol, by centrifuging 10 minutes. Again, the supernatant 
was discarded and the pellet was dried at 37°C for 10-20 minutes, before resuspending the DNA pellet 
in 40 μl EB buffer (Qiagen).  
 
-Buffer P1: 
50mM Tris-HCL pH 8.0, 10mM EDTA, 100ug/ml RNaseA (AppliChem) 
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-Buffer P2: 
200mM NaOH, 1% SDS (ROTH) 
 
-Buffer P3: 
3M potassium acetate pH 5.5  
 
-LB broth with agar: 
15 g/l Agar, 10 g/l Tryptone, 5 g/l Yeast Extract, 5 g/l NaCl  
 
-LB broth: 
10 g/l Tryptone, 5 g/l Yeast extract, 5 g/l NaCl  
 
-SOC medium: 
2% Vegetable Peptone, 0.5% Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 
20 mM Glucose  
6.1.5 Plasmid DNA isolation 
For the isolation and purification of plasmid DNA from overnight cultures, the QIAprep Spin Miniprep 
Kit (Qiagen) was used. The isolation was performed according to the manufacturers protocol. The DNA 
was eluted with 30μl EB buffer (Qiagen).  
6.1.6 Determination of DNA and RNA concentration 
DNA and RNA concentrations were measured at a spectrophotometer (NanoDrop 2000c, Thermo 
Fisher Scientific). The samples with the DNA or RNA were exposed to ultraviolet light with a spectral 
range of 190-840nm. To verify the purity of the DNA and RNA samples, the ratio of absorbances at 260 
nm and 280 nm was calculated. A260/A280 ratios above 1.8 for DNA and 2.0 for RNA indicate pure 
samples. Due to protein contamination, the ratio decreases.  
6.1.7 Digestion of DNA samples  
To verify the insertion of the desired DNA fragments in plasmids or to prepare the DNA for other 
cloning processes, a restriction digest was performed. By using appropriate restriction enzymes and 
associated buffers (NEB) DNA molecules were cleaved at selected sites. The reaction mixture was set 
up as follows: 10 μl DNA (200-1000 ng), 2 μl 10× CutSmart Buffer, 0.5 μl Enzyme I (10 U/μl), 0.5 μl 
Enzyme II (10 U/μl) and filled up to 20 μl with nuclease-free water. The reactions were incubated at 
37 °C for 1 hour.  
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6.1.8 Sequencing 
Plasmids were diluted to 100ng/μl in 15 μl and sequenced at LGC genomics. 
6.2 MCF10A WT and SMAD2/SMAD4 reporter cell lines  
Human breast epithelial MCF10A cells were cultured in DMEM/F-12 medium (Thermo Fisher Scientific) 
supplemented with 5% horse serum (PAN-Biotech), 20 ng/ml epidermal growth factor (EGF, 
PeproTech), 0.5 μg/ml hydrocortisone (Sigma-Aldrich), 100 ng/ml cholera toxin (Sigma-Aldrich) and 10 
μg/ml insulin (Sigma-Aldrich), penicillin and streptomycin (Thermo Fisher Scientific) at 37 °C and 5% 
CO2 (Debnath et al, 2003). When required, the medium was supplemented with selective antibiotics 
to maintain transgene expression (400 μg/ml geneticin disulphate (G418, ROTH), 50μg/ml hygromycin 
B (Thermo Fisher Scientific), 5 μg/ml blasticidin S hydrochloride (ROTH) or 0.5 μg/ml puromycin 
dihydrochloride (ROTH). We generated lentiviral reporter constructs for SMAD2 and SMAD4 using the 
MultiSite-Gateway recombination system (Invitrogen) by fusing the protein coding sequence to the 
yellow fluorescent protein Venus (YFP) under the control of a constitutive human Ubiquitin C promoter 
(UbCp). We infected MCF10A cells with corresponding lentiviral particles together with viruses 
expressing histone 2B fused to cyan fluorescent protein (H2B-CFP) under the control of UbCp as a 
nuclear marker. Furthermore, I generated a combined fluorescent reporter cell line (E9) by fusing 
SMAD4 to YFP and SMAD2 to the red fluorescent protein mCherry under the control of UbCp.  As an 
inverse variant I generated a combined cell line (A3) by fusing SMAD2 to YFP and SMAD4 to mCherry. 
In addition, both cell lines also stably express the nuclear marker histone H2B-CFP to enable automated 
image analysis. Subsequently, stable clonal cell lines were established and validated.  
6.3 SMAD7 transient knock down cell line 
A clonal cell line (F10) with inducible shRNA expression for SMAD7 gene silencing in the background of 
the SMAD2-YFP reporter cell line (6.2) was generated (transient SMAD7 knock down cell line). Therefor 
the SMAD2-YFP cell line was infected with pTRIPZ lentiviral inducible vectors which are engineered to 
be TET-ON and produce induction of shRNA expression in the presence of doxycycline (2µg/ml) 
(Thermo Scientific Open Biosystems Expression Arrest TRIPZ Lentiviral shRNAmir). Four different TRIPZ 
inducible lentiviral shRNA (RHS201904993, 201904238, 201903626 and 201902033) for regulatable 
SMAD7 gene silencing were applied together. Since the vector contain a puromycin drug resistance 
marker, 0.5 μg/ml puromycin dihydrochloride (ROTH) was used to select stable cell lines. 
Subsequently, stable clonal cell lines were established and validated. For time-lapse microscopy 
experiments 0,5 x 105 cells (F10) were plated in 35mm poly-D-lysine-coated glass bottom plates 
6.4 SMAD7 knock out in MCF10A using CRISPR/Cas9 
169 
 
(MatTek Corporation) two days before experiments, whereby doxycycline (2µg/ml) was added to the 
medium and the horse serum (PAN-Biotech) was replaced by BSA (Sigma-Aldrich) for all conditions. 
6.4 SMAD7 knock out in MCF10A using CRISPR/Cas9 
A SMAD7 knock out cell line in MCF10A was created utilizing the CRISPR/Cas9 system. The knock out 
of SMAD7 affects both alleles of the gene to ensure a complete loss of the corresponding protein. To 
this end, we first infected SMAD2-YFP reporter cells (6.2) with lentiviruses expressing Cas9 under 
control of a doxycycline-inducible promoter (Wang et al, 2014). A clonal SMAD2-YFP Cas9 reporter cell 
line was generated and acted as a new control cell line. This clonal cell line was further infected with 
viruses expressing a single guide RNA (sgRNA) targeting exon 2 of SMAD7 (TCCTTACTCCAGATACCCGA) 
(Shalem et al, 2014) and cultured for 11 days in the presence of doxycycline (1µg/ml, Sigma-Aldrich) 
to create a polyclonal SMAD7 knock down cell line. By annealing two oligos and utilizing Gibson 
Assembly the final sgRNA was cloned by Caibin Cheng. The sgRNA is a noncoding RNA which directs 
the Cas9 endonuclease to the desired genomic locus and exon 2 of the endogenous SMAD7 gene was 
targeted and cleaved. Multiple rounds of target sequence cleavage induced DNA double-stranded 
breaks (DSBs) which are mainly repaired by nonhomologous end joining (NHEJ). Because NHEJ is an 
error prone mechanism, it facilitates the occurrence of nucleotide deletions or insertions (indels) at 
the site of cleavage, which can lead to frameshift mutations or premature stop codons (Ran et al, 
2013). Next step was to determine from the resulting polyclonal cell line the mutation status of the 
genomic loci by using T7 endonuclease assay.  
T7 endonuclease recognizes and cleaves non-perfectly matched DNA that results from annealing DNA 
strands that have been modified after a sgRNA/Cas9 mediated cut to DNA strands without 
modifications. This assay was used to get a first estimate of whether our targeting was effective or not. 
The assay consisted of three steps: 1. Isolation of genomic DNA (6.1.1) and amplification of SMAD7 
gen region by PCR (6.1.2) 2. Denaturation and annealing of DNA fragments 3. Digestion with T7 
Endonuclease and gel-analysis (6.1.3). 200 ng of genomic DNA of MCF10A clones were obtained 
according to section 6.1.1 and PCR was performed with SMAD7EXON2_fwd 5´TCC CGA GTG CGC TAG 
GAA TG 3´ and SMAD7EXON2_rev 5´CCC CAA GCC TTT GCC TAC AC 3´ primer and Phusion DNA 
polymerase (NEB) (6.1.2) and the desired Exon 2 locus was amplified. The PCR product was run on a 
1% gel, DNA was extracted and purified according to section 6.1.3. In preparation for the T7 
Endonuclease digest, 175 ng extracted DNA of SMAD7 clones was mixed with equal amounts of 
SMAD2-YFP Cas9 reporter cell line, 2 µl of NEB buffer 2 and Elution buffer (Qiagen) up to 19 µl were 
added. Using a touchdown PCR program (starting at 95°C and gradually decreasing down to 25°C) DNA 
was denatured and annealed. 1 µl T7 Endonuclease (NEB) was added directly to the DNA mix and 
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incubated at 37°C for 1 hour. Whole sample volume was then applied on a 2% gel and extend of 
cleavage was analyzed (6.1.3). The results of the PCR products of the SMAD7 locus around exon2 
according to the T7 endonuclease assay are shown in Figure 51. While the SMAD2-YFP Cas9 reporter 
cell line reveals just one band, three bands are identified for the polyclonal SMAD7 knock out SMAD2-
YFP Cas9/sgRNA cell line after cleavage of the DNA due to mutations in the SMAD7 gene. Since a large 
portion of the original PCR product band 1 is no longer present, it indicates a high level of mutated 
genomic DNA. 
 
6.4 Figure 51. T7 endonuclease assay. 
Results of T7 endonuclease assay analyzed on an agarose gel. While the SMAD2-YFP reporter cell line reveals one band, 
three bands are identified for the polyclonal SMAD7 knock out SMAD2-YFP Cas9/sgRNA cell line after cleavage of the DNA 
due to mutations in the SMAD7 gene. 
Finally, I established and screened clonal cell lines for alterations of the SMAD7 locus by sequencing 
and I selected a cell line with non-sense mutations in both alleles. Genomic DNA of MCF10A clones 
were obtained and (6.1.1) PCR was performed by using the primer SMAD7 EXON2 fwd and rev (6.1.2). 
The product was used for TA- Cloning with the pGEM-T Vector (Stratagene). For A-tailing 5µl of PCR 
product was then mixed with 1 µl 10x Taq-buffer, 0.2 µl dNTP and 1 µl Taq polymerase and incubated 
for 20 minutes at 70°C. Subsequently, 5µl of 2x rapid ligation buffer, 1µl pGEM-T vector (50ng), 2µl of 
A-tailing product, 1µl of T4 DNA ligase and 1 µl H2O were mixed and incubated for 1h at room 
temperature. 1µl of the reaction was transformed in chemical competent E. coli cells (DH5α, NEB) 
(6.4). 70 µl of the transformed bacteria were plated on X-Gal (ROTH) and IPTG (Isopropyl β-D-1-
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thiogalactopyranoside, ROTH) added LB- ampicillin (AppliChem) plates. If β-galactosidase is produced, 
X-gal is hydrolyzed to form 5-bromo-4-chloro-indoxyl, which spontaneously dimerizes to produce an 
insoluble blue pigment called 5,5’-dibromo-4,4’-dichloro-indigo. The colonies formed by non-
recombinant cells, therefore appear blue in color while the recombinant ones appear white. The white 
colonies were picked and cultured. Isopropyl β-D-1-thiogalactopyranoside (IPTG) is used along with X-
gal for blue-white screening. IPTG is a non-metabolizable analog of galactose that induces the 
expression of lacZ gene of the pGEM-T vector. A test digest with ScaI or BsaI (NEB, positive fragment 
3600bp, negative 3000bp) was performed (6.1.7) and then sent for sequencing (6.1.8). 
6.5 TGFβ and inhibitor and treatments 
Suspended cells were stained with trypan blue (Sigma-Aldrich) and then counted in an automated 
TC10TM cell counter (Bio-Rad) and depending on the experiment seeded 48h prior to TGFβ treatment. 
Recombinant human TGFβ 1 was obtained from R&D Systems (#240-B-002) and stored at -80°C in 4mM 
HCl, 1mg/ml bovine serum albumin (Sigma-Aldrich) at 390nM. In Western blot, RT-qPCR and 
immunofluorescence experiments media were replaced with fresh ones containing DMSO (control 
condition, Sigma-Aldrich) or the inhibitors shown in Table 3, 45 minutes before TGFβ treatment 
(usually 100pM TGFβ). For microscopy experiments media were replaced with fresh ones (6.2) and the 
inhibitors or DMSO (Sigma-Aldrich) were added after one unstimulated round of images 45 minutes 
before TGFβ treatment (usually 100pM TGFβ). TGFβ 1 was prepared in 500µl media and added after 
one unstimulated round of images or in addition to inhibitors to achieve the final concentration in 
2.5ml media. Re-stimulations were carried out by aspirating old medium and changing to new medium 
with desired TGFβ concentration, while leaving the plates in the incubator.  
Inhibitor Final concentration Supplier 
AZD6244 1µM Axon Medchem 
BIRB796 5µM Axon Medchem 
Dorsomorphin 2µM Selleckchem 
DRB (5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside) 100µM Cayman  
Dynamin Inhibitor, Dynasore 50µM Santa Cruz 
Gefitinib 3µM Cayman 
JNK Inhibitor VIII  0.5-20µM Cayman 
LDN 193189 100nM Selleckchem 
MG132 10µM Calbiochem 
Noggin 10ng/ml Biomol 
Nystatin 50µg/ml Sigma-Aldrich 
Okadaic acid 25nM Sigma-Aldrich 
RO3306 3µM Axon Medchem 
SB202190 10µM Axon Medchem 
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Sanguinarine chloride 1µM TOCRIS 
Sorafenib 10µM LC Laboratories 
TGF-β RI Kinase inhibitor VI SB431542 10µM Calbiochem 
UO126  10µM NEB 
5Z-7-Oxozeaenol 2µM Sigma-Aldrich 
Table 3. Inhibitors used in experiments. 
6.6 Time-lapse microscopy 
For live-cell time-lapse microscopy, 2x105 reporter cells were plated in 35mm poly-D-lysine-coated 
glass bottom plates (MatTek Corporation) two days before experiments. Before starting the 
experiment, cells were washed twice with 1xPBS and media was changed to RPMI 1640 lacking phenol 
red and riboflavin (PAN-Biotech) supplemented with all growth factors (6.2), 5% horse serum (PAN-
Biotech) and antibiotics. In addition the media contained HEPES buffer (10 mM) and GlutaMAX (2 mM) 
(both from Thermo Fisher Scientific). Six glass bottom plates fit in the tray of the movable microscope 
stage, which made it possible to observe six conditions during one time-lapse experiment. Per plate 
ten positions were selected using transmitted light to prevent bleaching or stressing the cells. Lids of 
the plates were replaced by glass discs to prevent evaporation, while making it easy to access the 
plates for further additions. The microscope was surrounded by a custom enclosure to maintain 
constant temperature (37°C), CO2 concentration (5%), and humidity. Cells were imaged on a Nikon Ti 
inverted fluorescence microscope with a Hamamatsu Orca R2 or Nikon DS-Qi2 camera and a 20x plan 
apo objective (NA 0.75) using appropriate filter sets (Venus: 500/20 nm excitation (EX), 515 nm dichroic 
beam splitter (BS), 535/30 nm emission (EM); CFP: 436/20 nm EM, 455 nm BS, 480/40 nm EX). Images 
were acquired every 5 minutes for the duration of the experiment (usually 24 hours) using Nikon 
Elements software. To calibrate raw images, eliminate background noise from the camera and 
normalize differences of fluorescence illumination, flat field images were acquired after each 
experiment. To this end, 2.5 ml DMEM/F-12 medium were imaged with increasing exposure times, 
starting with 0 ms, until the signal saturated. From these images the offset and gain for every pixel was 
calculated. This information was then used to correct images, which were taken during time lapse 
experiments. 
6.7 Cell tracking and image analysis  
Cells were tracked throughout the duration of the experiment using custom-written Matlab 
(MathWorks) scripts based on code developed by the Alon lab (Cohen et al, 2008) and the CellProfiler 
project (Carpenter et al, 2006). In brief, we applied flat field correction and background subtraction to 
raw images before segmenting individual nuclei from nuclear marker images using adaptive 
thresholding and seeded watershed algorithms. Segmented cells were then assigned to corresponding 
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cells in following images using a greedy match algorithm. Only cells tracked from the first to last time 
point were considered. Upon division, we followed the daughter cell closest to the last position of the 
mother and merged tracks from mothers and offspring. We quantified nuclear fluorescence intensity 
and measured the fluorescence intensity in the cytoplasm using a 4-pixel wide annulus around the 
nucleus. The results of the automated image analysis were further processed and normalized. If all 
cells of a certain time point show spikes simultaneously, it indicates that the flickering of the 
fluorescent lamp is the reason. Therefore, all spikes were removed by interpolation. Another factor, 
which can influence the analysis is cell division. To identify cell divisions, we normalized for each cell 
the nuclear area and the integrated fluorescence intensity of the nuclear marker to their respective 
means, smoothed them and combined the two trajectories by averaging. In the next step, the median 
fluorescence for nuclear and cytoplasmic measurements were calculated, which are more robust 
against fluctuations than the mean intensity. Finally we estimated the nuc/cyt ratio for each cell over 
time and analyzed the resulting single-cell trajectories computationally (Strasen et al, 2018). 
 
6.7 Figure 52. Image analysis example.  
Cells were segmented according to the nuclear marker and cytoplasm was segmented using a 4-pixel wide annulus around 
the nucleus. The cells were assigned to corresponding cells at following time points. The nucleus of tracked cells is colored 
in red (Images by Lennart Schnirch, 2015). 
6.8 Clustering approach  
To compare single cell trajectories a measure for similarity/dissimilarity must be established. 
Therefore, Marcel Jentsch used Dynamic Time Warping (DTW), a standard method to address the 
temporal alignment (Sakoe & Chiba, 1978; Berndt & Clifford, 1994; Keogh & Pazzani, 2000, Strasen et 
al, 2018). DTW results in a non-linear mapping of one trajectory to another by warping the time axis 
iteratively until an optimal match between the two trajectories with respect to the used metric is 
found. DTW takes into account that distinct patterns within trajectories may differ in frequency and 
length and affect the shape of an individual time courses.  He then used DTW to generate a dissimilarity 
matrix  by computing pairwise dissimilarities between single cells. Based on the pairwise dissimilarity 
matrix estimated by DTW he applied clustering to group cells with similar dynamic patterns. In 
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addition, he used the silhouette method (Rousseeuw, 1987) for visualizing clustering quality. The 
silhouette method quantifies how similar an object is to objects within its own cluster compared to 
objects from other clusters and gives a useful graphical representation to assess allocation quality. The 
silhouette coefficient can range from -1 to 1. The higher the silhouette coefficient for all objects the 
better the clusters are separated. The assignment of single cell trajectories to signaling classes provides 
a different separation than grouping cells according to ligand dose.  
6.9 Western blot analysis 
For western blot experiments 5 x 105 MCF10A WT cells were seeded on 5 cm tissue culture plates in 5 
ml medium two days before experiments. After stimulation, cells were harvested at the indicated time 
points after treatment. We kept the cells on ice for the whole process, while the medium was aspirated 
and cells were washed once with 4 ml cold phosphate-buffered saline (PBS), before adding a final 
volume of 2 ml PBS. Using a cell scraper cells were detached from the tissue culture plate and 
centrifuged during 5 minutes at 6000 rpm at 4°C. Subsequently the supernatant was aspirated. 
Samples were then shock frozen in liquid nitrogen and stored at -80°C. Cell pellets were resuspended 
in 40-50μl of lysis buffer in the presence of protease and phosphatase inhibitors by vortexing 10 
seconds and incubated 20 minutes on ice and centrifuged at 4°C during 20 minutes at 14000 rpm. The 
supernatant was transferred to a new tube. From here on samples could be stored at -20°C. Total 
protein concentrations were measured by BCA assay (Thermo Fisher Scientific). The concentration was 
determined in technical duplicates using a bovine serum albumin (BSA) standard curve (2, 1, 0.5, 0.25, 
0.125, 0.0625 and 0 mg/ml). 25 μl of each standard or 2.5 μl of each sample (diluted to 25 μl in H2O) 
and 200 μl of Working Reagent (50:1, Reagent A:B) were transferred to a 96-well plate, followed by 
incubation of 25 minutes at 37°C and 5 minutes at room temperature (RT). The absorbance was 
measured at 595 nm in a microplate reader (EL800 Universal Microplate Reader) and concentration 
calculated by Bio-Tek Instruments software. Equal protein amounts (15-20 μg depending on protein 
concentration) obtained from MCF10A WT whole cell lysate were denatured in sample buffer (NuPAGE 
LDS Sample Buffer (4X), Thermo Fisher Scientific) and dithiothreitol (DTT) by heating for 10 minutes at 
70°C. Proteins were separated by electrophoreses for 35 minutes at 200 V on 4–12% NuPAGE Bis-Tris 
gradient Mini Gels (Thermo Fisher Scientific) in SDS Running Buffer (NuPAGE, Thermo Fisher Scientific) 
in a Novex Mini-Cell chamber (Thermo Fisher Scientific) with 5 μl Precision Plus Protein Dual Color 
marker (Bio-Rad). Subsequently proteins were transferred to nitrocellulose membranes (Roti NC, 0.2 
m, ROTH) by electroblotting (Trans-Blot Turbo Transfer System, Bio-Rad). A blotting sandwich was 
assembled from the anode to cathode as follows: three layers of 3 mm Whatman paper, nitrocellulose 
membrane, SDS gel, three layers of 3 mm Whatman paper. The papers as well as the gel and membrane 
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were pre-incubated in 1x Transfer Buffer. Semi-dry blotting was carried out for 30 minutes at 25 V. We 
blocked membranes for one hour with 5% non-fat dried milk or 5% bovine serum albumin (ROTH) in 
tris-buffered saline with Tween20 (TBST) according to the antibodies manufacturer's 
recommendations, incubated them overnight with primary antibody (Table 4) at 4°C and shaking with 
12 rpm, washed them in TBST, incubated them for one hour at RT with secondary antibody coupled to 
horseradish peroxidase (HRP, Table 5) in 5% non-fat dried milk in TBST, washed again and detected 
protein levels using Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare Life 
Sciences) according to manufactures manual. Chemiluminescent images were captured with 
ChemiDoc XRS System and Image Lab Software was used for the analysis (Bio-Rad).  
 
Buffers used (all reagents from ROTH, unless otherwise stated):  
- PBS 
10 mM sodium hydrogen phosphate + 2 mM monopotassium phosphate + 137 mM sodium chloride 
+ 2.7 mM potassium chloride, pH 7.4  
- Lysis buffer 
50 mM Tris pH 7.5 + 100 mM sodium chloride + 1% Triton X-100 + 0.5% sodium deoxycholate + 0.1% 
SDS + 50 mM sodium fluoride + 1 mM sodium orthovanadate + 1:100 Protease Inhibitor Cocktail Plus 
+ 1:100 Phosphatase Inhibitor Cocktail (Sigma-Aldrich)  
- Transfer buffer 
25 mM Tris + 192 mM glycine + 20% methanol  
- TBST 
50 mM Tris pH 7.5 + 150 mM sodium chloride + 0.1% Tween-20  
 
Primary antibody Dilution Supplier 
SMAD2 (D43B4) XP® Rabbit mAb #5339S 1:1000 Cell Signaling 
Phospho-SMAD2 (Ser465/467) (138D4) Rabbit mAb #3108 1:1000 Cell Signaling 
SMAD4 (B-8) #sc-7966 1:500 Santa Cruz 
GAPDH #G9545 1:10000 Sigma-Aldrich 
TGFβ Receptor I Antibody (H-100) #sc9048 1:500 Santa Cruz 
PP2C-alpha (PPM1A, D18C10) XP® Rabbit mAb #3549P 1:1000 Cell Signaling 
SMAD3 (C67H9) Rabbit mAB #9523 1:1000 Cell Signaling 
Phospho-SMAD3 (Ser423/425) (C25A9) Rabbit mAB #9520 1:1000 Cell Signaling 
SMURF2 (H50) #sc-25511 1:200 Santa Cruz 
Phospho-HSP27 (Ser82) (D1H2) XP rabbit mAB #9709 1:1000 Cell Signaling 
anti-p21WAF1 (Ab-1) Mouse mAb (EA10) 1:500 Merck Millipore 
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) Antibody #9101 1:1000 Cell Signaling 
Table 4. Primary antibodies for western blot analysis. 
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Secondary antibody Dilution Supplier 
Goat anti-Rabbit IgG Secondary Antibody, HRP conjugate  1:10000 Thermo Fisher Scientific  
Goat anti-Mouse IgG Secondary Antibody, HRP conjugate  1:10000 Thermo Fisher Scientific  
Table 5. Secondary antibodies for western blot analysis. 
6.10 RT-qPCR 
For Real-Time qPCR (RT-qPCR) experiments 5 x 105 MCF10A WT cells were seeded on 5 cm tissue 
culture plates in 5 ml medium two days before experiments. After stimulation, cells were harvested at 
the indicated time points after treatment. Total RNA was extracted using High Pure RNA Isolation kit 
(Roche) according to manufactures manual and concentration was determined by using a 
photospectrometer (6.1.6, NanoDrop 2000c, Thermo Fisher Scientific) and stored at -80°C. Afterwards, 
complementary DNA (cDNA) was synthesized via reverse transcription. The following components 
were mixed and heated for 5 minutes at 70°C in a thermocycler (PEQLAB, VWR):  
 
-1 μg of total RNA   
-2 μl of Oligo d(T)23 VN (50 μM) (New England Biolabs) 
-1 μl of dNTP solution mix (10 mM) (New England Biolabs)  
-Up to 10 μl of DEPC-treated H2O (ROTH) 
 
Next, the following reagents (all from New England Biolabs) were added, and the resulting mix was 
incubated at 42°C for one hour:  
 
-4 μl of 5X ProtoScript II Buffer 
-2 μl of DTT (0.1 M) 
-1 μl of ProtoScript II Reverse Transcriptase  
-1 μl of RNase Inhibitor, Murine  
The resulting cDNA was stored at -20 °C or diluted 1:10 and quantitative PCR was performed. 3 μl of 
cDNA were mixed with 9.5 μl of primer mix and 12.5 μl of SYBR Green reagent (Roche).  
Primer mix: 
6.4 μl forward primer (100 μM) + 6.4 μl reverse primer (100 μM) + 987.2 μl DEPC-treated H2O 
The final concentration of each primer in the reaction mix was 243.2nM.  
Quantitative PCR was performed in triplicates on a StepOnePlus PCR machine (Applied Biosystems) 
with the following thermal profile: 
1) 95°C for 10 minutes 
2) 40 cycles: 95 °C for 15 seconds, 60 °C for one minute  
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To determine the level of expression for each gene of interest the comparative CT (∆∆CT) method was 
used. First, the difference between the CT value of a housekeeping gene (β‐actin) and the CT value of 
the gene of interest was calculated resulting in the ∆CT value. Then, the difference in the ΔCT values 
between the experimental and control samples is calculated resulting in the ∆∆CT value.  
 
β-Actin forward:  GGC ACC CAG CAC AAT GAA GAT CAA 
β-Actin reverse:  TAG AAG CAT TTG CGG TGG ACG ATG 
SnoN forward:   GGC TGA ATA TGC AGG ACA G  
SnoN reverse:   TGA GTT CAT CTT GGA GTT CTT G 
SMAD7 forward:  ACC CGA TGG ATT TTC TCA AAC C  
SMAD7 reverse:  GCC AGA TAA TTC GTT CCC CCT  
PAI1 forward:   GGC TGA CTT CAC GAG TCT TTC A  
PAI1 reverse:   ATG CGG GCT GAG ACT ATG ACA 
Snail forward:   GCT CGA AAG GCC TTC AAC TGC AAA 
Snail reverse:  AGG CAG AGG ACA CAG AAC CAG AAA 
PPM1A forward: TAC GGC TGT GAT CGG TTT GC 
PPM1A reverse: ATA CAG CCA GAG AGC CAT TCA C 
TIEG forward:   GCC AAC CAT GCT CAA CTT CG 
TIEG reverse:   TGC AGT TTT GTT CCA GGA ATA CAT 
SMAD2 forward:  GGA GCA GAA TAC CGA AGG CA 
SMAD2 reverse:  CTT GAG CAA CGC ACT GAA GG 
SMAD4 forward:  GAC TGA GGT CTT TTA CCG TTG G 
SMAD4 reverse:  CTT CAA GCT CTG AGC CAT GC 
p21 forward:   TGG ACC TGT CAC TGT CTT GT 
p21 reverse:   TCC TGT GGG CGG ATT AG 
SARA forward:   TGG TTT GCT GAT GGG ATC TT 
SARA reverse:   TTC CAA CAG GAC TTC CAA CC 
SMAD6 forward:  CAA GCC ACT GGA TCT GTC CGA 
SMAD6 reverse:  TTG CTG AGC AGG ATG CCG AAG 
Table 6. Primers used in RT-qPCR.  
Oligonucleotide primers used in SYBR green RT-qPCR for several human genes. β-actin was used as reference gene. All primers 
were from Eurofins Genomics. 
6.11 TGFβ measurement 
We used in collaboration with Prof. Dr. Petra Knaus and Dr. Daniel Horbelt (Institute for Chemistry and 
Biochemistry, Freie Universität Berlin) Mink lung epithelial cells (MLECs) stably transfected with a 
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reporter containing a truncated PAI-1 promoter (3TP promoter with three consecutive TPA response 
elements) fused to the firefly luciferase gene (Abe et al, 1994).  MLECs were plated at 10000 cells/well 
in 96 well plates. MCF10A SMAD2 reporter cells were seeded two days before stimulation with 25 pM 
or 100 pM and supernatants from live-cell microscopy experiments (6.6) were collected 1, 2, 3, 4, 5, 6, 
7, 8, 9, 10, 13, 14, 16, 18 and 24 h post stimulation. Samples were frozen at -80°C and transported on 
dry ice. 50 µl were added in triplicates to MLEC reporter cells together with 50 µl DMEM/0% FCS per 
well. To create a standard curve, triplicate measurements were performed for different TGFβ 
concentrations (0, 5, 10, 20 40, 60, 80, 100 and 200 pM) in RPMI 1640 lacking phenol red and riboflavin 
(PAN-Biotech) supplemented with all growth factors (6.2), 5% horse serum (PAN-Biotech), HEPES, 
Glutamax (both from Thermo Fisher Scientific) and antibiotics (6.6). After incubation overnight, cells 
were lysed and thawed. Luciferase activity was measured by 10-second well readings on a Berthold 
Mithras LB940 plate luminometer using the Promega dual luciferase reporter gene assay kit by Dr. 
Daniel Horbelt. Marcel Jentsch did further final analysis by using the Hill equation to also reflect 
nonlinear parts of the calibration curve. The fit to the standard curve was used to convert measured 
relative luciferase activities into absolute TGFβ concentrations. The estimated TGFβ concentrations at 
different time points post stimulation were assembled into time courses and fitted using an 
exponential decay model to estimate the TGFβ decay and half-life for the different initial 
concentrations (Strasen et al, 2018). 
6.12 Single molecule RNA fluorescence in situ hybridization (smFISH) 
For smFISH experiments 2 x 105 reporter cells were seeded in 35mm glass bottom plates with a 500 
µM relocation grid (Grid-500 glass bottom dish, Ibidi) with 2,5 ml medium one day before live-cell time-
lapse microscopy experiments were performed (6.6). For basal smFISH measurements cells were fixed 
with 2% paraformaldehyde for 10 min at room temperature before TGFβ stimulation and the time-
lapse microscopy experiments started. Otherwise cells were fixed at appropriated time points, washed 
and permeabilized over night with 70% Ethanol at 4°C. Custom probe sets for single molecule FISH (Raj 
& Tyagi, 2010) labeled with CalFluor-610 were designed using Stellaris RNA FISH probe designer 
(Biosearch Technologies) on the reference sequences NM_005904.3 (SMAD7) and NM_000602.4 
(PAI1). Hybridization was performed at a final concentration of 0.1 μM probe following manufacturers 
instructions (Stellaris RNA FISH Protocols - Adherent cells). Coverslips were mounted using Prolong 
Gold Antifade (Thermo Fisher Scientific). For single molecule RNA quantification, 17 z-stacks of each 
cell were acquired with 300 nm step size. With Image J the maximum projection was calculated and 
quantification of RNA counts per cell was performed using the Star Search analysis tool for spot 
detection (http://rajlab.seas.upenn.edu/StarSearch/launch.html). Tracked cells from the microscopy 
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experiments were manually matched to cells analyzed in StarSearch.  The coefficient of variation (CV) 
is defined as the ratio of the standard deviation to the mean and was calculated.  
6.13 Immunofluorescence 
For immunofluorescence experiments 2,5 x 105 MCF10A WT cells were seeded on coverslips coated 
with poly-L-lysine (Sigma-Aldrich) in 6-well plates two days before experiments. Cells were fixed at 
indicated time points with 2% paraformaldehyde in PBS for 10 minutes after washing with PBS. Cells 
were washed again in PBS and permeabilized with 0.1% Triton X-100 in PBS for 20 minutes, blocked 
with 10% goat serum (PAN-Biotech) in PBS for 30 minutes, incubated with primary antibody in 1% BSA 
in PBS overnight at 4°C (Table 7), washed with 0.1% Triton X-100 in PBS, and incubated with secondary 
antibody conjugated with Alexa Fluor 488 or Alexa Fluor 647 (Thermo Fisher Scientific, Table 8) in 1% 
BSA in PBS for 30 minutes. After washing with 0.1% Triton X-100, cells were stained with 2µg/ml 
Hoechst 33342 (Thermo Fisher Scientific) in 0.1% Triton X-100/PBS for 5 minutes and embedded in 
Prolong Antifade (Thermo Fisher Scientific). Images were acquired with a 20x plan apo objective (NA 
0.75) using appropriate filter sets. Automated segmentation was performed in Matlab (MathWorks) 
with algorithms from CellProfiler (Carpenter et al, 2006). 
Primary antibody Dilution Supplier 
SMAD4 (B-8) #sc-7966 1:50 Santa Cruz 
SMAD2 (D43B4) XP® Rabbit mAb #5339S 1:200 Cell Signaling 
TGFb RII #sc-17792 1:50 Santa Cruz 
Table 7. Primary antibodies for immunofluorescence. 
Secondary antibody Dilution Supplier 
Alexa Fluor™ 488 NHS Ester (Succinimidyl Ester) 1:500 Thermo Fisher Scientific 
Dextran, Alexa Fluor™ 647 1:500 Thermo Fisher Scientific 
Table 8. Secondary antibodies for immunofluorescence. 
6.14 siRNA treatment 
For siRNA experiments 2 x 105 reporter cells were seeded in 6-well plates one day before siRNA 
treatment for RT-qPCR knock-down tests and in parallel 2 x 105 reporter cells were seeded in 35mm 
poly-D-lysine-coated glass bottom plates (MatTek Corporation) for time-lapse microscopy 
experiments. For siRNA treatment, co-transfection complexes were prepared by adding 6.8 μl of a 10 
μM siRNA stock solution and 7.5 μl of TransIT-X2 Dynamic Delivery System (Mirus Bio LLC) to 250 μl of 
Opti-MEM I Reduced Serum Media (Thermo Fisher Scientific). This mix was incubated for 15-30 
minutes at room temperature. Then, it was added drop-wise to different areas of the well, and the 
plate was gently rocked for homogeneous distribution. Two days after siRNA treatment the cells for 
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the knock-down tests were harvested (RT-qPCR, 6.10) or used for time-lapse microscopy (6.6), 
respectively. The transfection with scrambled siRNA was done the same way. The sequence of the 
silencer select validated siRNA PPM1A (ID: s10919, Ambion/Thermo Fisher Scientific) was sense 5´-
3´GAC UUG AAG UCA CUG AUG tt, antisense 5´-3´UCA UCA GUG ACU UCA AGU C tg and of the control 
siRNA was CGU ACG CGG AAU ACU UCG ATT (Zheng et al, 2013) ordered from Eurofins Genomics.
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7.1 Appendix figures  
 
7.1 Figure A1. SMAD2 and SMAD4 show similar dynamics in the same individual cell. 
Median nuc/cyto SMAD2 and SMAD4 ratio of the combined SMAD2-YFP- SMAD4-mCherry (A3) reporter cell line 
stimulated with 0, 1, 2.5, 5, 25 or 100pM TGFβ and tracked over 24h. Shaded area represent data between 25th and 75th 
percentiles. 
 
 
7.1 Figure A2. SMAD2 and SMAD4 show similar dynamics in the same individual cell. 
Time-resolved analysis of SMAD2 (blue lines) and SMAD4 (red lines) translocation in the same individual (A3) reporter cells 
stimulated with varying concentrations of TGFβ. 
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7.1 Figure A3. SMAD2 and SMAD4 show similar dynamics in the same individual cell. 
Heat map of correlation coefficient of SMAD2 and SMAD4 translocation in (A3) reporter cells is shown as indicated in the 
legend (left panel) and correlation coefficient over 24h (right panel). 
 
 
7.1 Figure A4. Inhibition of transcription by DRB attenuates early adaptation. 
Heat maps of SMAD2 translocation in individual cells over 24h. Cells were stimulated with 25pM TGFβ and treated with 
DMSO or DRB 0.25h pre TGFβ stimulus. Each horizontal line represents a single cell and the nuc/cyto ratio is shown as 
indicated in the legend. Cells were sorted by the time of the first division as indicated by red marks. 
 
 
7.1 Figure A5. Inhibition of transcription by DRB attenuates early adaptation. 
Signaling features for the SMAD2 reporter cells at 1.25h and 3.25h stimulated with 2.5, 25 or 100pM TGFβ and treated 
with DRB at indicated time points. White lines indicate median; boxes include data between the 25th and 75th percentiles; 
whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
 
7 APPENDIX 
183 
 
 
7.1 Figure A6. Sustained SMAD7 knock out affects SMAD2 dynamics.  
Signaling features for nuclear SMAD2 level in the reporter cells stimulated with 5 or 25pM TGFβ as indicated. Red lines 
indicate median; boxes include data between the 25th and 75th percentiles; whiskers extend to maximum values within 
1.5× the interquartile range; crosses represent outliers. 
 
 
7.1 Figure A7. Sustained SMAD7 knock out affects SMAD2 dynamics.  
Heat maps of nuclear SMAD2 translocation in the reporter cells stimulated with 5 or 25pM TGFβ as indicated over 24h. 
Cells were stimulated with varying concentrations of TGFβ. Each horizontal line represents a single cell and the nuc/cyto 
ratio is shown as indicated in the legend. Cells were sorted by the time of the first division as indicated by red marks. 
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7.1 Figure A8. Inhibition of proteasomal degradation boost nuclear SMAD accumulation.  
Heat maps of SMAD2 translocation in individual cells over 24h. Cells were stimulated with 100pM TGFβ and treated with 
MG132 at indicated time points. Cells were sorted by the time of the first division as indicated by red marks. 
 
 
7.1 Figure A9. Inhibition of proteasomal degradation boost nuclear SMAD accumulation. 
Median nuc/cyto SMAD4 ratio, median cytoplasmic and nuclear SMAD4 level of the SMAD4-YFP reporter cells stimulated 
with 100pM TGFβ and treated with the proteasome inhibitor. MG132 at indicated time points. Shaded area represent 
data between 25th and 75th percentiles. 
7 APPENDIX 
185 
 
 
 
7.1 Figure A10. Inhibition of proteasomal degradation boost nuclear SMAD accumulation.  
Exemplary individual nuc/cyto SMAD4 ratio trajectories (thin lines) for the SMAD4-YFP reporter cells stimulated with 
100pM TGFβ and treated with MG132 0.75h pre 100pM TGFβ compared to the median nuc/cyto SMAD4 ratio of the entire 
population (thick line). 
 
 
7.1 Figure A11. Inhibition of proteasomal degradation boost nuclear SMAD accumulation.  
Signaling features for the nuc/cyto SMAD4 ratio in the SMAD4 reporter cells stimulated with 100pM TGFβ and treated 
with MG132 at indicated time points. Red lines indicate median; boxes include data between the 25th and 75th 
percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
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7.1 Figure A12. Receptor internalization and degradation: Endocytotic pathways.  
Heat maps of SMAD2 translocation in individual cells over 24h. Cells were stimulated with 100pM TGFβ and 0.75h 
pretreated with Nystatin. Cells were sorted by the time of the first division as indicated by red marks. 
 
 
7.1 Figure A13. Receptor internalization and degradation: Endocytotic pathways.  
Signaling features for the nuclear SMAD2 level in the SMAD2 reporter cells stimulated with 100pM TGFβ and 0.75h 
pretreated with Nystatin. Red lines indicate median; boxes include data between the 25th and 75th percentiles; whiskers 
extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
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7.1 Figure A14. Receptor internalization and degradation: Endocytotic pathways.  
Signaling features for the nuclear SMAD2 level in the SMAD2 reporter cells stimulated with 100pM TGFβ and 0.75h 
pretreated with Dynasore. Red lines indicate median; boxes include data between the 25th and 75th percentiles; whiskers 
extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
 
 
7.1 Figure A15. TGFβ signaling shows a refractory period.  
Heat maps of SMAD2 translocation in individual cells over 24h. Cells were stimulated with 5pM TGFβ and restimulated 
with 5pM TGFβ at indicated time points. Cells were sorted by the time of the first division as indicated by red marks. 
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7.1 Figure A16. TGFβ signaling shows a refractory period.  
Nuc/cyto SMAD2 ratio of the SMAD2 reporter cells stimulated with 5pM TGFβ and restimulated with 5pM TGFβ at 
indicated time points at 1, 4, 7 and 9h. White lines indicate median; boxes include data between the 25th and 75th 
percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
 
 
7.1 Figure A17. TGFβ signaling shows a refractory period.  
Heat maps of SMAD2 translocation in individual cells over 24h. Cells were stimulated with 5pM TGFβ and restimulated 3h 
post with 5pM TGFβ and 0.25h pretreated with DRB. Cells were sorted by the time of the first division as indicated by red 
marks. 
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7.1 Figure A18. Inhibition of p38 modulates the dynamics and localization of SMADs. 
Heat maps of SMAD2 translocation in individual cells over 24h. Cells were stimulated with 100pM TGFβ and 0.75h 
pretreated with p38 inhibitors. Cells were sorted by the time of the first division as indicated by red marks. 
 
 
7.1 Figure A19. Inhibition of p38 modulates the dynamics and localization of SMADs. 
Median nuc/cyto SMAD4 ratio of the SMAD4-YFP reporter cells stimulated with 100pM TGFβ and 0.75h pretreated with 
p38 inhibitors (SB202190 & BIRB796). DMSO and only p38 inhibitors were used as controls. Shaded area represent data 
between 25th and 75th percentiles. 
 
 
7.1 Figure A20. Inhibition of p38 modulates the dynamics and localization of SMADs. 
Exemplary individual nuc/cyto SMAD4 ratio trajectories (thin lines) for the SMAD4-YFP reporter cells stimulated with 
100pM TGFβ and 0.75h pretreated with p38 inhibitors compared to the median nuc/cyto SMAD4 ratio of the entire 
population (thick line). 
 
 
7.1 Figure A21. Inhibition of p38 modulates the dynamics and localization of SMADs. 
Median nuc/cyto SMAD4 ratio of the SMAD4-YFP reporter cells stimulated with 2.5pM TGFβ and 0.75h pretreated with 
p38 inhibitors. Shaded area represent data between 25th and 75th percentiles. 
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7.1 Figure A22. Inhibition of p38 modulates the dynamics and localization of SMADs. 
Nuc/cyto SMAD4 ratio of the SMAD4 reporter cells stimulated with 2.5 or 100pM TGFβ and 0.75h pretreated with p38 
inhibitors at time points 1.75 and 15h. White lines indicate median; boxes include data between the 25th and 75th 
percentiles; whiskers extend to maximum values within 1.5× the interquartile range; crosses represent outliers. 
 
 
7.1 Figure A23. TAK1 Inhibition modulates the dynamics and localization of SMADs. 
Heat maps of SMAD2 translocation in individual cells over 24h. Cells were stimulated with 100pM TGFβ and 0.75h 
pretreated with 5Z-7-Oxozeaenol (TAKi) at indicated concentrations. Cells were sorted by the time of the first division as 
indicated by red marks. 
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7.1 Figure A24. TAK1 Inhibition modulates the dynamics and localization of SMADs. 
Exemplary pictures of SMAD2 fluorescence intensities in MCF10A WT cells stimulated with 100pM TGFβ and 0.75h 
pretreated with 5Z-7-Oxozeaenol (TAKi) by immunofluorescence at 1, 3 and 8h. Nuclear staining was carried out with 
Hoechst 33342.  
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7.1 Figure A25. TAK1 Inhibition modulates the dynamics and localization of SMADs. 
Heat maps of SMAD4 translocation in individual cells over 24h. Cells were stimulated with 100pM TGFβ and 0.75h 
pretreated with 5Z-7-Oxozeaenol (TAKi) at indicated concentrations. Cells were sorted by the time of the first division as 
indicated by red marks. 
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7.1 Figure A26. TAK1 Inhibition modulates the dynamics and localization of SMADs. 
Median nuc/cyto SMAD4 ratio, nuclear and cytoplasmic level of the SMAD4-YFP reporter cells stimulated with 2.5pM TGFβ 
and 0.75h pretreated with 5Z-7-Oxozeaenol (TAKi). Shaded area represent data between 25th and 75th percentiles. 
 
 
7.1 Figure A27. TAK1 Inhibition modulates the dynamics and localization of SMADs. 
Heat maps of SMAD4 translocation in individual cells over 24h. Cells were stimulated with 100pM TGFβ and 6h post TAKi. 
Cells were sorted by the time of the first division as indicated by red marks. 
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7.1 Figure A28. TAK1 Inhibition modulates the dynamics and localization of SMADs. 
Nuc/cyto SMAD4 ratio of the SMAD4 reporter cells stimulated with 100pM TGFβ and 6h post TAKi at indicated time points. 
White lines indicate median; boxes include data between the 25th and 75th percentiles; whiskers extend to maximum 
values within 1.5× the interquartile range; crosses represent outliers. 
 
 
7.1 Figure A29. Inhibition of ERK signaling alters long-term SMAD dynamics. 
Heat maps of nuc/cyto SMAD2 ratio in individual cells over 24h. Cells were stimulated with 100pM TGFβ and 0.75h 
pretreated with p38 inhibitors and/ or Gefitinib (Gef). Cells were sorted by the time of the first division as indicated by red 
marks. 
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7.1 Figure A30. TGFβ response depends on EGF concentration. 
Signaling features for nuclear SMAD2 level of the SMAD2 reporter cells stimulated with 100pM at varying EGF 
concentrations. White lines indicate median; boxes include data between the 25th and 75th percentiles; whiskers extend 
to maximum values within 1.5× the interquartile range; crosses represent outliers. 
 
 
7.1 Figure A31. TGFβ response depends on EGF concentration. 
Heat maps of nuclear SMAD2 level in individual cells over 24h. Cells were stimulated with 100pM TGFβ at varying EGF 
concentrations as indicated. Cells were sorted by the time of the first division as indicated by red marks. 
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7.1 Figure A32. TGFβ response depends on EGF concentration. 
Median nuclear SMAD4 level of the SMAD4-YFP reporter cells stimulated with 100pM TGFβ at varying EGF concentrations. 
 
 
7.1 Figure A33. TGFβ response depends on EGF concentration. 
Signaling features for nuclear SMAD4 level of the SMAD4 reporter cells stimulated with 100pM at varying EGF 
concentrations. White lines indicate median; boxes include data between the 25th and 75th percentiles; whiskers extend 
to maximum values within 1.5× the interquartile range; crosses represent outliers. 
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7.1 Figure A34. TGFβ response depends on EGF concentration. 
Responders in % of the SMAD4-YFP reporter cells stimulated with 100pM TGFβ at varying EGF concentrations. 
 
 
 
7 APPENDIX 
198 
 
7.1 Figure A35. PPM1A is probably involved in the ERK-mediated TGFβ response. 
Individual cells were clustered into six cluster (Figure 50 G) and the corresponding median nuclear SMAD2 level over 24h 
are shown for the individual cluster. Shaded area represent data between 25th and 75th percentiles.  
7.2 List of abbreviations 
BMP   bone morphogenetic protein  
CFP  cyan fluorescent protein 
CV   coefficient of variation  
DRB   5,6-dichloro-1--D-ribofuranosylbenzimidazole 
DTW   dynamic time warping 
EEA1  early endosome antigen-1 
EGF   epidermal growth factor 
EGFR   epidermal growth factor receptor  
EMT  epithelial -mesenchymal transition 
ERK  extracellular signal-regulated kinase 
EtBr   ethidium bromide  
Fucci     fluorescent, ubiquitination-based cell cycle indicator  
I-SMADs  inhibitory SMADs 
IPTG  Isopropyl β-D-1-thiogalactopyranoside  
JNK   c-Jun N-terminal kinase 
KTR  kinase translocation reporter 
MAPK   mitogen-activated protein kinase  
MKK  MAP kinase kinase 
MLEC  mink lung epithelial cells  
NEB  New England Biolabs 
NF-κB   nuclear factor kappa B  
nuc/cyto nuclear/ cytoplasmic 
PAI-1  plasminogen activator inhibitor 1 
R-SMADs  receptor-regulated SMADs  
RPMCs  rat peritoneal mast cells 
RT  room temperature  
SARA   SMAD anchor for receptor activation 
smFISH  single molecule fluorescent in situ hybridization  
TAK1  TGFβ-activated kinase 1 
TGFβ   transforming growth factor beta 
TGFβRi  TGFβReceptor I Kinase inhibitor SB431542 
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TGFβRI   TGFβ type I receptors 
TGFβRII  TGFβ type II receptors 
WT  wild type  
YFP   yellow fluorescent protein 
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bei all denjenigen bedanken, die mir die Erstellung meiner Dissertation ermöglicht haben. 
 
Mein erster und ganz besonderer Dank gilt Herrn Prof. Dr. Alexander Löwer, der mir dieses spannende 
Forschungsthema übergeben hat. Ich danke ihm für die engagierte Betreuung, für das Vertrauen, das 
er mir und meiner Arbeit stets entgegengebracht hat, für die Freiheiten in der Forschungsausrichtung, 
für die freundschaftliche Atmosphäre und für den stets regen und konstruktiven Ideenaustausch. 
Insbesondere danke ich ihm für die Möglichkeit an nationalen und internationalen Konferenzen 
teilnehmen zu können.  
 
Weiterhin möchte ich mich bei Prof. Dr. Andreas Herrmann bedanken, der sich bereit erklärt hat mein 
Betreuer an der Humboldt Universität zu Berlin zu sein und ein Gutachten zu verfassen. Insbesondere 
möchte ich mich bedanken für seine unkomplizierte Art auch auf spontane Promotionsverlängerungen 
zu reagieren.  
 
Weiterhin möchte ich mich beim MDC- Max Delbrück-Zentrum für molekulare Medizin in der 
Helmholtz-Gesellschaft und insbesondere dem BIMSB- the Berlin Institute for Medical Systems Biology 
für die herausragenden Möglichkeiten und Strukturen, die einen breiten Forschungsaustausch 
gefördert haben, bedanken. 
 
Viele Menschen haben dazu beigetragen, dass die Dissertationszeit eine glückliche und wertvolle 
Zeitspanne für mich darstellt. Deshalb danke ich allen Kollegen und Freunden der Arbeitsgruppe Löwer 
für die wunderbare Zusammenarbeit und das harmonische Miteinander- Ana Finzel Pérez, Elena 
Cristiano, Dhana Friedrich, Caibin Sheng, Marcel Jentsch, Andrea Katzer, Gitta Blendinger, Silke 
Dusatko, Ilias Nolis und  Felix Hoevelmann. 
Derya Guenes und Lennart Schnirch danke ich für ihr Engagement und die hervorragende 
Zusammenarbeit im Rahmen ihrer Bachelorarbeiten, die ich betreuen durfte und deren Ergebnisse in 
diese Arbeit einflossen. 
Ana und Elena danke ich im Besonderen für die einzigartige Atmosphäre, die wertvollen Diskussionen, 
die gegenseitige Unterstützung und die fantastische Zeit bei den Konferenzen. 
Dhana danke ich vor allem für die wunderbare Einführung in die smFISH- Welt und ihrer lebhaften und 
inspirierenden Art.  
10 ACKNOWLEDGEMENT 
227 
 
Marcel danke ich für seine bioinformatorische Unterstützung, die erst so manche Analyse möglich 
gemacht hat.  
 
Bei Dr. Stefan Legewie und Uddipan Sarma vom Institute of Molecular Biology (IMB) Mainz möchte ich 
mich für die wissenschaftliche Zusammenarbeit und das Erstellen eines Modells auf Grundlagen 
meiner Experimente danken. Weiterhin bedanke ich mich bei Dr. Daniel Horbelt und Prof Dr. Petra 
Knaus vom Institut für Chemie und Biochemie, Freie Universität Berlin, für die erfolreiche 
Zusammenarbeit beim TGFβ assay. 
 
Mein ganz besonderer Dank gilt meinen Eltern Marion & Max, meiner Schwester Rike und meiner Omi 
& meinem Opi für die aufmerksame, liebevolle und vielseitige Unterstützung während dem Verfassen 
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